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ABSTRACT 
HYDRATION IN ADVANCED CANCER 
 
The role of hydration in causing or alleviating suffering in patients with advanced 
cancer is poorly understood and remains controversial. Most dying cancer patients 
have reduced oral intake in the last days of life. This may be related to symptoms 
arising from the cancer or its treatment, such as dysphagia, anorexia, nausea, 
vomiting, or mechanical problems such as bowel obstruction. Accordingly, the 
subject of clinically assisted hydration (CAH) is emotive amongst patients and their 
carers, with the omission or withdrawal of CAH potentially viewed as hastening 
death in some instances. Current hydration assessment methods are limited in 
cancer patients approaching death. Bioelectrical impedance vector analysis (BIVA) is 
an accurate validated method of assessing body composition; however its clinical 
use in advanced cancer is uncertain. This study aims to measure hydration in 
advanced cancer patients using BIVA, in order, to determine the relationship 
between symptoms, physical signs and biochemistry. 
BIVA was used to evaluate hydration in advanced cancer patients within a hospice 
in the UK. Total body water (TBW) was estimated using the impedance index 
(Height2/Resistance [H2/R]). Regression analysis determined the predictive 
properties of clinical variables on H2/R. Assessed items included: performance 
status (ECOG), symptoms (Burge-4 score), physical signs (Morita Dehydration Score) 
and biochemistry. 
Ninety patients participated (recruitment rate = 76.3%). Hydration status was 
normal in 43 (47.8%), ‘more hydrated’ in 37 (41.1%) and ‘less hydrated’ in 10 
(11.1%) patients. A multiple regression analysis was conducted. H2/R was 
significantly predicted by female gender (Beta = -13.85, p<.001), the Burge-4 score 
(Beta = -0.29, p=.04), the Morita dehydration score (Beta = -2.55, p=.02) and 
oedema (Beta = 2.55, p<.001). Median survival was significantly shorter in ‘less 
 
 
 
hydrated’ patients (44 vs. 68 days; p=.04) and in pre-renal failure (44 vs. 100 days; 
p=.003). Higher values of H2/R were associated with improved survival (HR=0.98 
[95%CI= .96, .99], p=0.01). 
The results demonstrate that in advanced cancer, hydration status (as measured by 
H2/R and BIVA) relates to clinically measurable signs and symptoms. Lower TBW 
volume was associated with female gender and also linked with higher scores for 
symptoms and physical signs. Higher TBW was associated with oedema. H2/R, BIVA 
and pre-renal failure were independent predictors of survival. Further work is 
needed to determine how BIVA can be used to guide the management of fluid 
states in advanced cancer. 
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AIMS AND OBJECTIVES 
AIM 
To improve the understanding of hydration states of advanced cancer, through the 
addition of bioelectrical impedance vector analysis (BIVA) to the best available 
clinical assessment tools and biochemical investigations. 
This aim will be achieved through completion of the following objectives: 
OBJECTIVE 1 
Bioelectrical impedance analysis (BIA) will be used to evaluate hydration states in 
individuals with advanced cancer, in order, to determine the relationship of 
hydration with biochemical investigations, clinical examination and patient self-
reported symptoms. 
OBJECTIVE 2 
To conduct an analysis of BIA data using the method of vector analysis (BIVA) and 
the RXc graph, in order, to facilitate group comparisons of hydration status 
according to specific clinical characteristics. Additionally, this analysis will compare 
hydration states of other cancer populations through use of BIVA data derived from 
the literature.  
OBJECTIVE 3 
Survival, from date of first assessment, will be analysed according to BIVA hydration 
status, the impedance index and clinical biochemistry. 
OBJECTIVE 4 
An analysis of individuals receiving repeat BIVA assessments will be conducted to 
evaluate the longitudinal change in hydration status (from first to last assessment) 
to determine whether this change is associated with survival. 
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CHAPTER 1: INTRODUCTION 
 
SECTION 1: CARE OF THE DYING IN THE 21st CENTURY 
1.1.1 A BRIEF HISTORY OF PALLIATIVE CARE 
The World Health Organization (WHO) first formally defined the term palliative care 
in 1989;1 this was revised in 2010 to describe palliative care as an approach that: 
“…improves the quality of life of patients and their families facing the problem 
anticipated with life-threatening illness, through the prevention and relief of 
suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and social.”2 This 
concept of palliative care comes from a history spanning four decades, over which, 
the subject has gained increasing acceptance within healthcare and society.3 
Palliative care is a relatively new speciality and originates from the work of key 
individuals, dating back to the nineteenth century, who endeavoured to improve 
the care of dying patients, who were often in societies where there was little 
provision for the infirm and the dying.  
In the nineteenth century, Jeanne Garnier, Mary Aikenhead and Rose Hawthorne 
shared a common purpose in their concern for the care of the dying, and in 
particular the dying poor. In the countries they resided (France, USA and Australia 
respectively) they were pivotal in opening homes which cared for the dying. These 
homes would lead to the establishment of many similar care homes around the 
world.  Although the places they founded did not offer sophisticated medical or 
nursing care, they created some of the conditions for the development of modern 
hospices. 4 
The twentieth century saw rapid changes in medicine. Advances in the diagnosis 
and treatment of disease led to the development of many different medical and 
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surgical specialities, in which the emphasis was on treatment and rehabilitation. 
Conditions and disease previously considered as incurable were now potentially 
curative. Consequently, a shift in the view of medical care emerged, with the 
inability to cure becoming viewed as a failure. The creation of the United Kingdom 
(UK) National Health Service (NHS) in 1948 provided a healthcare system which was 
free at the point of use for all citizens.5 The effect of the NHS on the UK population 
was the overall improvement of the health of the nation; this was particularly 
attributable to better treatment of infectious disease (previously a major cause of 
mortality) which resulted in a longer life expectancy and the greater risk of the 
development of age-related illness, such as cancer.6 At the same time, death in 
hospital, rather than at home, was becoming the norm and the dying patient was 
often viewed as a ‘hopeless case’ and failure of medical practice.4  In the 1960s, 
Dame Cicely Saunders was instrumental in drawing attention to the end-of-life care 
needs of patients with advanced cancer.3 The work of Dame Cicely Saunders, and 
other pioneers such as John Hinton, Robert Twycross , Elizabeth Kubler Ross and 
Colin Murray-Parkes, heralded the start of the hospice movement.7 These hospices 
aimed to deliver multifaceted care of terminally ill cancer patients and experienced 
rapid expansion in the 1980s.3 
Palliative care continued to progress in specialisation. The work of the Macmillan 
organisation (now Macmillan Cancer Support8) and the Marie Curie Memorial 
Foundation (now Marie Curie Cancer Care9) were important in the establishment of 
a wide range of care and the delivery of education and research. The development 
of the Association of Palliative Medicine (APM), in addition to the Royal College of 
Physicians recognising Palliative Medicine as a medical sub-speciality of medicine in 
1987, resulted in greater operational capacity and integration of services into the 
NHS.3 These factors led to in greater research, education and the elevation of 
palliative care within general medicine in the United Kingdom.10 The past decade 
has seen continual acknowledgement of the need to improve care for patients 
approaching the end of their lives. In the year 2000, the Department of Health’s 
NHS Cancer Plan was the first ever comprehensive strategy to tackle the disease in 
the England.11 The report outlined the requirements expected of services providing 
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specialist care to individuals approaching the end of their lives. This was built upon 
by the NHS End of Life Care Programme (2004 – 2007),12 the Gold Standards 
Framework for primary care,13 the Liverpool Care of the Dying Pathway (LCP),14 
Preferred Priorities of Care (PPC)15 and the National End of Life Care Strategy in 
2008.16 These reports detail a strategy to facilitate the delivery of high quality 
palliative care in the UK. Notably, they provide evidence that most people in the UK 
wish to die at home;16 however, the reality is that 60% of people currently die in 
hospital and this is due to increase by approximately 20% due to longer life 
expectancy and a projected increase in the UK population.17 Recent analysis 
suggests a reversal in this trend, with the proportion of home deaths, increasing 
from 18.4% in 2004 to 20.8% in 2010.18 This result is partly due to the use of 
palliative care home services which have been proven to be successful in increasing 
the likelihood of a home death and reducing symptom burden, without impacting 
on caregiver grief.19  
1.1.2 FUTURE CHALLANEGES FOR PALLIATIVE CARE DELIVERY 
Advances in multimodal cancer-directed treatment have improved survival for 
metastatic cancer patients.20 In the Western world the combination of various 
demographic, health-related and sociological factors will contribute to an increase 
in morbidity and mortality over the next decade. On a societal level, there is a shift 
to patient choice. This is combined with increasing awareness and dialogue about 
the end-of-life care in the media, with an emphasis on supportive care tailored to 
the individual.21 Collectively these issues provide several challenges to the future of 
palliative care provision in Europe. 
Different conceptual models of palliative care delivery have been used to define the 
role of the service. Initially, specialist palliative care (encompassing all hospice and 
specialist palliative care services) were concentrated on cancer patients who were 
referred once their disease had reached a point where no further curative 
treatment was possible.20 However, as the range of treatments for cancer has 
grown and palliative care has developed, patients now may continue receiving 
active treatments as they approach death.22 A response is to argue that specialist 
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palliative care should be available to patients across their disease trajectory (from 
diagnosis to death) and not just restricted to end of life.23 24 In light of this, the 
General Medical Council define end-of-life care as a component of palliative care, 
comprising of the last 12 months of life.25  
Historically, palliative care services were focused on those with incurable cancer; 
however the current view is that palliative care should be available based on need 
rather than diagnosis. Consequently, palliative care services have expanded to 
include those with non-malignant disease; this has created several challenges.26  
Patients with non-malignant disease have needs which may not be met in a system 
of care that is based on cancer.27 The delivery of care for these patients requires a 
broad range of specialist knowledge, in order to provide appropriate care. 
Furthermore, non-cancer diseases have varying illness trajectories which may 
create difficulties in prognostication and advance care planning.28 29 Notable 
examples include dementia, chronic obstructive pulmonary disease and congestive 
cardiac failure. Such patients may be prone to acute exacerbations of their 
condition, which may require active treatment and liaison with other services.27 
The combination of an increasing life expectancy and the desire to increase the 
number of patients receiving end-of-life care at home is challenging. A specific 
challenge relates to how services will organise care in the future. Palliative care 
operates from numerous settings, notably hospice, community and hospital; 
however, the needs of patients, and the availability of services, may differ 
significantly between these areas. Additionally, certain populations are currently 
under-represented, such as those from lower socioeconomic classes, ethnic 
minorities and the homeless.30 There is a need to ensure equity of services and 
access for users wherever they receive care.31 Additionally, it is necessary to ensure 
the ongoing delivery of high quality undergraduate and postgraduate training 
programmes that are necessary to educate a future workforce that is likely to be 
generalist.32 33 Care delivery and education needs to be supported with research, in 
order to generate the evidence base that is required to meet the needs of an 
increasingly complex population.34 Despite the importance of these issues, 
palliative care receives significantly less research funding compared to other 
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specialities.35 These issues, combined with ongoing financial austerity will create 
several challenges for the provision of end-of-life care into the future. 
1.1.3 RECENT MEDIA COVERAGE OF PALLIATIVE CARE IN THE UNITED 
KINGDOM 
An Integrated Care Pathway (ICP) determines a structured, locally agreed, 
multidisciplinary care plan which details essential steps in the care of patients with 
specific problems.36 37 Over the past two decades, the use of ICPs has been adopted 
in various settings, including those approaching the end of their lives.38 Examples of 
ICPs for the care of the dying include the Liverpool Care Pathway of the Dying 
Patient (LCP)14 and the All Wales Integrated Care Priorities for the Last Days of Life 
(ICP).39 In the UK, the use of ICPs came under scrutiny with sustained concerns 
about the safety of implementing end-of-life care pathways.40 The media 
highlighted poor examples of care which were attributed to the use of ICPs.21 41-44 
However, many of the complaints detailed in these accounts were related to poor 
care and communication issues, which, although are not specific to the ICPs were 
invariably linked to these tools at the end-of-life.45 
The media reported alleged instances of sub-optimal care in which some patients, 
who were able to drink, were not provided with oral fluids.41 Additionally, the 
rationale of decisions relating to clinically assisted hydration (CAH) for dying 
patients was debated, with accusations that the non-use (or withdrawal) of CAH 
was causing some patients to die prematurely of dehydration.46 In light of these 
concerns of poor care, an independent review of the LCP was commissioned by the 
UK government which set out to evaluate the use of the LCP in the management of 
dying patients. The review concluded that the LCP should be withdrawn and 
replaced by individualised care plans for dying patients.24 An outcome of the review 
was the acknowledgement of a lack of research in key areas and the 
recommendation for greater investment research is needed to improve care of the 
dying. The review led to the formation of the Leadership alliance for the care of 
Dying People (LACDP), a coalition of 21 national organisations concerned to ensure 
high quality, consistent care for people in the last few days and hours of life.47 In 
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June 2014, the LACDP published a Government guidance document entitled ‘One 
chance to get it right’. This report outlines the future requirements of care for all 
dying people in England, irrespective of whether organisations were previously 
using the LCP or not. The approach focuses on putting the dying patient as the 
focus of the care, through the achievement of five Priorities for Care. The priorities 
for a person thought be in the last hours to days of life are as follows:47 
1. The possibility that the person is dying is recognised and communicated 
clearly, decisions made and actions taken in accordance with the person’s 
needs and wishes, and these are regularly reviewed and decisions revised 
accordingly.  
2. Sensitive communication takes place between staff and the dying person, 
and those identified as important to them.  
3. The dying person, and those identified as important to them, are involved in 
decisions about treatment and care to the extent that the dying person 
wants.  
4. The needs of families and others identified as important to the dying person 
are actively explored, respected and met as far as possible.  
5. An individual plan of care, which includes food and drink, symptom control 
and psychological, social and spiritual support, is agreed, co-ordinated and 
delivered with compassion.  
Currently (due to a variety of practical, ethical and methodological issues) there is a 
lack of research evidence to address these areas. 
1.1.4 RESEARCH CHALLENGES IN PALLIATIVE CARE 
Palliative care is a relatively young speciality which has developed outside 
traditional University and NHS systems. Consequently, hospices often lack a 
research governance infrastructure which limits the potential for research to be 
conducted in these areas. Formal arrangements for NHS indemnity from 
neighbouring hospitals is varied by location and is often complex.  Palliative care 
staff may face difficulties in conducting research studies, due to a lack of research 
training and dedicated research time. The 2011 consultant census by the Royal 
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College of Physicians revealed that the mean number of academic programmed 
activities by palliative medicine consultants was almost half that of other 
specialities (0.4 vs. 0.7).48 Additionally, there are relatively few clinical academic 
posts compared to other specialities, with only 15 joint University-NHS academic 
posts in England.48 These infrastructural and workforce issues contribute to an 
environment that is not conducive for research. 
Research involving patients who are approaching death is methodologically and 
ethically challenging.49 50 This group of patients often have significant symptomatic 
burden, including pain, fatigue and psychological distress.  Researchers may 
struggle to engage and recruit participants due to concerns about the ability of 
patients to comply with assessments and provide consent.51 Consequently, low 
levels of recruitment, small sample sizes and high attrition rates often have a 
deleterious impact on the methodological quality of research.52 However, there is 
developing evidence which demonstrates that patients are keen to be involved in 
palliative care research.34 49 53  
A careful, evidence-based approach is necessary to address the inevitable 
challenges, which will be posed by an increasingly aged population that will require 
supportive care towards the end of their lives.17 49 Further investment in palliative 
care research is required to generate the evidence which will improve the care 
delivered to patients approaching death.24 35 49 51 54 55 Currently, funding for end-of-
life and palliative care research is inadequate. Data on UK research funding by 
National Cancer Research Institute partners in 2010 show that just 0.24% was 
allocated to palliative and end-of-life care research. Similarly, in 2010 the USA 
National Cancer Institute only awarded 1% its funding to palliative care research.35 
The disparity in research funding reflects the preferential investment to oncological 
studies which offer curative and life-sustaining treatment. Whilst this is 
commendable the outcomes of such studies often focus on survival measures with 
a lack of importance given to quality-of-life. Consequently, patients may endure 
treatments which cause significant morbidity, with adverse effects to their quality-
of-life, despite an increased chance of survival. Provided with enough information, 
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patients may opt for measures which aim to improve or maintain their quality-of-
life, rather than undergo further aggressive treatments. However, irrespective of 
the quantity or intensity of treatment, many oncological patients will require 
palliative care as their condition deteriorates. 
The lack of investment in palliative care research may also be a reflection of the 
lack of attention society has given to dying. In Western society, a combination of 
demographic and sociological factors has contributed to a lack of focus on end-of-
life issues. In the UK, the current population can expect longer life expectancy with 
fewer children later in life.56 Additionally, society is reportedly more disparate and 
less community-engaged compared to previous generations. Consequently, 
bereavement may not be experienced till later in life which can be a source of fear 
and trepidation. Individuals affected by disease are more likely than ever to be 
living by themselves with a lack of support from their local community.57 
Campaigns, such as Dying Matters Coalition coordinated by the National Council for 
Palliative Care,58 have attempted to elevate the issue of dying to the public 
consciousness. The recent media attention to end-of-life issues demonstrates that 
people are recognising that end-of-life issues are important. However, until society 
demands that quality-of-life is regarded to be equal in value as survival, it is unlikely 
to receive appropriate attention or funding. Therefore, the challenge is to engage 
with society to have an honest debate to encourage investment in end-of-life care 
and research. 
1.1.5 THE NEED FOR HIGH QUALITY RESEARCH IN END-OF-LIFE CARE 
There is a need to improve the opportunities for patients to participate in research. 
Polls conducted by Ipos Mori (a leading market research company in the UK and 
Ireland59) demonstrate that the public are keen to take part in research.60 However, 
in the health service there are several barriers which result in patient not being 
provided with the opportunity.61 The National Institute for Health Research (NIHR) 
conducted ‘mystery shopper’ report to evaluate research activity in several 
healthcare settings. The report highlighted that in the 82 hospitals studied, 91% 
lacked information about research opportunities for patients.62 The lack of 
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opportunities for research may be more prevalent in end-of-life care due to various 
barriers faced by those in the palliative phase of their illness.51 Investment is 
required to improve research opportunities for patients receiving palliative care in 
different healthcare and community settings.49 61 
Several areas within palliative medicine lack research evidence, which creates 
complexity and uncertainty for healthcare professionals when attempting to 
provide best practice to patients.  An area lacking evidence involves the clinical 
assessment and management of hydration in advanced cancer patients.  
The independent review of the Liverpool Care of the Dying Pathway (LCP) in the UK 
notes that many complaints about end-of-life care involved decisions concerning 
hydration and nutrition.24 Decisions surrounding the administration of CAH to 
patients at the end-of-life can be challenging, with many healthcare professionals, 
patients and carers presenting differing opinions on appropriate management.63-68 
The General Medical Council (GMC) of the UK has released guidance concerning the 
administration of CAH at the end-of-life for patients who are expected to die within 
hours or days, and those who are not expected to die within this timeframe. 
Clinicians are required to assess hydration status in both circumstances.25 However, 
decisions about appropriate management are often difficult due to a limited 
understanding of hydration mechanisms in advanced cancer, and a lack of evidence 
to guide healthcare professionals.63 68 69  
The lack of evidence in the area of hydration at the end-of-life creates particular 
challenges. Firstly, without appropriate understanding of how hydration affects 
quality-of-life it is not possible determine if patients are receiving appropriate care. 
Furthermore, the limited understanding concerning the management of fluid states 
creates uncertainty of when CAH should be used or discontinued. In light of these 
issues, the independent review of the LCP called for research to improve the 
evidence relating to hydration in palliative care.24  The review specifically 
highlighted the need for studies to evaluate the usefulness of laboratory and other 
biological evidence, to improve accuracy of diagnostic tools and to conduct mixed 
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methods trials involving specific hydration interventions.24 These recommendations 
were accepted fully by the LACDP.47 
Ultimately, the goal of research is the acquisition of new knowledge which will 
result in tangible benefit for patients. The current societal discussion about 
palliative care demonstrates many are interested in issues at the end-of-life and 
desire to see excellent care provided to those requiring support. It is important to 
acknowledge that an important aspect of care of the dying is the management of 
hydration. Consequently, for issues concerning hydration at the end of life, it is 
essential to improve the evidence to improve the care for patients and their 
families.  
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SECTION 2: HUMAN BODY COMPOSITION 
1.2.1 INTRODUCTION 
This section of the thesis outlines the importance of human body composition. It 
details human body fluid compartments and provides an overview of different 
methods of its assessment.  
1.2.2 BODY FLUID COMPARTMENTS 
Water is essential for human life, functioning as a substrate for biochemical 
reactions and a mechanism of transportation of substances.70 The maintenance of a 
relatively constant volume and stable composition of body fluids is essential for 
homeostasis.71 Total Body Water (TBW) is included with the Fat Free Mass (FFM) 
compartment of the human body. TBW consists of two components including, 
intracellular water (ICW) and extracellular water (ECW).71  
In the average adult weighing 70kg, water constitutes approximately 60% (42 litres) 
of body weight.70 Intracellular fluid consists of fluid within body cells and accounts 
for 40% (28 litres) of total body weight (Figure 1).71 The percentage of body water 
in an individual is affected by their age, sex, degree of obesity and illness.72 Ageing 
is associated with a loss of muscle and an increased percentage of body fat, which 
reduces the percentage of body water.72 Women normally have more body fat than 
men and therefore contain slightly less body water than men in proportion to their 
weight.70 71 
The ECW consists of fluid outside of the cells and is classified into three 
subdivisions: the interstitial compartment, the plasma compartment and the third 
space. The interstitial compartment is the fluid space that surrounds the cells of a 
given tissue. It is filled with interstitial fluid which comprises of approximately 15% 
body weight (10.5 litres). Interstitial fluid is rich in ions, proteins, and nutrients and 
allows for their movement across the cell membrane. The fluid is continuously 
exchanged and eventually recollected by the lymphatic channels.73 Blood plasma is 
the intravascular (blood vessels) part of the ECW; it holds the blood cells in whole 
blood in suspension and comprises 55% of total blood volume. The third-space 
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refers to the non-functional space between cells. Fluid will move to this area from 
the intravascular space (blood vessels) for a variety of reasons, such as an increase 
in fluid volume, hypoalbuminemia or hyponatraemia.74 An excess of fluid in the 
third space may manifest clinically as oedema.72 
 
FIGURE 1: DISTRIBUTION OF BODY WATER FOR AN AVERAGE MALE 
ADULT WEIGHING 70KG (REPRODUCED WITH PERMISSION)72
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FIGURE 2: PRESENTATION OF THE MULTI-COMPARTMENT MODELS. 
REPRODUCED WITH PERMISSION.75  
 
1.2.3 BODY COMPOSITION AND ITS IMPORTANCE  
Differences in the shape and size of individuals can mark health differences among 
individuals or population groups.76 Changes in the structure of normal cellular 
structure caused by disease can adversely affect function, leading to increased 
morbidity and eventual mortality.  Accurate and reliable measures of anatomical 
and physiological parameters are important to understand how pathological 
processes effect health.76 
The human body can be structured into different levels which provide a structural 
framework for studying human body composition.77 There are different models for 
categorising human body composition, which involve the classification of the 
human body into either a two or multi-compartment system (Figure 2).75 A two 
compartment (2C) model comprises of fat mass (FM) which constitutes the fat 
content of the body, and fat free mass (FFM) which includes everything that is not 
body fat.71 78 
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The 2C model is the most widely used approach to estimate body composition in 
adults and benefits from its simplicity. The 2C model assumes that the proportions 
of FFM, water, protein and minerals are stable. 75 79 Body water is presumed to be 
0.732 l/kg (i.e. 73% of soft tissue)80 and body potassium is estimated at 68.1 
meq/kg.70 81 These requirements of the 2C model mean that body composition 
estimates may be inaccurate in situations where the assumptions of the model are 
not met. This may occur with particular conditions such as aging, pregnancy, weight 
reduction in obese people, and in various disease states.77 
The four compartment (4C) model (at an atomic, molecular and cellular level) is the 
most accurate available measure of body composition and is frequently used as a 
reference method against which new body composition methods are compared. 
The 4C model involves the measurement of various factors, including body mass or 
weight, total body volume, TBW, and bone minerals; however, the 4C method is 
limited practically as these methods depend on use of specialised laboratory 
equipment which are not available in routine clinical practice.77 
Body composition analysis provides various methods to evaluate human nutrition 
and physiology in relation to the structural multi-compartment model (Figure 2).82 
83    
1.2.4 BODY COMPOSITION METHODS  
Body composition methods comprise of two categories: direct and indirect 
assessment. Direct methods include total body water measurement, total body 
potassium counting, neutron activation, body density (Db), dual energy X-ray 
absorptiometry (DEXA) and imaging methods. 
Isotope dilution is a method of measuring total body water and involves the 
administration of an isotope tracer, either orally or intravenously. The 
concentration of the tracer excreted in the urine is then measured in order to 
estimate the total fluid volume.75 
Total body potassium counting involves measurement of naturally radioactive 
potassium in the body. Because potassium is found almost entirely within cell 
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bodies, this measurement can provide an estimate of body cell mass. Consequently, 
fat-free mass can be estimated once total body potassium is known;75 84 however, 
this assumes a constant concentration of potassium in FFM.81 Neutron activation 
involves the use of radiation to cause radioactivity in an atomic cell nucleus. This 
causes the nucleus to become excited and release gamma rays, which can be used 
to measure many elements, including carbon, nitrogen, sodium, and calcium.75 
Body density (Db) is often referred to as a gold standard for body composition 
measurements. Body density measurements include hydrodensity (also known as 
underwater weighing) a technique that estimates body composition using measures 
of body weight, body volume, and residual lung volume. In recent years, the 
hydrodensity has begun to be replaced by air-displacement plethysmography, 
where the subject placed in a closed air-filled chamber rather than in water.75  
DEXA involves the use of two low energy X-ray beams, which provides information 
about body composition based on the differing radioactive absorptive properties of 
tissues. This provides a method of quantifying fat, lean, and bone tissue.75 84 
Other imaging techniques involve assessment of body compartments with 
computer tomography (CT) and magnetic resonance imagining (MRI). Indirect 
assessment methods describe anthropometry and bioelectrical impedance analysis 
(BIA). Anthropometry provides assessments of body mass, size, shape, and 
adiposity through measurement of abdominal circumference, body mass index, and 
skinfold thickness. Although these assessments are simple to perform in clinical 
environments the accuracy is altered by changes in weight. Furthermore, the 
findings describe adiposity, and do not measure hydration or muscle mass. 
These methods of body composition have several practical limitations (expensive, 
time consuming, require specialist equipment and staff) which mainly restrict their 
use to research centres.85-87 In light of these issues, BIA has emerged as a popular 
tool to assess body composition due to characteristics which are comparably 
favourable to other assessment tools. BIA will be discussed in greater depth within 
the next section of the thesis.   
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SECTION 3: BIOELECTRICAL IMPEDANCE ANALYSIS (BIA) 
1.3.1  INTRODUCTION 
The electrical properties of tissues were first described in 1871.88 Thomasett 
demonstrated the relationship of human bio-impedance with TBW.89 Tomasset’s 
studies measured impedance through the use of two subcutaneous needles to 
generate an impedance index (see below) of TBW.89 90 Impedance measurement, 
using a four pole technique was later developed by Hoffer 91and Nyboer.92 In 1969, 
Hoffer et al demonstrated high correlation (r=0.92) between whole body electrical 
impedance and total body water.91 The foundations of BIA were in place by the 
1970s, leading to the publication of key work by Lukaski in 1985, 87 in which BIA was 
validated against reference methods of deuterium dilution and body potassium 
measurement. Further research followed, leading to the development of low cost 
commercial impedance analysers in the 1990s.93 Researchers and practitioners 
were excited about the potential for a low cost, non-invasive, portable method of 
body composition assessment. The BIA method has a 2 to 4% measurement error,94 
which is similar to routine laboratory tests.95 In 1996, the National Institute of 
Health in the USA detailed the need for further standardisation of analysers and 
reference data on the application of BIA technology in practice.96 This was further 
updated in 1999 with an emphasis on improving the science to determine the 
influence of potential confounding factors with BIA assessments.97  
This chapter covers the scientific background and clinical applicability of BIA and 
BIVA. 
1.3.2 THEORECTICAL PRINCIPLES OF BIOELECTRICAL IMPEDANCE 
ANALYSIS 
Living tissue forms a mixture of ionic conductors and inhomogeneous dielectrics 
(diverse electrical insulator that can be polarised by an applied electric field); 
consequently, it functions as a material which has a capacitor-like ability to store 
energy.98 Bioelectrical impedance analysis (BIA) uses this attribute to assess body 
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composition by affecting the physiological flow of ions in response to the 
application of electrical current.99  
The concept of impedance is fundamental to adequately understand non-invasive 
bioelectrical assessments. Ohm’s Law states that the flow of an electrical current (I - 
amperes) passing through two points of a conductor is equal to the voltage drop (V 
- volts) divided by the electrical resistance (R – ohms) between these two points.100 
I = V/R or R =V/I 
This concept is based on the introduction of a direct current into a simple 
conductor with a cylindrical shape. If the current remains constant, the change in 
voltage across the circuit is equal to the change in the resistance to the current 
flow. The application of Ohm’s law to an alternating current creates the concept of 
electrical impedance (Z), or just simply the term ‘impedance’: 
Z = V/I 
In humans, impedance of a physiological electrical circuit consists of two 
parameters: Resistance (R - the opposition of an alternating current through intra- 
and extracellular ionic solutions, representing the real part of Z) and Reactance (Xc 
– the capacitive component of tissue interfaces, and cell membranes and 
organelles, representing the imaginary part of Z).101 Generally, higher R indicates 
more fat mass (and lower body water); whereas healthy lean tissue is characterised 
by lower resistance. Lower Xc indicates a breakdown in a cell membranes’ 
permeability whereas higher Xc indicates healthier tissue. The arc tangent (Xc/R), 
also known as Phase Angle (PA), is a derived measure obtained from the 
relationship between the direct measures of R and Xc (Figure 3).102 The PA is the 
geometrical representation of the phase shift attributable to the measured 
electrical current that is stored by the cell membranes, causing the current to lag 
behind the voltage.103 104  
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FIGURE 3: GRAPHICAL REPRESENTATION OF THE BIOELECTRICAL 
IMPEDANCE ANALYSIS RAW MEASUREMENTS: IMPEDANCE, 
REACTANCE, RESISTANCE AND PHASE ANGLE. REPRODUCED WITH 
PERMISSION.105  
 
 
Several electrical circuits have been used to describe the behaviour of biological 
tissues.93 Examples include the arrangement of R and capacitance in series or 
parallel circuits, whilst other models are more complex. The electrical circuit 
commonly used to describe the bio-impedance model was proposed by Fricke106 
and expanded by Cole.107-109 This model describes an electrical  circuit that is 
representative of anatomical and physical processes which is derived from 
theoretical mathematical equations.101 In the bio-impedance model, the circuit 
describes extracellular and intracellular ionic fluids as parallel resistors (a 
component that determines the flow of electricity in a circuit element) with the cell 
membrane functioning as the capacitor (an electrical component used to store 
electrical charge) (Figure 4).99  
 
R and Xc can be measured over a range of frequencies (most single-frequency BIA 
analysers operate at 50-kHz).93 The volume of intra and extracellular ionic solutions 
is (inversely) related to the R component of Z. The amount of soft tissue structures 
containing the solutions is (directly) related to the Xc component of Z.  At low 
frequencies (<50 kHz), the electrical current cannot penetrate cell membranes and, 
therefore, can be used to predict extracellular water (responsible for R0 of the 
body’s R). At infinite frequency (or very high frequency), the cell membrane acts as 
a (near) perfect capacitor; this allows current to penetrate cell membrane to 
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estimate both intracellular and extracellular fluid compartments (representing Rinf 
of total R).93 110 111  
 
FIGURE 4: DIAGRAM TO ILLUSTRATE THE EQUIVALENT ELECTRICAL 
CIRCUIT TO DESCRIBE THE BIOELECTRICAL COMPONENTS OF A CELL 
 
When a radiofrequency, alternating current, is applied to the body, it is attenuated by water and 
electrolytes in the extracellular (Re) and intracellular (Ri) fluids and characterised as resistance (R). 
The current is stored and released at cell membranes; it is measured as reactance or cellular 
capacitance (Cm). Both resistance and reactance are frequency dependent. Reproduced with 
permission.
99
 
1.3.3 USE OF BIA TO PREDICT FLUID VOLUMES 
BIA is able to predict fluid volumes using the principle that the impedance (Z) of a 
cylindrical conductor corresponds to its length (L), cross-sectional area and the 
applied signal frequency.112 The volume (impedance index) is obtained by means of 
the Nyboer formula:92 Volume = height (H)2/R. Further information about the 
calculation of the impedance index is presented in Appendix 1. 
 
1.3.4 THEORECTICAL IMPEDANCE MODELS 
In order to improve accuracy of the impedance assessment, various models have 
been developed on account of theoretical properties of tissues which may affect 
impedance. Consequently, bio-impedance assessments may consist of either a 
simple assessment at a fixed frequency (i.e. single frequency BIA at 50kHz) or 
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alternative methods. These alternative methods include the Cole-Cole and the 
Hanai methods. 
The theoretical basis of impedance utilises the concept of R0 and Rinf levels of R. 
However, several practical aspects prevent the use of these frequencies of R for 
impedance assessments. The Cole-Cole method predicts the ideal measurement 
frequencies (i.e. the Cole–Cole plot).113 114 In this model R0 represents the R of the 
extracellular fluid and Rinf represents the combined R of ICW and ECW (i.e. TBW). At 
50 kHz, the current passes through both ICW and ECW, although the proportion 
varies depending on the characteristics of tissues.  
Another parallel model, proposed by Hanai,115 acknowledges the effect of ‘mixing’ 
on electrical conduction. Mixing theory predicts that the R of fluids conducting 
electricity increases as the amount of non-conducting material increases. This 
means that electrical current will encounter more resistance as it travels around 
non-conducting material, such as cells in the human body.93 Further assumptions 
(i.e. body density and ratio of intracellular and extracellular resistivities are 
presumed to be constant) are required to extrapolate the in-vitro Hanai formula for 
use in vivo models.116 117Although the intended purpose of modelling is to improve 
accuracy of impedance assessments the improvement seen Cole-Cole and Hanai 
methods may have little advantage over impedance values measured at fixed 
frequencies due to estimation errors in the modelled data.118 
1.3.5 VALIDATION OF BIA 
Extensive validation studies have taken place to evaluate the relationship of BIA to 
both direct and indirect reference body composition methods.93 119 In 1969 Hoffer 
et al91 demonstrated high correlation (r=0.92) between whole body electrical 
impedance and TBW. The foundations of BIA were in place by the 1970s, leading to 
the publication of many validation studies over the following decade. H2/R has been 
found to be a strong predictor of TBW when evaluated against direct reference 
methods assessment. 89 91 120 This index was found to explain 99% of variation of 
TBW in a cross sectional analysis of a mixed heterozygous population 112 (consisting 
of adults, pre-pubertal children, pre-school children and premature low birth-
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weight neonates) and reported to be the best single predictor of TBW or density of 
FFM (dFFM) by multiple regression in validation studies involving specific 
population groups.82 85-87 121-135 Specifically in cancer patients, BIA-derived changes 
in H2/R significantly predict changes in TBW assessed by deuterium dilution. 92 136  
1.3.6 USE OF BIA PREDICTION EQUATIONS 
BIA, as an indirect method of assessment, simplifies the human body as 
one cylinder. However, the body is more accurately described as five anatomical 
cylinders (two arms, two legs and trunk). Differences in body composition occur 
between groups, based on various factors (unaccounted for by the BIA 2C model), 
such as gender, ethnicity, age and body mass index.119 The estimation of the human 
body compartments from BIA requires adjustment using regression analysis, which 
aims to improve prediction accuracy by taking account of factors known to affect 
the BIA 2C model.103 Consequently, greater accuracy of body composition estimates 
are obtained through the addition of variables (e.g. weight, height, age, sex and 
ethnicity) to equations to adjust for potential differences between individuals and 
the relative underrepresentation of the trunk by whole body impedance.112 
Therefore, although H2/R is proportional to TBW it requires refinement (via 
regression equations) to accurately predict volume. These prediction equations 
have been developed using linear regression and adhere to basic assumptions 
including: the shape of the body, the relationship between trunk and leg lengths, 
the level of hydration (as soft tissue hydration is estimated at 73%80) and fat 
fraction.103 No universal equation exists for different populations; therefore, 
specific validated equations need to be selected in reference to the individual’s age, 
ethnicity and the clinical condition being studied.103 Kyle et al119 has summarized 
the prediction equations that are available for use in a variety of populations. All 
equations have been validated against reference methods with good accuracy. 
However, prediction equations are not suitable in situations where the basic 
assumptions of the bio-impedance method are not met. Many cancer patients are 
at extremes of body mass and hydration; therefore, prediction equations are not 
suitable in these patients.103  
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1.3.7 DIFFERENT METHODS OF BIA 
Different methods of BIA are available. The single frequency (SF) is the most simple, 
comprising of an alternating current of 50kHz applied to the participant through 
four electrodes (typically comprising of two hand and two foot electrodes) on the 
skin. The method estimates TBW through the measuring the sum resistance to ECW 
and ICW. SF-BIA is popular because if its simplicity and standardised approach.  
At 50 kHz BIA does not measure TBW but provides a weighted sum of ECW and ICW 
resistivities. The application of prediction equations and mixture theory to the SF-
BIA method facilitates estimation of FFM and TBW; however, it is unable to provide 
detail of ICW volume.93 Furthermore, as the 50-kHz current does penetrate tissue 
completely it is unable to measure entire muscle volume.111 
Multi-frequency BIA (MF-BIA) uses several impedance frequencies i.e. (0, 1, 5, 50, 
100, 200 to 500 kHz) to estimate FFM, TBW, ICW and ECW. MF-BIA is based on the 
principle that the body’s R is dependent on the frequency of the alternating current 
applied. Low frequencies (<50kHz) enable quantification of ECW whereas higher 
frequencies (>200kHz) enables evaluation of ICW volume.137 Empirical linear 
regression models are used to estimate subject results.  
Bioelectrical impedance spectroscopy (BIS) uses a series of frequencies according to 
the principle of the Cole-Cole model113 114 and Hanai formula115 to generate 
relationships between R and body fluid compartments.93 Up to 256 impedance 
frequencies are used to calculate R0 and Rinf frequencies,
111 allowing for the 
prediction of ICW, ECF and TBW volumes.138 139 
Another application of BIA is termed ‘segmental BIA’, which involves use of 
additional BIA electrodes on the limbs in order to evaluate body composition 
specific to a particular segment of the body. This method is to overcome the 
potential variation in assessment attributable to differences in trunk of the body as 
it only contributes 10% to whole body impedance despite representing up to 50% 
of body mass.140 The method may be useful in the evaluation of  conditions 
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associated with anatomically defined fluid shifts, such as post-surgery, renal failure 
and ascites.93 
The main theoretical advantage that MF-BIA and BIS offers compared to SF-BIA is 
that they provide direct quantification of the ICW compartment (rather than 
through estimation of TBW and ECW volumes of SF-BIA) which enables more in-
depth evaluation fluid shifts within different fluid compartments.93 111 However, 
there is disagreement about the reproducibility of these different methods of these 
compared to SF-BIA. There are some discrepancies that emerge from the prediction 
of different fluid compartments according to different clinical scenarios.116 119 This is 
notable with BIS, where outcomes of TBW can vary significantly depending on 
which BIS method is used.141 A potential drawback of all of these models is the 
dependence on formulae and regression equations (typically based on healthy 
individuals) which rely on assumptions about their physiological status. These are 
limited in advanced cancer patients as some of the fundamental assumptions may 
be voided (for example, the individual may be at extremes of weight and hydration 
status).  
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SECTION 4: BIOELECTRICAL IMPEDANCE VECTOR ANALYSIS (BIVA)  
1.4.1 INTRODUCTION  
Further useful information about BIA is possible through analysis of raw bio-
impedance measurements. Piccoli and colleagues have devised an alternative 
assessment method which uses the raw BIA measurements (i.e. Xc, R and PA) to 
generate clinical relevant outcomes.142 This method involves use of mathematical 
multivariate normal distribution and consists of plotting the impedance vector (Z) 
as a bivariate vector from its components (i.e. Xc, R and PA) on the Resistance-
Reactance (RXc) graph, against a known distribution (bioelectrical impedance vector 
analysis – BIVA).103 143 144 BIVA will be further discussed in the next section of the 
thesis. 
1.4.2 PRINCIPLES OF BIVA 
Bioelectrical impedance vector analysis (BIVA), can be compared to the 
electrocardiogram, it uses graphical vectors to provide a visual analysis of BIA 
data.144 Using this method the impedance vector (Z) is plotted as a bivariate vector 
from its components, R (X axis) and Xc (Y axis), after being standardized by height 
(H); this forms two correlated normal random variables (i.e. a bivariate Gaussian 
vector).142 145 Elliptical probability regions of the mean vector can be plotted on the 
RXc plane forming elliptical probability regions on the RXc plane, which are 
tolerance ellipses for individual vectors and confidence ellipses for mean vectors.142 
144 146-148  
1.4.3 THE RXC GRAPH METHOD IN CLINCIAL BIO-IMPEDANCE: 
TOLERANCE ELLIPSES  
Tolerance ellipses (also known as prediction ellipses, or iso-density probability 
ellipses, or confidence ellipses) are the bivariate reference intervals of a normal 
population for an observation. The RXc graph features three tolerance ellipses: the 
median, the third quartile, and the 95th percentile (i.e. 50%, 75% and 95% of 
individual points). This allows for more detailed analysis of vector position than the 
two (75% and 95%) originally used in the first article detailing the RXc graph 
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method.142 This results in the development of a five-point scale by consideration of 
the upper and lower halves of tolerance ellipses that are greater than 50% (Figure 5 
and 6). 
Formulas for the calculation of the bio-impedance confidence and tolerance ellipses 
are presented in Appendix 1. 
FIGURE 5: THE RXC GRAPH WITH 95%, 75% AND 50% TOLERANCE 
ELLIPSES (REPRODUCED WITH PERMISSION)149  
 
 
 
1.4.4 INTERPRETATION OF BIVA USING THE RXC GRAPH 
The statistical properties of the RXc graph allow the following analyses to be 
conducted: 
1) Vector analysis of an individual subject at a defined moment in time (RXc 
point graph). 
2) Evaluation of longitudinal body composition assessment through successive 
measurements in individual patients (RXc path graph - vector migration). 
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3) Evaluation of a group of subjects within a sample (RXc mean graph - 
confidence ellipse of a mean vector).150 
4) Comparison of BIVA patterns for different population groups based on data 
from previous studies (Z score graph).144 
 
1.4.4.1  INTERPRETATION OF INDIVIDUAL VECTOR POSITIONS: THE 
RXC POINT GRAPH  
When assessing an individual, a point bivariate mean vector is placed on the 
reference RXc point graph (chosen from an appropriate reference population for 
the analysis). Plotting the two components R/H and Xc/H as an individual 
impedance vector (a point) on the RXc graph, allows for the  distance from the 
reference mean vector to be ranked through the tolerance ellipses (RXc point 
graph). The point vector position can be evaluated to determine whether this lies 
within the 50%, 75% or 95% tolerance ellipses of the reference population.151 The 
tolerance ellipses can be used to divide the RXc graph into five sections which 
allows hydration status to be evaluated (Figure 6). 
 
1.4.4.2  LONGITUDINAL BIO-IMPEDANCE ASSESSMENTS IN AN 
INDIVIDUAL OVER TIME: THE RXC PATH GRAPH (VECTOR MIGRATION) 
Individual subjects can be followed up over time with successive bio-impedance 
readings. Repeated measurements are plotted successively on the RXc path graph 
to determine variation of the bio-impedance readings over time. Change in vector 
position is termed ‘vector migration’ and provides information of the characteristic 
change in body composition (Figure 7). This can be used to evaluate the clinical 
course of a condition, for example a weight loss programme or haemodialysis 
therapy (Figure 8). 
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FIGURE 6: RXC GRAPH DIVIDED INTO A 5-POINT SCALE ACCORDING TO 
50th AND 75th PERCENTILE TOLERANCE ELLIPSES TO CLASSIFY 
HYDRATION STATUS 
 
 
FIGURE 7: BIVA PATTERNS FOR STEADY STATE AND VECTOR 
MIGRATION USING THE RXC GRAPH 
 
A forward or backward displacement of vectors parallel to the major axis of ellipses was associated 
with dehydration or fluid overloading, respectively, reaching extremes out of the poles. Vectors 
above or below the major axis (meaning upper-left or lower-right half of ellipses) were associated 
with more or less cell mass in soft tissues, respectively, with extremes along the minor axis. Figure 
kindly supplied by the author.
144 152
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FIGURE 8: IMPEDANCE VECTOR MIGRATION ASSOCIATED WITH 
HAEMODIALYSIS DEPICTED ON THE RXC GRAPH 
 
Reference values for an individual vector (thin arrow to the centre of ellipses) are depicted as 50%, 
75%, and 95% tolerance ellipses (male, Italian population).
146
 Solid circles represent vectors at the 
start and the end of the session. Open circles represent vectors after 30 (label a), 60 (label b), 120 
minutes (label c), and in the next days, after 24 (label d), 48 (label e), and 68 hours (label f). The 
vector lengthening during the haemodialysis session is represented by the bold arrow in the 
direction of the major axis. The trajectory followed by vector shortening after dialysis is represented 
by segments of a path still parallel to the major axis of tolerance ellipses. Small, hatched ellipses 
represent the 95% confidence of the mean, pre (lower ellipse) to post (higher ellipse) dialysis vector 
displacement in a large Italian population.
150
 Reproduced with permission.
153
 
 
1.4.4.3  EVALUATION OF A GROUP OF SUBJECTS WITHIN A SAMPLE: 
THE RXC MEAN GRAPH (CONFIDENCE ELLIPSES FOR MEAN VECTORS) 
Mean impedance vectors are useful for the evaluation of a group of subjects from a 
particular population (for example, advanced cancer patients). This vector is 
obtained from plotting the mean components of R/H and Xc/H on the RXc mean 
graph for all the subjects studied. This is an estimate of results that would be 
obtained if the total population (i.e. all patients with advanced cancer) were 
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studied. The 95% confidence ellipse of this vector, will establish the variability in the 
population and the likelihood the true value lies within the confidence ellipse. In 
vector analysis, two mean vectors with non-overlapping 95% confidence ellipses are 
considered significantly different (P<0.05); however, this is not always true vice 
versa (Figure 9). Significance testing can be further evaluated using the Hotelling's 
T2 tests (section 1.4.5). 
 
FIGURE 9: EXAMPLE OF RXC MEAN GRAPH ANALYSIS 
 
Mean vectors of 95% confidence limits patients with cancer compared with controls. Abbreviations: 
CS =control subjects; LDD =cancer patients with locally advanced or disseminated disease; WD = 
cancer patients without disease. Reproduced with permission. 
98
 
 
1.4.4.4  COMPARISON OF BIVA DATA FROM PREVIOUS STUDIES 
In statistics, a standard ‘z-score’ analysis can used to compare a measurement to a 
reference value or population. The ‘z-score’ is the number of standard deviations 
away from the mean value of the reference group.154 ‘Z-scores’ provide information 
about the individual score relative to others in the distribution.155 A clinical example 
of the ‘z-score’ is the standardisation of the differing units reported by bone density 
machines to facilitate the calculation of bone fracture risk.156 Similarly, ‘z-scores’ 
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can be used with BIVA to facilitate standardisation for the different types of bio-
impedance assessments and analysers. This is because the relationship between Xc 
and R is a reflection of the different electrical properties of tissues that are affected 
in various ways by disease, nutritional status and hydration status.93 Therefore, 
transformation of these measurements to ‘z-scores’ to facilitate comparisons 
between different conditions and diseases (from different studies) provided each 
population is evaluated directly against its reference population (Figure 10).144 
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FIGURE 10: DATA DRAWN FROM THE LITERATURE AND PLOTTED ON 
THE RXC-SCORE GRAPH AFTER TRANSFORMATION OF THE 
IMPEDANCE MEASUREMENTS FROM SEVERAL DISEASE GROUPS INTO 
BIVARIATE ‘Z-SCORES’ (WITH RESPECT TO THEIR REFERENCE 
POPULATION). 
 
 
Solid and open circles represent male and female, respectively. A forward or backward displacement 
of vectors parallel to the major axis of ellipses was associated with dehydration or fluid overloading, 
respectively, reaching extremes out of the poles. Single score vectors are from athletes,
157
 obese 
subjects of class I to III
147
 or patients with chronic renal failure in conservative treatment, nephrotic 
syndrome (oedema), lung cancer,
158
 acquired immunodeficiency syndrome in stages WR 3 to 5 or 
WR 6,
159
 and anorexia nervosa.
160
 Repeated score vectors are from climbers before and after high 
altitude dehydration,
161
 Haemodialysis patients, either lean
162
 or obese,
147
 before and after fluid 
removal with a dialysis session, and dehydrated patients with cholera before and after fluid 
infusion.
163
 Vectors above or below the major axis (meaning upper left or lower right half of ellipses) 
were associated with more or less cell mass in soft tissues, respectively, with extremes along the 
minor axis. Abbreviations: CRF = chronic renal failure; HD= haemodialysis; HDo= obese 
haemodialysis patients; HIV= human immunodeficiency virus stages 1-6; Ob/1-3= obese subjects of 
classes I to III; WR= Walter Reed stages 1-6.  Reproduced with permission.
144
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1.4.5 STATISTICAL TESTS FOR THE RXC GRAPH  
The statistical tests used to analyse the RXc graph are outlined below. 
 
1.4.5.1  HOTELLING’S TWO-SAMPLE T2 TEST STATISTIC  
The Hotelling’s two-sample T2 statistic is a multivariate extension of Student’s t test 
for unpaired data to compare mean vectors from two groups. This assumes that 
data is normally distributed but is robust against departures form normality.151  
 
1.4.5.2  HOTELLING’S PAIRED ONE-SAMPLE T2 TEST  
The Hotelling’s paired one-sample T2 test is a multivariate extension of the 
Student’s t test for paired data in comparison of mean difference in vectors in one 
sample only. This is useful for determining difference in vectors on repeated 
measurements in the same subject. This test assesses vector displacement of 
confidence ellipse from the origin (i.e. 0,0 on the RXc graph). A 95% confidence 
ellipse crossing the origin is not statistically significant.151 
 
1.4.5.3  MAHALANOBIS GENERALISED DISTANCE (D) 
Both of the Hotelling’s tests utilise functions of Mahalanobis' generalised distance 
(D), a statistical method to discriminate between groups by accounting for the 
variance of each variable and the covariance between variables. In this case, D uses 
vector variation to compare differences between means within groups.151 
 
1.4.6 CLINICAL APPLICATION OF BIA AND BIVA 
The relationship between Xc and R is a reflection of the different electrical 
properties of tissues that are affected in various ways by disease, nutritional status 
and hydration status.93 Measurement using BIA provides a simple, non-invasive 
method of obtaining assessment of body composition states. The BIA instrument 
consists of a small portable device, which is robust and relatively low cost in 
comparison to other assessment methods which are impractical in routine clinical 
practice.76 BIA provides estimates of fat-free mass, body fat, body cell mass, total 
body water, extracellular water and intracellular water. Consequently, BIA has been 
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used in a wide range of settings and populations (for example sports medicine,110 
paediatrics,164-167 renal medicine95 150 153 168-177 and the elderly82 111 146 178). 
Specifically, impedance analysis has been used for assessments of hydration, 
malnutrition and rehabilitation, metabolism, prognosis and disease assessment.179 
BIA equipment is commercially available, affordable and has been incorporated into 
standard health equipment, such as home weighing scales and exercise machines, 
thus providing the ability to use BIA measurements for health-related outcomes. 
The European Society for Clinical Nutrition and Metabolism (ESPEN) has outlined 
the role and methodological requirements of BIA in clinical practice for a wide 
variety of populations and disease groups.78 119  
As previously discussed, BIA uses simple or multiple regression equations to make 
predictions of masses and volumes of body compartments in subjects with fixed 
and normal 73% hydration of soft tissues.101 However, impedance measurements 
may be inaccurate in situations where these presumptions are not met, for 
example, in abnormal hydration conditions. Additionally, the standard error of the 
estimate of the best BIA regression equations is large (95% prediction interval 
greater than ± 3 to 6 kg or L) which may limit its use in clinical practice.75 180 
Consequently, Piccoli and colleagues devised an alternative assessment method 
which uses the raw BIA measurements (i.e. Xc, R and PA) to generate clinical 
relevant outcomes.142 As these methods are independent of regression equations 
they are able to provide accurate assessments in individuals who fail to meet 
presumptions of standard prediction equations. Firstly, phase angle (PA) has been 
utilised as a prognostic marker in various patient groups, including: Human 
Immunodeficiency Virus (HIV),181 182 dialysis patients,169 183 184, breast cancer,185 lung 
cancer,186 187 colorectal cancer,188 mixed advanced cancer189 and pancreatic 
cancer.190 In these studies, a lower phase angle is associated with worse prognosis.  
PA has been found to be a sensitive indicator of overall health with a high 
correlation found between PA and other comorbidities.191 In lung cancer, the PA 
was closely associated with tumour volume.192 Lower PA was associated with 
increased fatigue and poorer muscle endurance in advanced cancer patients.193 In 
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one study, a PA value less than the 5th percentile was found to be an independent 
predictor for impaired nutritional status, poor physical function and shorter survival 
in cancer patients.194 PA is reduced in haemodialysis patients and those with renal 
transplants when compared to normal populations.175 195 In HIV, PA is linked to 
disease severity, with lower values significantly correlated to worse disease.196-198 
PA has shown significant inverse correlation with nutrition markers, such as pre-
albumin and albumin.183 184 Additionally, PA has been found to be significantly 
lower in malnourished children, and showed a good correlation with other 
anthropometric measures.167 Furthermore, PA shows linear correlation with items 
of the subjective global assessment (SGA) tool, a malnutrition identification tool, 
with lower phase angles observable in severely malnourished patients.165 199  
Overall, the literature illustrates how PA appears to relate to morbidity and 
mortality in several clinical conditions, but there is a lack of standardized cut-off 
values for comparison. Future studies may also show its usefulness in monitoring 
nutritional interventions. By way of contrast there is a lack of data from cancer 
populations.105 Cancer (and other wasting diseases) reduces ICW through cachexia, 
such that the TBW derived from equations for normal populations will become less 
accurate.200  
The advantage of BIVA is that it allows information to be obtained simultaneously 
about changes in tissue hydration or soft-tissue mass, independent of regression 
equations, or body weight. This allows for accurate interpretation of BIVA readings 
even if patients are at extremes of weight or volume distribution. When the R and 
Xc are plotted graphically after standardising for height, different 
disease/conditions appear to form distinct clusters (figure 10). Consequently, BIVA 
measurements can be compared with reference populations to enable comparisons 
with healthy populations and other diseases.144 BIVA has been used to study 
hydration in a variety of different diseases (e.g. renal failure, cholera, congestive 
cardiac failure),95 98 158 163 201-205 and to undertake general body composition 
assessments in lung cancer98 158 and cancers of the head and neck.206 These studies 
provide many examples of how BIVA has been used to facilitate comparisons in 
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patients using the features of the RXc graph. Changes in the shape and direction of 
plotted vectors (vector migration) on repeated measurements in the same 
individual allow change in hydration status over time to be recorded.103 150 BIVA has 
been used in this way to assess longitudinal change in hydration in oedematous 
patients receiving haemodialysis.150 173 However, it is important to note that 
although BIVA is capable of detecting fluid imbalances it is unable to quantify actual 
fluid volumes of compartments.207 
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SECTION 5: HYDRATION IN CANCER 
1.5.1 INTRODUCTION TO THE SYSTEMATIC LITERATURE REVIEW 
A systematic literature review of the clinical methods of assessing hydration in 
advanced cancer (physical examination, symptom assessment and biochemical 
measures) is presented in this section of the thesis. In addition, this review will 
critically appraise the evidence about dehydration-related symptoms that are 
associated with advanced cancer. BIA was evaluated to examine its potential use in 
the assessment of hydration. The section concludes with a discussion of the 
possibilities for future research based on the strengths and limitations of the 
evidence base. 
This systematic review has helped to inform the development of this study. A 
preliminary version of this review was published in the Journal of Pain and 
Symptom Management.105 This thesis will further build on this literature, using the 
published systematic review as a basis. This text has been modified for production 
in this thesis with permission from the publisher. The literature was searched 
between August 2012 and December 2013. Four electronic databases were 
searched (Medline, Cochrane Database of Systematic Reviews, Cochrane Central 
Register of Controlled Trails and Scopus) using combinations of the keywords which 
were combined in a systematic fashion (Table 1). The search was limited to English 
language literature published between 1960 – 2013. The search strategy for 
Medline is shown in Table 1 and was adapted for other databases.  
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TABLE 1: SEARCH STRATEGY APPLIED TO RECEIVE PAPERS FROM 
MEDLINE 
Query number  Query content 
#1 (((palliative care) OR hospice) OR terminally ill) OR terminal care 
#2 (((cancer) OR neoplasms) OR tumour) OR carcinoma) OR malignancy 
#3 dehydration 
#4 (water-electrolyte balance) OR fluid balance 
#5 bioelectrical impedance 
#6 #1 AND #2 
#7 #3 OR #4 
#8 #5 AND #6 
#9 #6 AND #7 
#10 #8 OR #9 
#11 Limit #10 to Humans and English language 
 
Bibliographies of relevant articles were manually searched to identify further 
articles for potential inclusion. Additionally, a hand search of the most recent issues 
(January 2010 to December 2013) of 12 relevant peer-reviewed journals was 
conducted (Table 2). 
TABLE 2: PEER REVIEWED JOURNALS SEARCHED AS PART OF REVIEW 
OF LITERATURE 
Journal of Pain and Symptom Management BMJ Supportive and Palliative Care 
Journal of Palliative Care Journal of the American Medical Association 
(JAMA),   
Palliative Medicine Annals of Internal Medicine 
Journal of Palliative Medicine Lancet Oncology 
New England Journal of Medicine Nutrition 
British Medical Journal (BMJ) American Journal of Clinical Nutrition. 
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Abstract data from five conferences was searched; this consisted of abstracts from 
the previous three years (2000 – 2013) published in the American Academy of 
Hospice and Palliative Medicine (AAHPM) conference, the European Association of 
Palliative Care (EAPC) conference, the Palliative Care Congress, the International 
Congress of Palliative Care and the Marie Curie Research Conference. In order to 
obtain further information about the grey literature abstracts, which were selected 
for inclusion in this study, the authors of these studies were contacted and asked to 
provide more information about the research in question. Further details of studies 
included in this review are presented in the Appendix 2.  
1.5.2 SELECTION CRITERIA 
The selection process for articles in the review is described in this section. A 
stepwise procedure was used to identify relevant studies. Studies addressing 
hydration assessment (physical examination, biochemical measures, symptom 
assessment, and bioelectrical impedance) in advanced cancer patients were eligible 
for inclusion in the review. For the purposes of this review, advanced cancer was 
defined as; a diagnosis of cancer where no further curative treatment is possible, 
which may be associated with metastases (histological or radiological). Articles 
were excluded if the studies were not in English or primarily reported paediatric 
populations.   
1.5.3 RESULTS 
Results of the literature search are summarised in Figure 11. The initial literature 
search using the keywords outlined in the Methods section returned 338 articles. A 
total of 316 of these articles were rejected after the review of the abstract as not 
relevant. The remaining 22 articles were examined by our inclusion and exclusion 
criteria. Three articles were excluded as they primarily reported non-cancer 
populations, resulting in the inclusion of 19 studies in the review. Details of the 
included studies are presented in appendix 2.  
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FIGURE 11: OVERALL SELECTION PROCESS FOR STUIDES INCLUDED IN 
THE REVIEW 
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1.5.4 DEHYDRATION DEFINITIONS AND PHYSIOLOGY IN CANCER  
Cancer is defined as an uncontrolled proliferation of cells that express varying 
degrees of fidelity to their precursors.208 Physiologically, dehydration has been 
defined as total body water (TBW) deficit, which is predominantly intracellular. 209 
This process is associated with hypernatraemia; with elevated serum osmolarity, 
which in turn stimulates the sensation of thirst from the thirst centre.210 This 
pattern may not be observable in advanced cancer, due to differences in fluid 
requirements and disease pathophysiology, when compared to non-cancer 
populations.200 211 In cancer, intracellular dehydration is associated with proteolysis 
and cachexia212 213 and leads to an increase in antidiuretic hormone (ADH) through 
stimulation of osmoreceptors or from direct release from the tumour.214 215 
Furthermore, weight loss, decreased renal perfusion and cachexia are associated 
with a loss of intracellular water and solutes affecting hypothalamic osmoreceptors, 
which in turn stimulates ADH release.216 ADH increases the water permeability of 
the distal tubule and collecting duct in the kidney, promoting water absorption and 
the maintenance of serum osmolarity and sodium at subnormal levels. 
Consequently, an abnormally low osmolarity may cause symptoms such as nausea, 
and confusion, which have been associated with dehydration.211 
In advanced cancer, hyponatremia is more common than hypernatremia.200 210 
Hyponatremia results from sodium loss in excess of water, resulting in a low sodium 
and serum osmolarity.210 Medications such as selective serotonin reuptake 
inhibitors (SSRIs) and non-steroidal anti-inflammatory drugs (NSAIDs) are 
associated with hyponatremia and are frequently given to cancer patients for 
symptom management.217 218  
Dying cancer patients may achieve adequate hydration with much lower volumes of 
water than that are recommended for the average medical and surgical patient.211 
This is likely to result from differences in body composition, such as a lower body 
weight due to cachexia and decreased clearance of free water caused by a variety 
of mechanisms. For example, patients with advanced cancer may have reduced 
insensible water losses due to a reduction in their physical activity. As hydration 
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studies are generally based on non-cancer populations, the subsequent research 
findings may not extrapolate to cancer patients.219 As a consequence, definitions of 
cancer dehydration vary throughout literature, with authors using different 
combinations of clinical parameters as diagnostic criteria.209 210 220 209 The lack of 
uniformity in definitions complicates study comparisons219 and makes decisions 
regarding the use of CAH difficult for clinicians. There is a need for further study in 
this area to address the limited research base. 
1.5.5 PHYSICAL EXAMINATION AND SIGNS OF DEHYDRATION  
Dehydration predominantly describes an intracellular process; however, the clinical 
assessment of hydration, through the process of physical examination, is a measure 
of the extracellular fluid compartment (i.e. extracellular water content (ECW); skin 
turgor, jugular venous pressure (JVP) and pulse).200 Consequently, clinical 
assessment is unable to diagnose intracellular dehydration.210 There are no routine 
bedside technologies that measure fluid in the intracellular space.221 Authors have 
attempted to address the issue by differentiating dehydration defined 
physiologically, from that derived from subjective clinical assessment.222 223 
Consequently, the term clinical dehydration is used to include all types of fluid 
deficit as they appear in the clinical setting.219 Therefore, conflict exists between 
the clinical experience of dehydration, compared to the biochemical and 
physiological definitions of dehydration commonly found in the literature.224 
Non-cancer studies have found certain variables to correlate with dehydration 
(defined clinically and biochemically) in elderly populations, these include: tongue 
dryness, longitudinal tongue furrows, dry mucous membranes, upper body muscle 
weakness, confusion, speech difficulty, sunken eyes,225 dry axilla,226 a fall in systolic 
blood pressure, decreased sternal skin turgor and low body mass index (BMI).219 
Based on the outcomes of these studies, Morita et al227 developed a dehydration 
score consisting of three variables (dryness of oral mucous membranes, axillary 
moisture and sunkeness of eyes) for use in cancer patients. This score was used to 
assess dehydration (in addition to assessments of delirium and peripheral oedema) 
in a study evaluating the association between CAH volume and symptoms in 
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terminally ill cancer patients with abdominal malignancies.227 Dehydration scores 
were significantly lower in the patients receiving CAH in the last 3 weeks of life 
compared to the non-CAH group; however, use of CAH was associated with 
increases in peripheral oedema. No significant difference in hyperactive delirium, 
communication capacity, bronchial secretions, agitation, myoclonus or serum 
biochemistry was evident between the two groups. A similar study, by the same 
author, studied the relationship between laboratory findings, artificial fluids, fluid 
balance and clinical measures of dehydration in terminally ill patients with 
abdominal cancer.228 The authors found no statistically significant difference in the 
fluid balance in patients with an increased clinical dehydration score compared to 
those without.228 Bruera and colleagues229 conducted a randomised controlled 
double blind trial involving dehydrated cancer patients receiving CAH. The authors 
found that myoclonus and sedation were reported less in the CAH group compared 
to placebo. However, these findings were not reproducible in a follow-up study by 
the same author230 or in a study by Morita et al227 which evaluated communication 
capacity and myoclonus as outcomes for cancer patients receiving CAH. 
There is conflict over the accuracy of physical findings in the assessment of 
hydration in advanced cancer. Skin turgor has been shown to poorly correlate with 
fluid deficit193 and clinical dehydration208 as cancer patients are prone to changes in 
subcutaneous tissue which may create inaccuracy in its interpretation.210 225 
Postural hypotension is identified as a feature of hypovolaemia (low blood volume), 
but lacks sensitivity as a test for dehydration.231-233 This highlights how different 
definitions of dehydration may create difficulty in interpreting study outcomes. 
Furthermore, postural hypotension may not be suitable in assessing some advanced 
cancer patients who are at risk of poor mobility, falls and taking medications known 
to cause hypotension, e.g. opioids and diuretics.234 235 Variations in body mass 
caused by cachexia and oedema may make BMI measurements unsuitable.200 210 236 
237 Although part of a standard medical examination, capillary refill is only able to 
detect hypovolaemia in children and lacks sensitivity in adults.231 238-240 
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1.5.6  BIOCHEMICAL MEASURES OF HYDRATION IN CANCER  
Biochemical tests include the analysis of blood (obtained from venepuncture) and 
urine samples. A change in urine and blood chemistry provides clues to the 
underlying cause of hydration disturbances and helps the clinician identify potential 
treatments.  Measures such as serum urea:creatinine ratio and urine:plasma 
osmolality ratio have been used to assess hydration status with ratios of ≥100 
(mmol/mmol) and  ≥1.2 respectively suggesting dehydration.209 210 219 241 242 
Biochemical dehydration occurs when intracellular water is lost, leading to 
transmembrane water migration from the intravascular compartment under 
osmotic pressure and increased relative plasma sodium concentration.210 243 244 
Electrolyte abnormalities, such as hyperkalaemia may suggest underlying causative 
factors of dehydration and may be useful prognostic indicators.245 Atrial naturietc 
peptide (ANP) level <15pg/ml has been used to define dehydration in palliative 
patients;246 however, the validity and reliability of this measure has not yet been 
determined. Observational studies have found that biochemical measures of 
dehydration poorly correlate with symptoms, such as thirst and dry mouth.247 
Biochemical investigations are performed for various reasons, including clinical 
monitoring in advance of medical procedures and assessment in response to 
change in the clinical condition of a patient. In these circumstances, abnormal renal 
function may prompt the clinician to consider the initiation of CAH; however, 
studies have shown that patients with advanced cancer may be prone to renal 
impairment at the end-of-life. The prevalence of pre-renal failure in cancer 
inpatients was 44% (n=27/62) in a study by Guo et al;248 no difference in length of 
stay was evident between patients with renal failure compared to those with 
normal renal function. Biochemical measures alone may not be able to detect 
clinically meaningful hydration changes in cancer patients, especially if 
measurements are performed without a record of the patient’s baseline renal 
function for comparison.  Authors have demonstrated worsening renal function in 
cancer patients approaching death, irrespective whether CAH is administered or 
not.227 228 249 Therefore, in advanced cancer, static abnormal renal function 
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measurements may provide incomplete assessments of hydration status.223 A 
prospective study by Waller249 and colleagues examining hydration indicators in 
patients found 87% (n= 59/68) of dying patients were biochemically dehydrated. No 
difference in serum biochemistry or consciousness was found between patients 
receiving intravenous fluids compared to those who received no fluids.  The authors 
concluded there was no clinical benefit to the administration of intravenous fluids 
in terminally ill cancer patients.   
1.5.7 SYMPTOMS OF DEHYDRATION  
Previous research has attempted to determine if symptom burden is related to 
dehydration and, consequently, whether the use of CAH improves these symptoms. 
The first quantitative estimate of dehydration symptoms in advanced cancer was 
conducted by Burge et al250 in 1993. This study involved a cross-sectional analysis of 
dehydration symptoms of 52 palliative cancer patients. A series of 100mm visual 
analogue scores (VAS) were used to evaluate the severity of seven symptoms 
(thirst, dry mouth, bad taste, nausea, pleasure in drinking, fatigue and pain) 
experienced by patients. Fatigue was the most severe symptom (65% rated greater 
than 50mm); dry mouth and thirst were also very prevalent (53.8% and 60% rated 
greater than 50mm respectively). The study found no association between 
symptom severity and fluid intake or between biochemical measures and thirst, a 
finding consistent with other studies.225  
Cerchietti et al251 demonstrated improvements in thirst and chronic nausea in 
symptomatic palliative cancer patients with limited oral intake, randomised to 
receive either CAH or standard medical therapy. Significant improvements in relief 
of thirst and chronic nausea were present in both groups at 24 hours; however, this 
effect was only maintained in the hydration group at 48 hours. Studies assessing 
oral symptoms and dehydration have found mixed results. Dry mouth and thirst 
were highly prevalent in a study of 82 palliative cancer patients at risk of 
dehydration.247 Of the 23 (28%) patients able to respond to the questions, 20 (87%) 
reported dry mouth and 19 (83%) complained of thirst. No association between 
thirst, dry mouth, respiratory tract secretions and biochemical dehydration was 
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found. Similarly, in a cohort of 88 palliative patients, Morita et al246 found thirst to 
be highly prevalent, but poorly associated with dehydration. Interestingly, the 
authors found thirst was associated with water depletion (defined by atrial 
natriuretic peptide). However, a lack of validity and reliability of ANP and the 
arbitrary cut-off level defined by the authors may indicate this area requires further 
study before definitive conclusions are drawn.  
Several studies have found no association between CAH and symptoms. Musgrave 
et al252 evaluated the effect of CAH on the sensation of thirst in 30 terminal cancer 
patients. Nineteen patients were able to communicate thirst intensity, but no 
association between level of thirst, intravenous fluids and biochemical parameters 
was demonstrated. Similarly, Yamaguchi et al,253 in a multicentre prospective 
observational study of 161 advanced cancer patients receiving CAH, found no 
significant difference in symptomatic burden between patients receiving high 
volumes (>1litre/24hours) compared to those receiving lower fluid volumes 
(<1litre/24hours). Additionally, Bruera et al230 found no statistically significant 
difference in symptoms, quality of life or survival between patients receiving 
1000mls of 0.9% saline daily compared to placebo (100mls daily) in 129 cancer 
patients recruited from six hospices. There is little evidence to support the role of 
CAH in the management of delirium in advanced cancer.254 255 A statistical analysis 
of hospital inpatient data, of 1125 advanced cancer patients, failed to demonstrate 
a relationship between hydration and delirium;256 this is a similar finding in other 
studies.227 251 253 However, hyperactive delirium was found to be more prevalent in 
patients with advanced abdominal cancers, receiving small volumes of CAH 
(<1litre/day), compared to patients receiving larger volumes (>1litre/day).253 
Previous studies have highlighted the potential that CAH may cause adverse effects 
in dying patients. Nakajima et al257 explored the influence of hydration on 
symptoms in a series of 75 patients with advanced abdominal cancer. The study 
found CAH improved oral membranous signs of dehydration but worsened 
peripheral oedema, ascites and chest secretions. Recently, Fritzson et al258 reported 
an association between dyspnoea and intravenous fluids in a retrospective analysis 
of 251 hospice inpatients receiving end-of-life care. Patients had a variety of 
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diagnoses with cancer most prevalent (n=194; 77.3%). Compared to controls, higher 
dyspnoea scores were reported for patients receiving larger CAH volumes 
administrated in the last 24 hours and seven days of life.  
1.5.8 USE OF BIA AND BIVA IN ADVANCED CANCER  
The clinical application of bio-impedance methods is discussed in section 1.4.6. The 
characteristics of bio-impedance analysis (e.g. portable and non-invasive) are 
favourable for the study of hydration in advanced cancer. Previous studies have 
used the technology to evaluate hydration in advanced cancer. Simons et al83 
evaluated the applicability of BIA to predict TBW (deuterium dilution, ∆-TBWdeu) in 
16 underweight and 25 normal weight cancer patients. The authors found that 
although H2/R was a strong predictor of ∆-TBWdeu, the use of prediction equations 
overestimated ∆-TBWdeu in underweight patients. The authors conducted a further 
study in 33 cancer patients using BIA to compare changes in H2/R correlated with 
changes in ∆-TBWdeu over a 12 week period.136 Changes in ∆-TBWdeu occurred in 
both directions (mean +0.2 +/- 1.6 L, range -3.3 to +3.1 L) and were significantly 
predicted by changes in H2/R (r2 = 0.43, P < 0.0001, SEE = 1.22 L), although precision 
was poor (residual SD = 1.2 L). The authors conclude that in underweight and 
normal-weight cancer patients, BIA-derived changes in H2/R significantly predict 
changes in total body water assessed by deuterium dilution. 
Recently, Davis et al200 performed a prospective observational study, using BIA, in 
patients with advanced cancer receiving CAH. BIA was done for 3 consecutive days 
from initiation of CAH. The authors found that a greater PA on day 1 of CAH 
predicted better survival; however, a rise in PA (indicating increased reactance and 
the distribution of fluid to the intracellular compartment) during CAH predicted 
shorter survival. The authors propose that an increase in PA during CAH reflects 
pre-existing intracellular dehydration, which occurs in patients who are more likely 
to have cachexia-anorexia syndrome, and hence, a worse prognosis compared to 
those without a PA rise during CAH. This may suggest that PA may be able to assist 
in prognostication and may highlight underlying physiological differences between 
cancer patients receiving CAH. Crawford et al259 used BIS to show that elevated 
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metabolic rate and accumulation of body fluids were indicators of poor prognosis in 
a series of palliative cancer patients. Although interesting, these recent studies 
focus on survival and do not explore issues regarding hydration assessment or the 
appropriateness of using CAH in these patients. To date, BIVA has yet to be used to 
specifically assess hydration in advanced cancer. Consequently, BIVA may provide a 
way to assess and monitor change in hydration over time in advanced cancer 
patients. 
1.5.9 MAIN FINDINGS OF THE REVIEW 
Clinical examination and biochemical tests are standard methods of assessing 
hydration, but limitations exist with these methods in advanced cancer.  For 
example, physical examination has a low sensitivity and specificity for identifying 
fluid deficit.210 260 Study outcomes are often conflicting and many variables lack 
evidence for their inclusion in assessing hydration status in adult cancer patients. 
Historically, evidence regarding hydration assessment originates from studies in 
non-cancer populations and particular components of a physical examination (e.g. 
capillary refill, skin turgor) appear to have less significance in advanced cancer. 
Equally, there is disagreement about the most appropriate biochemical tests and 
the diagnostic criteria to determine biochemical dehydration. The differences 
between local, national and international definitions of dehydration may cause 
clinicians to be unsure about the significance of biochemical results in advanced 
cancer patients. 
BIA is able to assess body composition and has been used as a prognostic marker in 
cancer studies.185 186 188 190 One study demonstrated PA increase in patients 
receiving CAH was associated with increased mortality.200 This may suggest cancer 
patients differ physiologically in their ability to handle fluids, with some more prone 
to adverse effects than others. The study is limited by small numbers of patients 
and a lack of standardisation of the type of fluid prescribed and the rate of volume 
replacement. If a true difference exists this may highlight the importance for 
clinicians to consider these factors when administering CAH. Furthermore, studies 
using bioelectrical impedance may potentially be a tool to enable clinicians to 
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better understand hydration in advanced cancer. BIA alone is limited in its ability to 
assess hydration in advanced cancer;103 however, interpretation using a vector 
analysis (BIVA), improves the accuracy of measuring static and dynamic hydration 
states.144 201 202 The non-invasive nature of the technology may be popular for 
researchers keen to utilise novel methodologies for assessing hydration in advanced 
cancer.  Consequently, BIVA shows promise as a method for assessing hydration 
and could be potentially used to further scientific study into the relationship 
between hydration and related symptoms. However, further study is required to 
establish whether measurements of fluid distribution in advanced cancer, as 
determined by BIA and BIVA, are clinically relevant. 
Several factors limit the viability of clinical and biochemical assessment techniques.  
For example, the elderly (which comprise the majority of cancer patients) may have 
abnormal biochemical profiles secondary to non-hydration related factors, such as 
altered muscle mass and pre-existing renal or metabolic conditions.211 Repeated 
venepuncture may cause pain, discomfort and be viewed as inappropriate for use, 
in the assessment of cancer patients, in certain circumstances (for example, in the 
dying phase).261 262 Consequently, clinicians may avoid performing venepuncture in 
situations where the risks of causing harm may outweigh the benefits of obtaining 
biochemical tests. In this review, we highlighted the concept of clinical dehydration 
defined by bedside physician assessment. Clinicians may argue that there is little 
utility in identifying biochemical dehydration in a patient without symptoms, hence, 
only clinically relevant signs and symptoms of (de)hydration will be managed; 
however, in this population, there is a lack of agreement of which signs and 
symptoms are clinically relevant. Additionally, without an understanding of the 
pathophysiology of disease and its resultant symptoms there is a risk that features 
of dehydration may be inaccurately interpreted and hence, inappropriately 
managed. Therefore, it is important for dehydration in cancer to be appropriately 
defined to enable associated signs and symptoms to be identified, thus allowing 
appropriate management to be initiated. For example, various symptoms have 
been used as indicators for dehydration, but there is disagreement about the 
accuracy of these. There is some evidence to suggest that nausea is improved 
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through the administration of CAH.229 However, the association of nausea with 
hydration (and other variables) has not been clarified. Despite a high prevalence of 
fatigue,250 the use of CAH does not appear to improve this symptom in cancer 
patients.229 Dry mouth and thirst are common in cancer; however, these variables 
may be unreliable indicators of (de)hydration due to their association with other 
factors.247 250 252 263 264 One study suggests the significance of thirst when serum ANP 
is used to define dehydration, but the validity and reliability of this measure has not 
yet been determined.246 Despite a greater prevalence of hyperactive delirium in 
patients receiving reduced volumes of CAH compared to larger volumes,253 the 
evidence is poor for the influence of hydration on delirium in advanced cancer.254 
256 Overall there is a lack of clinical assessment tools to evaluate hydration in 
advanced cancer, and unclear data about which symptoms are most related to 
dehydration. These findings, combined with the unclear benefits and burdens of 
CAH, make decisions about the use of CAH challenging for healthcare professionals. 
1.5.10  WHAT THIS REVIEW ADDS 
This review is unique in highlighting the potential of BIVA to assess hydration in 
advanced cancer patients. We have identified a lack of evidence relating to the 
assessment and symptomatic treatment of dehydration in cancer; a finding 
consistent with similar studies in this area.  
1.5.11  LIMITATIONS 
We recognise there are several limitations with this review. Although hand 
searching of relevant journals and grey literature took place, this was limited to the 
past 3 years and the abstract lists were unavailable for some conferences; 
consequently, there is the potential that data was excluded from this review. 
Although a structured process for identification and inclusion of articles was 
adopted, the reviewers were not blinded to the authors and institutions of the 
reviewed articles. Consequently, there is risk of the reviewers’ own bias relating to 
articles included or excluded from the review. Many of the included studies were 
small, descriptive, under-powered studies with differing definitions of dehydration. 
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These diagnostic definitions may have been based on biochemical criteria, clinical 
markers or a combination of both; therefore, comparisons between the studies are 
difficult. Studies involving patients with advanced cancer present ethical and 
methodological challenges that are compounded by the difficult issue of 
(de)hydration. It can be argued that researchers and ethics committees are still 
learning about suitable approaches for this subject, which will limit the number of 
high quality research studies. BIA and BIVA has been used to assess body 
composition in several populations; however, there is a lack of studies using this 
technology to report on clinically relevant outcomes (for example, symptoms 
burden, survival and the effect of CAH on these parameters) in advanced cancer. 
Additionally, we were unable to identify any literature reporting on the use of BIVA 
to evaluate hydration in advanced cancer. The intervention studies involving CAH 
used various routes of administration, different fluid preparations, over differing 
time periods at different stages of the subjects’ illness. Although the outcomes of 
these studies are interesting, the lack of harmony between methodology and 
outcomes limits the ability of this review to synthesise data.  
A lack of consensus of how to assess hydration in advanced cancer makes decisions 
regarding the use of CAH difficult for the clinician. Further complexity is added due 
to the limited number of high quality studies assessing the benefits and burdens of 
CAH for this population. This review has highlighted how advanced cancer patients 
may experience some benefits from receiving CAH, such as improvements in 
sedation, myoclonus and nausea.229 251 However, there is the potential to cause 
harm, in terms of worsening symptoms of fluid retention (e.g. dyspnoea, peripheral 
oedema, pleural effusion, ascites).63 68 253 258 On the basis of insufficient evidence, 
we are limited in our ability to draw definitive recommendations. Clinicians are 
therefore advised to make assessments based on the perceived benefits, risks and 
burdens to the individual.25 The clinician should be familiar with existing methods of 
hydration assessment and be aware of their limitations. 
Currently, no studies have used BIVA for the assessment of hydration in advanced 
cancer patients. Pilot studies using BIVA are required to determine its feasibility and 
efficacy before conclusions can be draw. If feasible, BIVA may have a role in 
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evaluating hydration in advanced cancer and improving knowledge of hydration in 
dying patients. BIVA could be used in combination with other hydration assessment 
methods to determine the scientific association of symptoms with dehydration, 
facilitating the creation of core-outcome measures for hydration, which can further 
support intervention studies using CAH. Consequently, future studies could use BIA 
and BIVA to determine its usefulness in predicting and monitoring clinical response 
to treatments (such as CAH) and survival through static and longitudinal 
assessments. 
1.5.12  SUMMARY OF CHAPTER 
There is a lack of evidence concerning the association of clinical symptoms and 
physical signs with hydration states in advanced cancer. Additionally, there is a lack 
of evidence concerning value of clinical interventions, such as CAH, in the 
management of fluid-related states of advanced cancer.  
This review highlights the potential value of BIVA, a validated method of assessing 
body composition, in the assessment of hydration. BIVA shows promise as a 
hydration assessment tool but requires further study in advanced cancer. 
Innovative methodologies for research are required to add to the evidence base 
and ultimately improve the care for the dying. 
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CHAPTER 2: MATERIALS AND METHODS 
This chapter describes the technical processes that were necessary for the project 
to be conducted. Firstly, we begin with a description of the study population and 
the research setting. The chapter then outlines the research management and 
governance issues. The experimental design of the study is highlighted, through the 
outline of the methodology, data collection tools and the research schedule. The 
chapter concludes with presentation of the statistical analysis plan. 
 
SECTION 1: DESCRIPTION OF THE STUDY POPULATION AND THE 
RESEARCH ENVIRONMENT 
2.1.1 STUDY POPULATION 
The study population for this project involved adults affected by advanced cancer 
receiving care in the Marie Curie Hospice Liverpool (MCHL). Advanced cancer was 
defined as a histological or radiological diagnosis of cancer which was  incurable. 
Participants were recruited according to the following eligibility criteria. 
2.1.2 ELIGIBILITY CRITERIA 
The eligibility criteria for entry into the study are listed below: 
2.1.2.1  INCLUSION CRITERIA 
- Admitted to the Marie Curie Hospice Liverpool (MCHL) from December 2013 
onwards. 
- Aged 18 years or above. 
- Known diagnosis of cancer (proven by histology or radiological imaging). 
- No further curative treatment possible. 
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- Able to understand and communicate in English (this may be through the 
use of communication aides and/or interpreter). 
- Serum urea and creatinine recorded by the clinical team in the previous 72 
hours. 
2.1.2.2  EXCLUSION CRITERIA 
- Patients with implantable defibrillator devices. 
- Patients unable to provide fully informed consent.  
- Active transmissible infections (including, Methicillin-resistant 
Staphylococcus aureus (MRSA), Clostridium Difficile Toxin (CDT) and  
Norovirus infections). 
- Receiving clinically assisted hydration (CAH) at time of assessment. 
- Currently receiving antineoplastic treatment. 
Participants were enrolled to the study providing they met the above eligibility 
criteria and were able to provide informed consent. BIA is safe, non-invasive with 
no history of adverse events. The use of BIA is not recommended in patients with 
implantable pacemakers as these devices are untested with the BIA technology. 
Only subjects who were able to provide full consent (with understanding of the 
reason for participation in the study and the potential risks and benefits) were 
included. Every effort was made to accommodate patients unable to communicate 
orally in English within the study, through individual assessment of the need for 
communication support for each participant. Patients with active transmissible 
infections were excluded, due to the risk of contamination of the research 
equipment resulting in subsequent transmission to other participants. These 
individuals would be eligible to participation once they were free of infection and 
deemed suitable (and able) to participate by the clinical team.  
All study participants were receiving specialised palliative care but were not 
necessarily at the end of their lives. All participants were free from antineoplastic 
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treatment and were not receiving clinically assisted nutrition or hydration at the 
time of assessment. 
2.1.3 DESCRIPTION OF THE RESEARCH SETTING 
The MCHL is a 30 bedded specialist palliative care unit situated in North West 
England and provides inpatient, outpatient and day care services. Specialist 
palliative care is provided for a broad range of palliative problems for a 
predominantly Caucasian population of approximately 890,971.265 Patients are 
admitted directly from community and/or hospital settings. Inpatients are reviewed 
daily by the medical team, which is led by a consultant in palliative medicine. All 
patients receive individualised supportive therapies and, if necessary, medical 
interventions. The hospice mainly cares for metastatic cancer patients (of various 
subtypes) but also cares for non-cancer patients (prevalence approximately 66% vs. 
34% respectively).266 Approximately, the length of stay for patients is two weeks; 
60% of patients are discharged, either to their own home or an alternative care 
facility. In the calendar year of 2012, the MCHL received 853 unique referrals for 
either inpatient, outpatient or day therapy care services.267 This included 740 
inpatient admissions (comprising of 387 patients) and 259 (67%) deaths.267  
The MCHL is integrated with the Marie Curie Palliative Care Institute Liverpool 
(MCPCIL), a partnership comprising of the MCHL, the University of Liverpool and 
the Royal Liverpool University and Broadgreen NHS Hospitals Trust.268 This 
relationship helped facilitate the development of the research infrastructure, which 
was necessary to conduct the study.  
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2.1.4 DEVELOPMENT OF A RESEARCH INFRASTRUCTURE IN THE 
HOSPICE SETTING 
Several factors create difficulties when attempting to conduct a research project 
with a hospice. This includes a lack of a research infrastructure within the 
institution, limited research personnel and, importantly, the absence of an over-
seeing research governance structure. Consequently, a formal plan to develop a 
research structure in the hospice was undertaken as part of this study, in order to 
facilitate the conduct of this research (and proposed future work) within the 
hospice setting. The research infrastructure involved the development of the 
following: 
Staff involvement 
A series of meetings were held with members of the multi-disciplinary teams 
providing care for patients in the hospice. These meetings provided the researcher 
with an opportunity to meet with staff members to introduce himself and the 
project, whilst providing explanations of the methodology, protocol and practical 
demonstrations of the equipment. 
Research in the Hospice 
Prior to commencement of the study, posters advertising the study (appendix 3) 
were placed on notice boards throughout the hospice. A factsheet was developed 
to provide healthcare professionals with a summary of the proposed study 
(appendix 4); this was distributed during multidisciplinary research seminars. 
Additionally, research support folders (containing the healthcare professional 
factsheet, participant information sheets, examples of data collection sheets, and 
the published systematic review by Nwosu et al105) were created and placed in the 
clinical ward areas, nurses’ offices, and the MCPCIL office.  
Meetings with the clinical consultants and a senior nurse matron were conducted 
to raise awareness of the study protocol and establish the roles and responsibilities 
of clinical and research staff. 
 
 
56 
 
SECTION 2: RESEARCH MANAGEMENT 
2.2.1 ETHICAL APPROVAL AND RESEARCH GOVERNANCE 
The research project adhered to the requirements set out in the Department of 
Health Research Governance Framework. This study received a favourable ethical 
opinion from the North Wales Research Ethics Committee - West (now renamed as 
Wales Research Ethics Committee 5). Local research ethics committee approval 
number = 12/WA/0200.  
The study was supported by the Cancer Research UK Liverpool Cancer Trials Unit 
(LCTU). The LCTU has UKCRC Clinical trials Unit full registration, ensuring high 
standards of regulatory and quality control. The study was sponsored by the 
University of Liverpool and adhered to its governance framework. The University of 
Liverpool was responsible for the authorisations and approvals associated with the 
research and the professional indemnity and clinical trials insurance applied as 
appropriate. 
The participant information sheet(s) stated that all information will be treated as 
confidential. The General Practitioner (GP) of the participant was contacted, in 
writing, to inform them of the involvement of their patient in the research study 
(appendix 5). 
The study was included in the LCTU portfolio. Individuals from the LCTU provided 
expert advice for aspects of the study. This included a statistician to provide 
guidance with the sample size calculation and statistical analysis; methodological 
support was provided from the research scientists. Monthly updates were made to 
the LCTU management board to provide details of the study progress. The senior 
hospice management team (consisting of the hospice manager and senior 
healthcare professionals) provided the research team with the necessary approval 
to allow the study to take place in the hospice. 
The research protocol was modified appropriately in light of external peer-review 
that was received from the joint scientific committee of Marie Curie Cancer Care 
and Cancer Research UK. 
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2.2.2 PROJECT MANAGEMENT GROUP 
A project management structure was created to provide direction and support for 
the research. This included a Project Management Group (PMG) to monitor and 
advise the progress of the research study. The group included individuals with 
relevant knowledge for the project, including care of the dying, research methods 
and data analysis. Specifically, the group included a professor in physiology, a 
professor in palliative care and a senior clinical-academic in palliative care. The 
group provided relevant specialist advice and support (clinical and research) at all 
stages of the project and met quarterly during the project.   
Relevant stakeholders were involved from study design through to completion.  
This included a service-user representative from the Merseyside and Cheshire 
Cancer Network who provided a lay perspective to the research study. A senior 
biochemist provided advice about the appropriate biochemical tests, method of 
collection, analysis and reference ranges.  
2.2.3 FUNDING 
The researcher’s salary was supported by funds from the MCPCIL and the Institute 
of Translational Medicine, University of Liverpool. Equipment and laboratory costs 
were funded by a £10,000 grant from the Friends of the University of Liverpool. 
2.2.4 COPYRIGHT AND INTELLECTUAL PROPERTY 
Prior to use and reproduction of the Dehydration Symptom Questionnaire (Burge 
1991269) and the Dehydration Score (Morita 2006228) permission was obtained from 
the authors and publisher possessing copyright to the material.270 271 
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SECTION 3: EXPERIMENTAL DESIGN 
2.3.1 PILOT NATURE OF THE STUDY 
This study was designed to be pilot in nature. Pilot studies are smaller versions of 
the main study that are run to test whether the components of the future main 
study can all work together. They are focused on the processes of the main study, 
for example to ensure recruitment, randomisation, treatment, and follow-up 
assessments all run smoothly.272 273  
It is envisaged that this study will lead to a future study, using similar methodology, 
to facilitate in-depth analysis of BIA with a larger sample size sub-analysed by age, 
gender, cancer diagnosis, body mass index (BMI) and performance status. 
Specifically, this study was designed to use BIA and BIVA to evaluate hydration 
states and determine its relationship with biochemical investigations, clinical 
examination and self-reported symptoms in advanced cancer. Furthermore, 
analysis of survival (using several variables) and the follow-up assessments were 
conducted to obtain information about survival patterns and the practicality, 
tolerability of repeat assessments. 
2.3.2 RECRUITMENT PROCESS 
A co-ordinated recruitment schedule was established for participants meeting the 
eligibility criteria (appendix 6). The research protocol was carefully designed to 
minimise any coercion. Potential participants were initially approached by a 
member of the clinical team, who discussed the research study with eligible 
subjects and were asked if they were happy to discuss the study with a researcher. 
Individuals expressing interest in the research were met by the researcher who 
explained the study in greater depth. All patients were provided with a participant 
information sheet (appendix 7) which provided a brief overview of the study. 
Following the initial meeting with the patient, the researcher returned 24 hours 
later to discuss questions or concerns and to determine whether the individual 
would like to participate in the study. Consequently, all individuals were provided 
with a minimum of 24 hours to decide on whether they were happy to participate. 
 
 
59 
 
Potential participants were informed that their clinical care would not be influenced 
by their decision to agree or decline participation in the study. Whilst discussing 
and undertaking the study, procedures to ensure confidentiality and privacy for, 
and reduce the possibility of influence on other patients were taken (e.g. using 
interview rooms where possible and ensuring privacy during assessments). Those 
expressing interest in participating were provided with more detailed study 
information (appendix 8) and a further opportunity to discuss with the researcher 
before proceeding to provide formal consent. 
The researcher had no day-to-day clinical responsibility for the research 
participants. The researcher was responsible for providing clinical cover to patients 
attending the community day-care centre and was part of an emergency out-of-
hours on-call rota for hospice inpatients. However, no research activity took place 
during these occasions and the research ethics committee were satisfied there was 
no conflict of interest.  
2.3.3 CONSENT PROCESS 
Fully informed consent was obtained from those willing to participate. Individuals 
agreeing to participate were screened to ensure eligibility for study entry (appendix 
9). Only those fulfilling the requirements for study entry were included. The 
researcher assessed the patients to ensure that they understood the research 
study, including the potential risks and benefits. Eligible patients were then asked 
to sign the consent form in the presence of the researcher (appendix 10). The 
original consent form was filed in the clinical case notes and copies were given to 
the patient and filed in the researcher file. A letter was written to patients’ general 
practitioner (GP) to inform them of their inclusion in the study.  
2.3.4 RATIONALE FOR BLOOD TEST PROTOCOL 
In order to be eligible for participation participants were required to have 
biochemical tests (serum urea and creatinine) taken within the previous 72 hours as 
part of their clinical care. The research team did not ask the clinical team to conduct 
blood tests for the purposes of the study. 
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The decision to only include individuals receiving blood investigations in the 
previous 72 hours was made to maintain the observational nature of the study and 
to avoid subjecting the participant to additional tests, which may be burdensome. 
Patients who wished to participate in the study who did not have blood tests 
performed in the previous 72 hours were eligible to enrol if/when the appropriate 
blood tests were taken by the clinical team. As the majority of inpatient admissions 
to the hospice receive a blood test at some point of their admission (usually for 
monitoring purposes) it was envisaged that most patients would have the 
opportunity to participate, provided that they satisfied the other eligibility criteria. 
Blood biochemistry is generally not performed in situations where they are deemed 
to offer little benefit (for example in the dying phase), and pending discharge.  
The 72-hour time interval was chosen to provide the opportunity for participation 
to as many patients as possible. Ideally, it may be argued that recruitment should 
occur on the same day the biochemical tests were taken (in order to effectively 
compare the study assessment methods). However, it was thought that this 
timeframe may have caused the exclusion of many participants. 
2.3.5 ASSESSMENT SCHEDULE 
All assessments were conducted in the morning, at a time convenient to the 
participant, between 9am – 12pm. A co-ordinated protocol for the study 
assessments was used for the research assessments in the study (appendix 11). 
Following this, participants were eligible to receive repeat ‘follow-on’ assessments 
if further biochemical blood tests were investigations repeated by the clinical team 
(see section 2.3.5.2).  
2.3.5.1  BASELINE ASSESSMENT 
All participants in the study received the following assessments below performed in 
this order: 
1. Demographic details 
2. Clinical assessment 
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3. Hydration questionnaire 
4. Height and weight assessmenti 
5. Bioelectrical impedance assessments 
6. Fluid intake review 
7. Medication review 
8. Urine collectionii 
2.3.5.2  SUBSEQUENT ASSESSMENTS 
Patients were eligible for repeat assessments on each subsequent occasion that 
serum biochemistry investigations (serum urea and creatinine recorded in previous 
72 hours) were performed by the clinical team (appendix 11). Eligible patients were 
identified on a daily basis through discussion with the clinical team, case-note 
review and review of the electronic blood result system. Subsequent assessments 
only took place if the participant provided assent on each occasion. Participants 
who were discharged and later re-admitted were eligible to receive ‘follow-on’ 
assessments provided that they still met the eligibility criteria. No further 
assessments were conducted if the participant declined or was unable to provide 
assent (for example, if unconscious). In these situations, the researcher would liaise 
with clinical team to determine their opinion of the appropriateness of the patients 
continued participation in the study. If the clinical team felt that participation was 
still possible, the researcher would re-approach the participant when they were 
more conscious. If the clinical team felt that research was currently inappropriate 
the researcher made no further approach, unless the condition of the participant 
improved to the level that they were able to re-engage in a discussion about the 
study. 
                                                          
i
 Weight was not recorded if the patient was physically unable to stand. 
ii
 Urine was not recorded if the patient was unable to provide a sample. 
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Repeat assessments for these patients included: bioelectrical impedance 
measurement, hydration questionnaire, fluid intake assessment, clinical assessment 
of hydration, medication review, biochemical investigations. No further 
measurements were collected from participants unable to consent or declining 
further participation in the study. Information concerning length of inpatient stay, 
date of discharge, date(s) of repeat admission(s) and of repeat discharge(s). All 
patients were followed up for 3 months upon the end of the data collection period; 
date of death was obtained from hospice records. A flow-chart summary of the 
research project is presented in appendix 12. 
2.3.6 MINIMISING HARM 
Abnormal blood results, of clinical significance, arising from the study (for example, 
hypercalcaemia detected through an add-on test of an existing serum biochemistry 
sample) were passed on to the clinical team. The researcher was not involved in any 
clinical decision making. In order to guide appropriate care, the researcher 
informed the clinical team about patients visibly scoring >50mm on the visual 
analogue scale for the first six symptoms (thirst, pain, dry mouth, nausea, 
unpleasant taste and fatigue) and <50mm for the final symptom (pleasure in 
drinking) of the Burge Dehydration Symptom Questionnaire. The document used 
for data collection is available in appendix 13. 
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SECTION 4: STUDY MEASUREMENT AND TOOLS 
2.4.1 DEMOGRAPHIC DETAILS 
The following information was obtained from the medical case notes: age (years), 
gender (male/female) and ethnicity. Ethnicity data was recorded according to the 
format defined by the National Ethnic Code classification as listed in Health and 
Social Care Information Centre (see Table 3).274 
TABLE 3: NATIONAL ETHNICITY CODE DATA (AS DEFINED BY THE 
HEALTH AND SOCIAL CARE INFORMATION CENTRE274) 
White Mixed Black or Black 
British 
Asian or Asian 
British 
Other 
British 
Irish 
Any other mixed 
background 
White and black 
Caribbean 
White and Black 
African 
White and Asian 
Any other mixed 
background 
Caribbean 
African 
Any other Black 
background 
Indian 
Pakistani 
Bangladeshi 
Any other Asian 
background 
Chinese 
Any other 
ethnic group 
 
Details of the cancer diagnosis were recorded according to the subtypes as defined 
by the International Classification of Diseases.267 Information recorded included: 
the primary site of cancer, presence of metastases (yes/no), location of metastases 
and disease co-morbidities (appendix 14). Date of admission and date of BIA 
assessment were recorded. 
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2.4.2 MEDICATION REVIEW 
All prescribed medications (name, dose and route) were recorded.  The presence of 
serotonin reuptake inhibitors (SSRI), serotonin noradrenaline reuptake inhibitor 
(SNRI) and diuretics were recorded (yes/no). These medications were identified 
from lists provided in the British National Formulary (Table 4).275 276  
TABLE 4: LIST OF SSRI, SNRI AND DIURETIC MEDICATIONS AS LISTED IN 
THE BRITISH NATIONAL FORMULARY (BNF) 
SSRI SNRI Diuretic 
Escitalopram 
Citalopram 
Fluoxetine 
Fluvoxamine 
Paroxetine 
Sertraline 
Duloxetine 
Venlafaxine 
Thiazides 
(bendroflumethiazide, 
chlortalidone, cyclopenthiazide, 
indapamide, metolazone, xipamide) 
Loop diuretics 
(furosemide, bumetanide, 
torasemide) 
Potassium-sparing diuretics 
(amiloride, triamterene) 
Potassium-sparing with other 
diuretics 
(co-amilozide, navispare, co-
amilofruse, co-triamterzide) 
Aldosterone antagonists 
(eplerenone, spironolactone) 
Osmotic diuretics 
(mannitol) 
Carbonic anhydrase inhibitors 
(acetazolamide) 
 
The Anticholinergic Burden (ACB) scale (appendix 15) 277 278 was used to calculate 
the burden of anticholinergic drugs. Here, medications receive a score in light of 
their reported anticholinergic effects (1 = mild, 2 = moderate; 3 = severe). A total 
ACB score was calculated for each patient through addition of the ACB score from 
each medication taken. A total ACB score of three or more is considered clinically 
significant. 
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Total daily opioid dose, at the time of assessment, was calculated. This included 
regular by the clock opioids by oral, subcutaneous and transdermal routes.  As 
required (PRN) medications were not included in this total. Opioid equivalency is 
highly disputed with notable variations in the opioid conversions utilised in clinical 
practice.279 Consequently, the Palliative Care Formulary280 and a recent systematic 
review about opioid conversions281 were evaluated to determine acceptable opioid 
conversions which could be used for the purposes of opioid conversions in this 
study. Although these references provide recent evidence of opioid equi-analgesia, 
it is acknowledging that there are variations in accepted practice (Table 5).280 281 
Medications were expressed in milligrams accordingly to their equivalence to daily 
24 hourly morphine dosages.  
TABLE 5: CONVERSION RATIOS FOR OPIOIDS (DEVELOPED FROM 
MERCADANTE ET AL 2011281 AND TWYCROSS ET AL 2011280) 
NAME Equivalence compared to 
oral morphine 
Calculation required compared 
to oral morphine 
PO Morphine 1:1 Same dose 
SC Morphine 2:1 Multiply by 2 
PO Oxycodone 1.5:1 Multiply by 1.5 
SC Oxycodone 2:1 Multiply by 2 
SC Diamorphine 3:1 Multiply by 3 
PO Hydromorphone 5:1 Multiply by 5 
SC Hydromorphone 10:1 Multiply by 10 
SC Alfentanil 30:1 Multiply by 30 
TD Fentanyl (micrograms 
per hour) 
100:1 Multiply fentanyl ug/hr dose by 
24 for total daily dose (mg) 
TD Buprenorphine 100:1 Multiply fentanyl ug/hr dose by 
24 for total daily dose (mg) 
PO Dihydrocodeine 1:5 Divide by 5 
PO Codeine 1:10 Divide by 10 
PO Tramadol 1:10 Divide by 10 
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2.4.3 CLINICAL ASSESSMENT 
Performance status was recorded using the Eastern Cooperative Oncology Group 
(ECOG) scale.282 ECOG performance status scale is a validated scale to record 
performance status using a six point scale (0= fully active, 5 = dead). 
TABLE 6: EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) 
PERFORMANCE STATUS SCALE282 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and 
about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
5 Dead 
 
The presence of audible secretions from the edge of the bed was recorded (yes/no). 
The presence of oedema (defined as the presence of superficial swelling on the 
face, trunk, abdomen or the upper or lower extremities) was also recorded 
(yes/no). 
2.4.4 DEHYDRATION SYMPTOM QUESTIONNAIRE – BURGE ET AL 
1991250 269 
Participants completed a brief hydration symptom questionnaire developed by 
Burge.269 This comprises of seven questions asking participants to rate the severity 
of their symptoms in the last 24-hours using a 100mm Visual Analogue Scale (VAS). 
The VAS is a simple visual rating scale which allows patients to rate symptom 
intensity. The seven symptoms included were thirst, pain, dry mouth, nausea, taste, 
fatigue and pleasure from drinking (appendix 16). In situations where the 
participant was unable to complete the questionnaire (for, example due to 
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weakness), the individual was asked to point to an approximate point on the line 
which was then marked by the researcher.  
The dehydration symptom questionnaire was developed based on the existing 
evidence that demonstrates self-reports of symptom distress are reliable and 
valid.283-285  Previous non-cancer studies have examined thirst and dry mouth VAS 
scores in dehydration.286-288 In these studies, test-retest reliability for the thirst and 
dry mouth VAS was good, reported at 0.79 (p<0.001) for week to week 
observations over two months for haemodialysis patients.286-288    
The Burge Dehydration Symptom Questionnaire features seven items (pain, dry 
mouth, thirst, unpleasant taste, fatigue and pleasure in drinking). The variables 
nausea, pain and fatigue were adapted from the Symptom Distress Scale, a thirteen 
item Likert self-report tool used in patients with chronic illness and cancer (internal 
consistency coefficient alpha 0.79-0.89).283 The oral symptom variables were 
incorporated on account of evidence reported in non-cancer studies.286-289 The 
overall reliability for the full questionnaire has a Cronbach’s alpha value of 0.62, 
which is below the ≥0.7 level commonly quoted as necessary to ensure reliability 
for research studies.285 290 291 However, when thirst, dry mouth, bad taste and 
fatigue were combined the reported alpha increased to 0.72. Cronbach's alpha is a 
measure of internal consistency (how closely related a set of items are as a group), 
a measure of the scale reliability. The validity of the assessment tool has not been 
examined outside of the original Burge thesis. The Burge Dehydration 
Questionnaire was chosen for this study as it is the only dehydration symptom 
questionnaire developed for use (and tested) in advanced cancer patients. The 
alpha value of 0.72 for thirst, dry mouth, bad taste and fatigue provides evidence of 
its reliability for use for this purpose and population. Additionally, the short testing 
time and ease of administration was suited to the target population. 
 
2.4.5 DEHYDRATION ASSESSMENT SCALE – MORITA ET AL 2005227  
A dehydration score was calculated using the approach taken by Morita et al,227 
based on a simple total of scores from three physical findings: moisture on the 
mucous membranes of the mouth (0: moist, 1: somewhat dry, 2: dry), axillary 
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moisture (0: moist, 1: dry), and sunkenness of eyes (0: normal, 1: slightly sunken, 2: 
sunken) (appendix 17). These signs were selected by the author on the basis of their 
significant correlations with biological dehydration, as previously confirmed in 
elderly patients.225 226 231 250 Empirical studies have found that the 
sensitivity/specificity of each sign in identifying dehydration is 85%/58%, 50%/82%, 
and 62%/82%, respectively.225 226 231 A total hydration status score was calculated 
from the sum of these scores (range 0-5) with higher scores indicating an increased 
chance of dehydration. A cut-off of ≥2 is predictive of biochemical dehydration and 
has been used by other authors to study hydration in advanced cancer patients.230 
292 Although the Morita Dehydration Assessment Scale has been used by various 
authors for the evaluation of fluid states, the reliability and validity of this tool has 
not been established in the literature. However, the tool was used in this study as it 
represented the best (and only) available clinical assessment tool evaluation of 
hydration-related physical signs in advanced cancer.  
2.4.6 ORAL INTAKE FLUID ASSESSMENT 
Fluid intake was documented for all patients based on standard nursing 
documentation. Patients routinely had fluid intake recorded on admission by 
nursing staff in reference to the patients’ fluid intake and oral health. Assessments 
were repeated on a weekly basis but were conducted in greater frequency in those 
with poor oral intake (appendix 18).293 The most recent assessment of fluid intake 
was documented. Oral fluid intake was classified into one of the following 
categories accordingly the fluid intake for the preceding 24 hours: 0 - 199ml, 200-
499ml, 500-799 or >800mls.  
2.4.7 HEIGHT AND WEIGHT ASSESSMENT 
Height (H) was measured, without shoes, to the nearest 0.1 cm using a portable 
stadiometer (SECA© 213 Height Measure / Stadiometer). Due to debility, some 
patients were unable to stand; in these instances their length was measured 
horizontally with the patient lying in the bed. The stadiometer was chosen as it 
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lightweight and collapsible, enabling horizontal assessments in the situations where 
participants were unable to stand. 
Body weight (W) was measured, in the morning to the nearest 0.1kg (SECA© 955 
High Capacity Electronic Chair Scale). Weight was not assessed in circumstances 
where the patient was unable to transfer safely to the weighing scale. Weight and 
height were used to calculate body mass index (W[kg]/H2[m]). 
2.4.8 BIOCHEMICAL INVESTIGATIONS 
The following biochemistry blood results were recorded if performed on admission: 
Urea (mmol/l), creatinine (µmol/l), serum sodium (mmol/l), serum albumin (g/L), 
adjusted calcium (mmol/l). Where possible, a urine sample was obtained from 
participant to obtain the urine osmolality (mosm/kg). The researcher contacted the 
laboratory to request the addition of the serum osmolality (mosm/kg) test to the 
current serum sample for all patients.  
Participants were defined as having pre-renal failure if the serum urea:creatinine 
ratio ≥100 (mmol/mmol)iii. For example, a patient with a urea of 33.8 mmol/l and 
creatinine of 176 µmol/l would have a urea:creatinine ratio of 192.05 mmol:mmol. 
The ≥100  cut-off is indicative of pre-renal failure which is often caused by 
hypovolaemia.294 295 This biochemical definition was chosen based on the similar 
work in previous studies and on the basis of expert recommendations from a 
clinical biochemist and a physiologist.210 228 248 296  
2.4.9 BIOELECTRICAL IMPEDANCE ANALYSIS (BIA) 
The EFG3 ElectroFluidGraph Vector Impedance Analyser (Akern©) was used for the 
bio-impedance assessments. The method involved a tetra-polar technique to 
deliver a single frequency current of 50kHz (±5%) to each participant. The external 
calibration of the analyser was checked with a calibration circuit of known 
impedance value (r= 470 Ω, Xc = 90Ω) in the morning of each testing session. All 
patients were assessed between 9am – 12pm.  The BIA testing procedure (appendix 
                                                          
iii
 In the UK creatinine is often reported as micromol. Therefore this value was divided by 1000. 
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19) was conducted in line with methods described by Lukaski86 and the BIA 
recommendations described elsewhere.78 119 The participants were lightly clothed, 
lying in the supine horizontal position on the bed, without shoes or socks. Their 
arms were positioned 30 degrees from the body with the legs positioned 45 
degrees away from each other. Two disposable pre-gelled aluminium electrodes 
(Akern©) were affixed to the dorsum of the right hand (one placed on the edge of 
an imaginary line bisecting the ulnar head and the other on the middle finger 
proximal to the metacarpal-phalangeal) and two to the dorsum of the right foot 
(one placed medially, to an imaginary line bisecting the medical malleolus at the 
ankle and the other proximal to the metatarsal-phalangeal joints) (Figure 12). The 
current-introducing electrodes are placed a minimum distance of the diameter of 
the wrist or ankle of the paired electrode.  
BIVA was chosen as the primary assessment tool as it provided a method to: (i) 
classify static hydration states of individuals according to the position of individual 
vectors on the RXc graph; (ii) to compare hydration between groups of patients 
according to various classifications (e.g. oedematous vs. not-oedematous); (iii) to 
evaluate change in fluid status over time through longitudinal assessments; and (iv) 
to compare hydration status for the sample with other cancer populations from the 
literature. The H2/R was also used in this study to measure hydration (due its high 
correlation of H2/R with TBW) between individuals. Compared to H2/R, the BIVA 
method provides more useful information about hydration as it involves the 
measurement of both resistance and reactance (as opposed to H2/R which only 
involves assessment of R). 
BIVA and H2/R were used for the main statistical analysis in this study in favour of 
individual raw BIA measurements (i.e. R, Xc and PA). Concerning hydration, more 
information is obtained through the interpretation of R and Xc as part of the BIVA 
method or the incorporation of R into the H2/R equation. PA was not studied in this 
analysis; although useful prognostic indicator its association with hydration has not 
been established. Therefore it was not felt that the inclusion of PA would improve 
the data analysis. 
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FIGURE 12: DIAGRAM SHOWING ELECTRODE PLACEMENT REQUIRED 
FOR THE BIA TEST 
 
2.4.9.1  CHOICE OF THE REFERENCE POPULATION 
BIVA requires standardisation to an appropriate reference population. For this 
study a non-cancer population was chosen as the reference.146 This reference 
comprises of an Italian hospital inpatient population of males (n=354) and females 
(n=372) Caucasian patients aged between 18- 85 without cancer (Table 7). The 
population was chosen as it was the most similar in characteristics (age, ethnicity 
and body mass) to this sample.  
TABLE 7: DETAILS OF THE REFERENCE POPULATION OF PICCOLI 1995146 
Popn. 
Size, N 
R/H 
Mean 
R/H    
SD 
Xc/H  
Mean 
Xc/H 
SD 
Correlation  
r (R/H, 
Xc/H) 
Sex 
(M/F) 
BMI Analyser 
354 298.6 43.2 30.8 7.2 0.47 m 16 -31 Akern-
RJL 
Systems 
372 371.9 49.0 34.4 7.7 0.41 f 16 - 31 Akern-
RJL 
Systems 
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SECTION 5: STATISTICAL ANALYSIS OF DATA 
2.5.1  STATISTICAL ANALYSIS PLAN 
The statistical analysis began with a descriptive analysis of the data (chapter 3). 
Initially, each target variable was assessed for normality using the Shapiro-Wilk test. 
Parametric and non-parametric tests were used as appropriate. Statistical Package 
for the Social Sciences (SPSS) version 21.0 was used for standard calculations. 
Frequency analysis with the chi-squared test, Student t test, the Mann-Whitney U 
test, as appropriate, to compare differences between groups and variables. For the 
independent t-tests, Levene’s test for homogeneity of variance was used to 
examine the quality of variances within a population to identify whether derivatives 
required exclusion or separate analysis from the cohort. The linear correlation 
coefficient r, Pearson’s correlation coefficient and Spearman’s rank correlation 
coefficient were appropriately used to evaluate correlations between variables. 
Multiple linear regression was used to evaluate associations of variables.  
BIA vector analysis was conducted using a Microsoft Excel programme developed 
by Professor Antonio Piccoli, University of Padova. Hotelling’s T2 test for vector 
analysis was used to compare for significant difference between mean vector 
distances (D). Survival was evaluated from the date of first BIA measurement to the 
date of death using log-rank Kaplan-Meier survival and hazard ratios, according to 
categorical bio-impedance and biochemical indices.  
The following methods were conducted to achieve the study objectives. 
2.5.1.1  OBJECTIVE 1 
Dehydration symptom scores were evaluated using box plot analysis of the 
participant reported scores obtained from the Burge symptom questionnaire. This 
data was compared to the original Burge study, in order, to determine the level of 
agreement between the two study populations. The impedance index (H2/R) was 
calculated from the BIA raw variables to provide a proxy measurement of total 
body water.  
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Multiple regression analysis was conducted to further study the relationship 
between several predictor variables with H2/R, in order, to evaluate potential 
relationships of TBW with patient demographics (age, gender), clinical 
measurements (Morita dehydration score, oedema presence) serum biochemistry 
(ur:cr) and self-reported symptoms (Burge-4 score). A separate regression analysis 
was performed to evaluate whether the Burge-4 score was associated with 
concurrent use of medications known to cause symptoms (dry mouth, thirst, 
unpleasant taste and fatigue). This analysis included the ACB score, total daily 
morphine dose, presence of diuretic medication and use of SNRI and/or SSRI 
medications.  
2.5.1.2  OBJECTIVE 2 
BIVA was conducted to evaluate hydration in the sample. The RXc point graph was 
used to assess participant’s hydration status according to tolerance ellipses from a 
non-cancer reference population.146 Data were plotted on the graph with the 50%, 
75% and 95% tolerance intervals.  
Hydration status was determined by the individual’s baseline bio-impedance vector 
position on the BIVA RXc normogram. The graph was divided into five parallel 
sections on the hydration axis (Figure 6). Individuals with vectors falling in (or 
above) the 76th percentile upper range were severely less-hydrated (point 1) and 
those with vectors in the 51–75% upper range were mildly less-hydration (point 2). 
Participants with vectors in the central 50th percentile ellipse were normally-
hydrated (point 3). Those with vectors in the lower 51 – 75% percentile range were 
mildly more-hydrated (point 4) whereas vectors in (or below) the lower 76th 
percentile range were severely more-hydrated (point 5). Based on the above 
criteria, hydration states were summarised into three categories, consisting of less-
hydration (severe and mild), normal hydration and more-hydration (severe and 
mild). Further simplification grouped participants as either less-hydrated (mild and 
severe) or not less-hydrated (normally-hydrated and more-hydrated patients). 
Less-hydrated and not less-hydrated patients were compared to assess for 
differences in biochemistry, self-reported symptoms (Burge questionnaire), clinical 
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signs (Morita dehydration questionnaire), oral fluid intake and performance status 
(ECOG). Student’s t-test was used to compare continuous variables and Mann U 
Whitney was used to evaluate ordinal data. 
BIVA mean vectors were plotted with their 95% confidence ellipses. Mean vectors 
were used to compare for differences between groups based on the following 
variables and associated cut-offs: oedema present (yes/no), Burge-4 score (mean), 
Morita dehydration score (< or ≥2iv), secretions present (yes/no), ECOG (< or ≥ cut-
off values of 2, 3 and 4) and whether pre-renal failure was present (yes/no).  
Burge-4 sub-items (thirst, dry mouth, unpleasant taste and fatigue) were further 
analysed, using cut-off VAS scores of < or ≥50mm. The two-sample Hotelling’s T2 
test was used to compare differences in the mean vectors between groups.150  
The mean R/H and Xc/H values for male and females were converted to Z-scores 
and plotted on the RXc Z-score graph. The R/H and Xc/H values for seven other 
cancer populations (lung cancer,98 158 breast cancer,297 head and neck cancer206 298) 
were obtained from the literature and converted to the Z-score graph in respect to 
their reference populations (Figure 10). The Z-score obtained from this population 
was compared from the data from these previous studies using the RXc Z-score 
graph method.144 
2.5.1.3  OBJECTIVE 3 
Survival was analysed using Kaplan-Meier log-rank test and Cox regression analysis.  
All patients were followed up for 3 months following the end of the study data 
collection. Survival time was recorded in days from the first data of assessment to 
the date of death (if applicable). Kaplan-Meier analysis was used to analyse survival 
according to hydration classification and the presence or absence of pre-renal 
failure. Cox regression analysis was used to obtain hazard ratios for death for ur:cr 
                                                          
iv
 Morita cut-off of 2 chosen based on previous work using this value.
230
 Bruera E, Hui D, Dalal S, 
Torres-Vigil I, Trumble J, Roosth J, et al. Parenteral hydration in patients with advanced cancer: a 
multicenter, double-blind, placebo-controlled randomized trial. J Clin Oncol 2013;31(1):111-8, 
257
. 
Nakajima N, Hata Y, Kusumuto K. A clinical study on the influence of hydration volume on the signs 
of terminally ill cancer patients with abdominal malignancies. J Palliat Med 2013;16(2):185-9.  
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ratio and H2/R. Hydration classification (according to BIVA), H2/R and ur:cr ratio 
were combined in a regression equation with other factors (age, gender, ECOG and 
the presence of metastatic disease) to evaluate the potential confounding influence 
of associated variables.  
2.5.1.4  OBJECTIVE 4 
The frequency of assessments was described for participants receiving multiple 
assessments. The overall change of vector position from the first and last 
assessments was evaluated by calculation of the difference of resistance (dR/H) and 
reactance dXc/H. The mean difference, standard deviation and r correlation of dR/H 
and dXc/H was plotted on the RXc paired graph with the associated 95% tolerance 
ellipse. Paired vector data was statically analysed using the paired Hotelling’s T2 
test. The difference in H2/R, and the ur:cr ratio was calculated for those receiving 
multiple assessments. Kaplan-Meier survival analysis was conducted to determine 
whether participants experiencing change in H2/R or ur:cr ratio affected survival. 
For this analysis, an increase in the H2/R (suggesting less TBW) was evaluated 
against no change or a decrease (suggesting static or more- hydrated states). 
Similarly, an increase in ur:cr ratio (suggesting worsening renal function) was 
evaluated against no change or a decrease (suggesting static or improving renal 
function). 
2.5.2 OUTCOME / DEPENDENT VARIABLES  
The dependent (outcome) variables consisted of the H2/R and the bio-impedance 
measures standardised by height (R/H and Xc/H) as part of a vector analysis of the 
BIA data.  
2.5.3 PREDICTORS / INDEPENDENT VARIABLES  
The independent variables were the summated score for four variables of the Burge 
Dehydration Questionnaire (thirst, dry mouth, unpleasant taste and fatigue); the 
individual Burge questionnaire symptom scores; the Morita Dehydration Score, 
presence (or absence) of oedema, ECOG performance status, and the ur:cr ratio.  
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2.5.4 SAMPLE SIZE CALCULATION 
A prospective sample size calculation was difficult in light of the absence of similar 
studies comparing the relationships between BIA, body composition, symptoms, 
and clinical examination and biochemical measures in palliative patients. In view of 
the lack of information available for potential recruitment rates, an exploratory 
sample size 90 patients was calculated, based on admissions data from the Marie 
Curie Hospice Liverpool.267 
To draw a vector for the palliative population on the RXc graph to enable 
comparisons with other reference populations:  A sample size of 90 will give a 95% 
confidence region for the mean vector of the vector random variable (Z(R), Z(Xc)) as 
an ellipse with semi-axes of approximate lengths of 0.33 and 0.16. For the two-
group analysis, a sample size of 45 for each of two groups will have power of 0.8 for 
detecting a difference of (0.5, 0.5) in the mean BIVA vectors either group, for 
significance level of 0.05.  
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CHAPTER 3: THE USE OF BIA TO EVALUATE 
HYDRATION AND INVESTIGATE ITS 
RELATIONSHIP WITH BIOCHEMICAL 
INVESTIGATION, CLINICAL EXAMINATION AND 
SELF-REPORTED SYMPTOMS IN ADVANCED 
CANCER 
SECTION 1: RECRUITMENT AND DEMOGRAPHIC DETAILS 
3.1.1  INTRODUCTION 
Within this section the demographics of the study participants are presented. This 
includes a description of the patient characteristics, which involves details about 
serum biochemistry, symptomatic burden, medication use, oral fluid intake and the 
bio-impedance measurements. Following this, section 2 presents the results of the 
multiple regression analysis which was conducted to evaluate how hydration (as 
measured by the H2/R) relates to clinical measurements, biochemistry and self-
reported symptoms. 
3.1.2 RECRUITMENT (FIGURE 13) 
Patients were recruited between the period of December 2012 and October 2013. 
A total of 118 patients were identified as eligible to enter the study and were 
initially approached by the clinical team. The study successfully achieved the 
indicative recruitment target of 90 patients with a recruitment rate of 76.3%. 
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FIGURE 13: RECRUITMENT RESULTS FLOWCHART 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patients identified by clinical 
team (n=118) 
Ineligible (n=2) 
- Pacemaker (n=1) 
- Unable to comply 
with assessments 
(n=1) 
Patients approached by 
researcher (n= 115) 
Patients declining 
invitation to speak to 
researcher (n=3) 
Exclusions (n= 23) 
- Patient declined 
(n=11) 
- Too unwell to 
participate (n=10) 
- Discharged before 
assessment took 
place (n=2) 
 
Eligible participants identified by 
researcher (n=113) 
Patients providing informed consent 
(n= 90) 
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3.1.3 PATIENT DEMOGRAPHICS (TABLE 8) 
Overall, there was a fairly equal gender split of participants with 42 (46.7%) males 
and 48 (53.3%) females. The mean age of participants was 71.2 with majority of 
Caucasian ethnicity patients (n=89, 98.9%). Nineteen different types of cancers 
were recorded with lung cancer the most common (n=14, 15.6%). Most participants 
had an ECOG performance status of 3 (n=36, 40%); no patients had a performance 
status of ECOG-0. Weight was measured in 28 patients (it was not possible to weigh 
the remaining patients due to physical debility). For these patients, mean weight 
was 69.45kg (SD=17.90), mean body mass index (BMI) for the sample was 25.17 
kg/m2 (SD=4.98). Oedema was present in a third of the sample (n=27, 30%). The 
mean results of the BIA raw variables of the study population are presented in table 
9. These mean values provide the BIA population data for this sample which will be 
useful for comparisons, using BIVA, with this dataset.  
TABLE 8: DEMOGRAPHIC DETAILS OF STUDY PARTICIPANTS  
Characteristic N % 
Mean age (± SD), years 71.17 (12.21)  
Male 42 46.7 
Female 48 53.3 
Mean height (± SD), cm 164.22 (9.6)  
Mean weight (± SD), kg 69.45 (17.9)  
Mean body mass index (± SD), kg/m
2
 25.17 (4.98)  
Race/ethnicity   
 Caucasian 89 98.9 
 Other 1 1.1 
ECOG   
 0 0 0 
 1 15 16.7 
 2 22 24.4 
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Characteristic N % 
 3 36 40.0 
 4 17 18.9 
Oedema present 27 30 
Metastatic disease present 64 71.1 
Cancer diagnosis   
 Lung 14 15.6 
 Colorectal 11 12.2 
 Prostate 10 11.1 
 Ovarian 6 6.7 
 Breast 6 6.7 
 Oesophageal 5 5.6 
 Myeloma 5 5.6 
 Pancreatic 4 4.4 
 Unknown 4 4.4 
 Cervical 3 3.3 
 Mesothelioma 3 3.3 
 Gastric 3 3.3 
 Brain 3 3.3 
 Melanoma 2 2.2 
 Soft tissue/muscle/connective tissue 2 2.2 
 Bladder 1 1.1 
 Liver 1 1.1 
 Groin 1 1.1 
 Uterus 1 1.1 
 Tongue 1 1.1 
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TABLE 9: MEAN BASELINE BIO-IMPEDANCE SCORES FOR THE SAMPLE 
(N=90) 
 Mean SD 
RH 341.58 82.22 
XcH 27.68 9.49 
PA 4.71 1.33 
H
2
/R 51.58 15.41 
 
3.1.4 STUDY OBSERVATIONS (TABLE 10) 
A total of 126 study assessments were undertaken. Twenty four (26.7%) 
participants received multiple assessments. Twenty-two patients (24.4%) were able 
to provide urine for analysis (the remainder were unable to provide a sample during 
the collection period or were without a catheter and were unable to mobilise)  
TABLE 10: THE NUMBER OF STUDY ASSESSMENTS  
Number of study assessments N % 
1 66 73.3 
2 15 16.7 
3 7 7.8 
4 1 1.1 
5 1 1.1 
Total 90 100 
   
Number or urine assessments N % (of 90) 
1 22 24.4 
2 4 4.4 
3 1 1.1 
Total 28 31.1 
 
3.1.5  MORITA DEHYDRATION SCORE (TABLE 11) 
The majority of sample had a Morita dehydration score of either one (n=25, 27.8%), 
two (n=23, 25.6%) or three (n=20, 22.2%) respectively. 
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TABLE 11: MORITA DEHYDRATION SCORE RESULTS FOR THE SAMPLE 
Morita dehydration score N % 
0 13 14.4 
1 25 27.8 
2 23 25.6 
3 20 22.2 
4 7 7.8 
5 2 2.2 
 
3.1.6  ORAL FLUID INTAKE (TABLE 12) 
Most patients had a daily oral fluid intake of 500 -799mls per day (n=42, 46.7%) 
whereas a lower fluid intake of 0-199mls/day was observed least frequently (n=4, 
4.4%). As few numbers of participants had an oral intake of less than 200mls, the 0-
199mls category was grouped together with the 200-499mls group to simplify the 
data analysis. The resultant category demonstrated how 27 (30%) patients had an 
oral intake of 0-499mls. 
TABLE 12:  ORAL FLUID INTAKE INFORMATION 
 N % 
Oral intake (mls)   
0-199 4 4.4 
200-499 23 25.6 
500 - 799 42 46.7 
≥800 21 23.3 
   
Modified Oral fluid intake (mls)  
0 - 499 27 30.0 
500 - 799 42 46.7 
≥800 21 23.3 
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3.1.7  MEDICATIONS (TABLE 13) 
The majority of patients were prescribed opioids (n=65,72.2%). The mean morphine 
dose was 60.8mg (SD=86.7) daily. However, this was much higher than the median 
(24.0mg) which suggests that the mean is higher on account of large doses taken by 
some of the study participants. Anticholinergic medications were commonly 
prescribed (n=57, 63.3%) with total Anticholinergic Burden (ACB) scores ranging 
between 0-7. About a third of all patients had an ACB score of 1 (n=31, 34.4%) 
whereas 15 (16.7%) had scores ≥3, which suggests severe anticholinergic burden. 
Both diuretics and SSRI/SNRI medications were prescribed in 14 (15.6%) of 
participants. 
 
TABLE 13:  CHARACTERISTICS OF MEDICATIONS TAKEN BY STUDY 
PARTICIPANTS 
 
Characteristic N % 
Opioids prescribed?   
 Yes 65 72.2 
 No 25 17.8 
Mean daily morphine dose (±SD), mg 60.78 (86.7)  
Median daily morphine dose (IQR), mg 24.0 (82.5)  
Anticholinergics prescribed?   
 Yes 57 63.3 
 No 33 36.7 
Anticholinergic burden score (ACB)   
 0 34 37.8 
 1 31 34.4 
 2 10 11.1 
 3 8 8.9 
 4 5 5.6 
 7 2 2.2 
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Characteristic N % 
Diuretics prescribed?   
 Yes 14 15.6 
 No 76 84.4 
SSRI and/or SNRI prescribed?   
 Yes 14 15.6 
 No 76 84.4 
 
3.1.8  ANALYSIS OF THE BURGE QUESTIONNAIRE – SYMPTOMS OF 
DEHYDRATION (TABLE 14; FIGURES 14 & 15) 
The Burge questionnaire demonstrates a high prevalence of symptoms at baseline. 
Overall, fatigue was reported the most severely (M= 63.60, SD =30.09) whereas 
nausea was less severe (M=25.61, SD=31.26). Pleasure in drinking scored highly 
(M=68.76 SD=29.08); this suggested that drinking fluids was pleasurable for the 
majority of patients. Boxplot analysis (Figure 14) provides a visual representation of 
the results, demonstrating how more than 50% (i.e. median) of patients reported 
VAS scores of >50mm for the following symptoms: pleasure in drinking (76.0%), 
fatigue (67.0%), dry mouth (61.5%), thirst (56.5%) and pain (53.5%). Four of the 
Burge symptom scores (thirst, dry mouth, unpleasant taste and fatigue) were 
combined to create the Burge-4 dehydration score (Figure 15). The mean Burge-4 
score was 222.07 (SD=95.40) was similar to the median and ranged from 4 to 
400mm. 
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TABLE 14: BASELINE DATA FROM THE BURGE DEHYDRATION 
QUESTIONNAIRE 
Variable Mean SD Median Range 
Thirst 56.11 29.49 56.50 0 - 100 
Pain 50.09 30.86 53.50 0 - 100 
Dry mouth 60.01 30.64 61.50 0 -  100 
Nausea 25.61 31.26 12.00 0 - 100 
Unpleasant taste 42.34 34.11 42.50 0 - 100 
Fatigue 63.60 30.09 67.00 0 - 100 
Pleasure in drinking 68.76 29.08 76.00 0 - 100 
Burge-4 score (thirst, 
dry mouth, unpleasant 
taste and fatigue) 
222.07 95.40 220.50 4 - 400 
 
FIGURE 14: REPRESENTATION OF SYMPTOM SCORES FROM THE 
CURRENT STUDY USING BOX AND WHISKER PLOTS 
 
Data is presented using a box plot and whisker plot. The lower and upper limits of the whiskers 
correspond to the minimum and maximum values respectively. The lower limit of the box is the 25% 
quartile, the black bar is the median and the upper limit of the box is the 75% quartile. 
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FIGURE 15: REPRESENTATION OF THE BURGE-4 SYMPTOM SCORE 
USING BOX AND WHISKER PLOTS  
 
 
The lower and upper limits of the whiskers correspond to the minimum and maximum values 
respectively. The lower limit of the box is the 25% quartile, the black bar is the median and the upper 
limit of the box is the 75% quartile. 
 
3.1.9  COMPARISON OF SYMPTOM SCORES WITH THE BURGE 1991 
DATASET (TABLE 15) 
Mean VAS scores were tabulated to compare this dataset to the Burge study 
1991.269 Comparatively, in this study, pain was reported with higher intensity (50.1 
vs. 33.5mm). Mean VAS scores for the other variables demonstrated a high level of 
agreement between the two studies r(7) = .90, p=0.006. 
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TABLE 15: TABLE COMPARING BASELINE MEAN SYMPTOM SCORES 
FOR THE BURGE 1991 AND NWOSU 2014 STUDIES 
 
Symptom Nwosu 2014  Burge 1991 
Thirst 56.1 53.8 
Pain 50.1 33.5 
Dry mouth 60.0 60.0 
Nausea 25.6 24.0 
Unpleasant taste 42.3 46.6 
Fatigue 63.6 61.8 
Pleasure in drinking 68.8 61.6 
N 7  
Spearman rank correlation (2 
tailed) 
.899  
P .006  
 
3.1.10  ANALYSIS OF THE BIOCHEMICAL INVESTIGATIONS (TABLE 16) 
The biochemical findings showed that 37 (41.1%) patients had pre-renal failure (i.e. 
ur:cr >100:1). The mean ur:cr ratio was 96.7 SD=53.16) with a mean eGFR of 72.1 
(SD=72.1); this is suggestive of an average eGFR stage of 1 (normal kidney function) 
or 2 (slightly reduced kidney function).299 
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TABLE 16: BIOCHEMICAL RESULTS FROM BASELINE  
 N Mean SD Median Range Normal 
reference 
range 
Sodium (mmol/l) 89 136.12 4.28 137 126 - 145 133 - 146 
Urea (mmol/l) 90 7.26 4.36 6.9 1.3 – 33.8 2.5 - 7.8 
Creatinine (μmol/l) 90 79.26 30.33 76.5 23 - 183 50 - 130 
eGFR 
(ml/min/1.73m
2
) 
90 72.1 18.77 76.0 24 - 90 0-90 
Ur:cr ratio 
(mmol/mmol) 
90 96.68 53.16 81.16 32.61 – 
383.61 
- 
Ur:cr ratio ≥100 (%) 37 
(41.1%) 
- - - - - 
Adjusted calcium 
(mmol/l) 
89 2.32 0.24 2.29 1.65 – 3.5 2.20 -2.60 
Serum albumin (g/l) 90 32.07 6.08 32 3 - 47 35 - 50 
Serum osmolarity 
(mosm/kg) 
61 286.36 10.03 288 260 - 311 275 - 295 
Urine osmolarity 
(mosm/kg) 
22 511.77 202.83 521 174 - 951 250 - 750 
Urinary sodium 
(mEq/L) 
22 71.68 51.34 59 13 - 188 >20 
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SECTION 2: MULTIPLE REGRESSION ANALYSES 
3.2.1 NORMALITY DISTRIBUTION OF DATA 
Data was tested for normality using histograms and the Shapiro-Wilk test. The 
findings were interpreted with the assistance of a statistician. Parametric and non-
parametric tests were used as appropriate. 
3.2.2 MULTIPLE REGRESSION ANALYSIS OF THE IMPEDANCE INDEX 
(H2/R) (TABLE 17) 
A multiple regression analysis was conducted to see which demographic factors 
independently predicted H2/R. The variables examined included the Burge-4 score 
(thirst, dry mouth, unpleasant taste and fatigue), age, ur:cr ratio, gender, presence 
of oedema, ECOG and the Morita dehydration score. Multiple linear regression 
analysis assumes that the residuals are not correlated serially from one observation 
to the next. The Durbin–Watson statistic is used in multiple linear regression to test 
whether the residuals are independent.300 The measured value is called ‘auto-
correlation’ and suggests that recorded observations are similar. A value of 2 
suggests that no autocorrelation (i.e. similarity between observations) exists within 
the sample. Values near 0 indicate positive autocorrelation whereas values toward 
4 suggest negative autocorrelation.301 In this analysis, the value of Durbin-Waston 
was 1.74, approximately equal to 2, which suggests that no serial correlation was 
present in this analysis. 
The R2 indicates how well the data fits the statistical model. Overall these variables 
significantly predicted H2/R, F(7, 82) = 11.58, p<.001, R2 = 0.50. This means that 50% 
of the variation of H2/R in this sample can be predicted by the variables included in 
this equation. In multiple regression analysis, the R2 will automatically increase as 
more variables are added to the equation. The adjusted R2 attempts to adjust for 
this phenomenon by only increasing when the added variable increases the R2 more 
than expected by chance.302 Consequently, R2 functions to quantify the relationship 
the linear relationship of data in the sample whereas the adjusted R2 provides an 
estimate of the degree of relationship in the underlying population. 
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In this analysis the adjusted of R2 score= 0.45 was close to the R2; this suggests that 
there has been minimal shrinkage of the prediction model. Four variables were 
statistically significant in the prediction of impedance index. Female gender was 
associated with a 13.85 decrease in H2/R (p<.001). Each one point increase of the 
Morita dehydration score corresponded with a 2.55 (p=.02) decrease of H2/R. 
Similarly, each one point increase of the Burge-4 score corresponded with a .29 
(p=.04) decrease of H2/R. These results suggest that the increasing values of the 
Burge-4 and Morita scores correspond with a decrease in TBW volume. The 
presence of oedema was associated with a 10.94 increase in H2/R (p<.001), which 
suggests increasing TBW volume.  
3.2.3 MULTIPLE REGRESSION ANALYSIS OF THE BURGE-4 SCORE 
(TABLE 18) 
A multiple linear regression analysis was undertaken to determine whether 
medications influenced the Burge-4 symptom analysis. The anticholinergic score, 
total daily morphine dose, the presence of diuretic medication and the use of 
SNRI/SSRI medications were entered into the regression equation. 
The value of the Durbin-Waston was 2.01. This is approximately equal to 2, 
indicating that there is no serial correlation between the variables. These variables 
did not independently predict the Burge-4 score, F(4, 84) = .975, p=.5321, R2 = 0.04. 
Here the R2 value of .04 suggests that 4% of the variation of Burge-4 score can be 
predicted the medication variables. The adjusted R2 score of -.006 was lower than 
the R2, and suggests the prediction model for the sample has provided an 
overestimate of the (limited) relationship in the underlying population.  
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TABLE 17: MULTIPLE REGRESSION ANAYSIS OF H2/R 
 
Variable B (standard error) P 
Constant 96.96 
(10.02) 
<.001 
Age .13 
(.11) 
.246 
Female -13.85 
(2.52) 
<.001 
ECOG -.55 
(1.38) 
.692 
Oedema present 10.94 
(2.89) 
<.001 
Urea:creatinine ratio -.02 
(.02) 
.423 
Morita dehydration score -2.55 
(1.1) 
.023 
Burge-4 score -.29 
(.14) 
.038 
R 0.71  
R squared 0.50  
Adjusted R squared 0.45  
Standard error of estimate 11.58  
Durbin-Watson 1.74  
No. of observations 90  
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TABLE 18: BURGE-4 LINEAR REGRESSION ANALYSIS 
Variable B (standard error) P 
Constant 54.78 (9.31) <.001 
Anticholinergic score .86 (1.16) .461 
Daily morphine dose .002 (0.19) .936 
Diuretic medication -1.68 (4.65) .719 
SSRI or SNRI -7.42 (4.42) .097 
R .198  
R squared .039  
Adjusted R squared -.006  
Standard error of estimate 15.45  
Durbin-Watson 2.01  
 
3.2.4 SUMMARY OF CHAPTER 
Ninety patients (recruitment rate 76.3%) participated in the study. Our data 
describes a sample consisting of mainly Caucasian individuals with various cancer 
diagnoses of which lung was the most common primary cancer site affected. 
Overall, participants had an average age of 71, an ECOG performance status of 2 or 
3 and a daily oral fluid intake of approximately 500 – 799mls. Pre-renal failure was 
present in 37 (41.1%) patients and mean eGFR was 72.1 ml/min/1.73m2. The 
sample was heavily symptomatic, with the highest mean scores recorded for 
fatigue, dry mouth and thirst. The prevalence of dehydration related symptoms was 
very similar to the last study to use the Burge assessment tool to evaluate 
symptoms in a palliative cancer population.250 Although many patients received 
medications (i.e. opioids, diuretics, anticholinergics, SNRIs and SSRIs) known to 
cause the same symptoms evaluated in the Burge-4 score (i.e. dry mouth, thirst and 
fatigue and unpleasant taste) regression analysis demonstrates that these 
medications were not predictive of the Burge-4 score. Four variables (gender, 
oedema, Morita dehydration score and the Burge-4 score) significantly influenced 
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H2/R. This may suggest that these factors are associated with (and can predict) TBW 
volume.  
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CHAPTER 4: THE USE OF BIVA TO COMPARE 
HYDRATION BETWEEN STUDY PARTICPANTS AND 
REFERENCE POPULATIONS 
4.1.1 INTRODUCTION 
The baseline BIVA results of participants are reported in this chapter. The RXc graph 
was used to classify hydration status of individuals relative to a non-cancer 
reference population. Statistical analysis was conducted to test for differences 
between hydration states according to clinical observations, biochemistry and self-
reported symptoms. Finally, the mean vectors for the entire sample were converted 
to Z-scores and compared to other cancer populations using the RXc Z-score 
graph.144  
4.1.2 BODY COMPOSITION CLASSIFICATION ACCORDING TO THE RXC 
GRAPH (TABLES 19 & 20; FIGURES 16 & 17) 
The hydration status of subjects was classified using the RXc graph. No significant 
difference in hydration classification was evident between men and women. The 
majority of the sample was normally hydrated (n=43, 47.8%); with more-hydration 
more prevalent than less hydration.  
TABLE 19: CLASSIFICATION OF HYDRATION AS A FIVE-ITEM SCALE 
ACCORDING TO THE RXC GRAPH  
 Male Female Total (%) P 
Very less-hydrated 5 2 7 (7.8) - 
Less-hydrated 2 1 3 (3.3) - 
Normal 18 25 43 (47.8) - 
More-hydrated 6 10 16 (17.8) - 
Very more-hydrated 11 10 21 (23.3) - 
Total 42 48 90 .49 
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TABLE 20: CLASSIFICATION OF HYDRATION AS A THREE-ITEM SCALE 
ACCORDING TO THE RXC GRAPH SCALE  
 Male Female Total (%) P 
Normal 18 25 43 (47.8) - 
Less-hydrated 7 3 10 (11.1) - 
More-hydrated 17 20 37 (41.1) - 
Total 42 48 90 .27 
 
FIGURE 16: VECTOR POSITIONS FOR MALES ON THE RXC POINT GRAPH 
(N=42) 
 
FIGURE 17: VECTOR POSITIONS FOR FEMALES ON THE RXC POINT 
GRAPH (N=48) 
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4.1.3 COMPARISON OF VARIABLES ACCORDING TO THE LESS-
HYDRATED AND NOT LESS-HYDRATED GROUPS (TABLES 21 – 22) 
The results of the hydration classification were simplified to compare less-hydrated 
patients (n=10, 11.1%) to those without less-hydration (n=80, 88.9%) (Table 21). 
Mann U Whitney (U) was used to analyse the ordinal scores of ECOG, the Morita 
Dehydration Score and the oral intake assessment. The Mann-Whitney test is non-
parametric test that is used to evaluate differences between two ordinal samples 
by comparing the mean rank of each variable. The mean rank for oral intake was 
significantly higher in patients without less-hydration compared to those who were 
less-hydrated (U(90) =257.5, p=0.048). Significant differences in bio-impedance 
measurements were observable based on hydration status (Tables 22). Notably, the 
H2/R was significantly lower in less-hydration (M=39.57, SD=9.28 vs. M=53.08, 
SD=15.40; t(90)=-2.71, p=0.008). Phase angle was higher in less-hydration (M=6.11, 
SD=2.16) compared with other patients (M=4.53, SD=1.09); t(9.58)=2.27, p=0.047. 
Less-hydrated patients also had significantly higher values for R/H (t(88)=4.16, 
p<.001) and Xc/H (t(88)=7.82, p<.001) compared to all other patients.  
Compared with the rest of the sample, less-hydrated individuals experienced higher 
scores for several variables; however, many of these items did not reach statistical 
significance. These included the Burge-4 score (M=257.6, SD=91.8 vs. M=217.6, 
SD=95.5; p=.21) the Morita dehydration score (U(90) = 269, p=.08), the ur:cr ratio 
(M=137.2, SD=101.3 vs. M=91.6, SD=42.2; p=.19), urine osmolality (M=540.5, 
SD=177.0 vs. M=505.4, SD=212.3; p=.35) and ECOG (M (326), p=.32). Sub-analysis of 
the Morita score demonstrated that axilla dryness was significantly higher in less-
hydrated participants compared to those not less-hydrated (U(90)=245, p=0.02).  
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TABLE 21: CLASSIFICATION OF LESS-HYDRATION ACCORDING TO THE 
RXC GRAPH 
 Male Female Total (%) P 
Less hydrated 7 3 10 (11.1) - 
Not less hydrated 35 45 80 (88.9) - 
Total 42 48 90 .18  
 
TABLE 22: COMPARISON BETWEEN LESS HYDRATED AND NOT LESS 
HYDRATED GROUPS ACCORDING TO SELF-REPORTED SYMPTOMS, 
BIOCHEMISTRY AND BIO-IMPEDANCE MEASUREMENTS 
 Less hydrated (n=10)  All other patients (n=80)   
 Mean SD  Mean SD T test p 
Burge-4 score (mm) 257.60 91.76  217.63 95.47 1.25 .21 
 Thirst 72.70 22.97  54.04 29.67 1.92 .06 
 Pain 45.50 39.42  50.66 29.88 -0.50 .62 
 Dry mouth 70.60 25.80  58.69 31.07 1.16 .25 
 Nausea 23.20 36.76  25.91 30.76 -0.26 .80 
 Unpleasant taste 52.20 37.51  41.11 33.71 0.97 .34 
 Fatigue 62.10 23.73  63.79 30.92 -0.17 .87 
 Pleasure in drinking 60.89 30.58  69.65 28.97 -0.86 .40 
        
Ur:Cr ratio 137.15 101.33  91.62 42.20 1.41 .19 
Na 134.10 4.77  136.38 4.17 -1.60 .11 
eGFR 71.00 24.68  72.24 18.09 -0.20 .85 
AdjCa 2.26 0.13  2.32 0.25 -0.81 .42 
Serum osmolality 281.75 18.46  286.68 9.38 -0.95 .35 
Albumin 29.70 3.95  32.36 6.25 -1.31 .19 
        
Urine osmolality 540.50 177.03  505.39 212.25 .31 .76 
Urine:plasma 
osmolality 
1.71 0.44  1.71 0.73 -.001 1.0 
Urinary Na 69.75 67.02  71.11 49.62 -.08 .94 
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 Less hydrated (n=10)  All other patients (n=80)   
 Mean SD  Mean SD T test p 
H
2
/R 39.57 9.28  53.08 15.40 -2.71 .008 
PA 6.11 2.16  4.53 1.09 2.27 .047 
RH 437.59 77.96  329.58 77.36 4.14 <.001 
XcH 44.77 10.76  10.76 6.83 7.82 <.001 
 
4.1.4 COMPARISON OF BIO-IMPEDANCE VECTORS ACCORDING TO 
CLINICAL OBSERVATIONS AND SELF-REPORTED SYMPTOMS (TABLE 23, 
FIGURES 18A-F) 
BIVA demonstrated statistically significant differences according to several 
dichotomous variables, which were analysed on account of the presence or 
absence of each characteristic. This included assessment of the ‘less-hydrated’ 
status (T2=6.3, p<.001), oedema (T2=12.1, p<.001), thirst score cut-off of 50mm 
(T2=11.2, p<.001), Morita dehydration cut-off of 2 (T2=33.6, p<.001) and ECOG 
performance status cut-off of 2 (T2=6.7, p=.04). These differences were further 
analysed with the RXc mean graph to determine their meaning.  
Less hydrated participants had higher values for R/H compared to those not less-
hydrated (T2=6.3, p<.001) (Figure 18a). This finding, coupled with the vector 
position, suggests lower TBW volume was present in less-hydrated individuals. The 
larger confidence ellipse in less-hydrated patients is possibly caused by the small 
number patients in the analysis (n=10). The mean impedance vector for 
oedematous participants was shorter with comparatively lower R/H values 
(T2=12.1, p<0.001) (Figure 18b). Compared with non-oedematous individuals, the 
oedematous vector was more inferiorly placed, suggesting relatively higher TBW.  
For thirst (sub-score of the Burge-4 score) R/H were higher for scores ≥50mm 
compared to <50mm (T2=11.2, p<0.001).  This suggests those with thirst scores 
≥50mm have lower TBW than those with scores <50mm (Figure 18c). Morita 
dehydration scores of ≥2 had higher R/H, suggesting less TBW, compared to 
individuals with scores <2 (T2=33.6, p<.001) (Figure 18d). Participants classified as 
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ECOG-4 had higher R/H, with a vector position that suggested less TBW, compared 
to an ECOG status of <4 (T2=6.7, p=.04) (Figure 18e). Women had significantly 
higher R/H scores compared to men (T2=16.1, p<.001) with a vector position (Figure 
18f) suggesting comparatively lower TBW volumes in females compared to males.
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TABLE 23: BIVA ANALYSES FOR THE SAMPLE ACCORDING TO SEVERAL CLINICAL VARIABLES (N=90)v 
Variable N R/H Mean R/H SD Xc/H Mean Xc/H SD (R/H, Xc/H) T
2
 F D P 
Less-hydrated 10 437.59 77.96 44.77 10.76 0.28 
61.3 30.3 2.63 <.001 
Not less-hydrated 80 329.58 77.36 25.55 6.83 0.54 
Oedema 27 299.8 88.8 23.7 5.7 0.49 
12.1 6 .8 <.001 
No oedema 63 359.5 76.1 29.4 10.3 0.53 
Burge-4 ≥222mm 45 355.79 78.02 29.42 11.20 0.48 
3.7 1.8 .41 .16 
Burge-4 <222mm  45 327.36 88.58 25.95 7.11 0.66 
Thirst ≥50mm 52 365.1 83.6 29.6 10.6 0.48 
11.2 5.5 .71 <.001 
Thirst <50mm 38 309.4 74.8 25.1 7.0 0.60 
Unpleasant taste ≥50mm 37 359.17 81.66 28.78 9.44 0.51 
2.8 1.4 .36 .26 
Unpleasant taste <50mm 53 329.30 84.55 26.92 9.54 0.56 
Dry mouth ≥50mm 58 356.23 75.33 28.54 10.03 0.54 
5.2 2.6 .5 .08 
Dry mouth <50mm 32 315.03 93.91 26.14 8.35 0.55 
Fatigue ≥50mm 63 350.88 77.23 27.78 7.80 0.47 
3.4 1.7 .42 .19 
Fatigue <50mm 27 319.87 96.72 27.46 12.77 0.65 
Secretions 6 363.54 114.22 26.6803 9.0837 0.809 
1 .5 .42 .61 
No secretions 84 340.01 82.35 27.76 9.56 0.53 
Morita dehydration ≥2 52 367.95 9.23 30.11 10.26 0.42 
33.6 16.6 1.24 <.001 
Morita dehydration <2 38 305.48 78.05 24.36 7.19 0.65 
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Variable N R/H Mean R/H SD Xc/H Mean Xc/H SD (R/H, Xc/H) T2 F D P 
Dry axilla 50 355.57 80.12 29.77 10.56 0.49 
6.1 3 .52 .05 
Moist axilla 40 324.09 86.92 25.08 7.26 0.61 
Sunken eyes 27 362.46 74.74 30.74 11.80 0.26 
4.5 2.2 .49 .12 
Eyes not sunken 63 332.63 86.99 26.37 8.07 0.70 
Ur:Cr ≥100:1 37 332.3 80.4 26.6 7.8 0.66 
2.3 1.1 .32 .33 
Ur:Cr <100:1 53 354.9 88.8 29.3 11.4 0.44 
ECOG ≥2 75 342.3 89.6 27.3 10.1 0.61 
1.3 .6 .32 .53 
ECOG<2 25 337.8 51.8 29.6 5.6 0.55 
ECOG ≥3 53 348.4 92.4 27.2 10.9 0.64 
2.6 1.3 .35 .28 
ECOG<3 37 331.8 71.0 28.4 7.1 0.53 
ECOG =4 17 387.6 69.3 30.2 14.1 0.32 
6.7 3.3 .7 .04 
ECOG <4 73 330.8 84.1 27.1 8.1 0.64 
Oral intake ≥800mls 23 306.06 76.293 25.78 7.20 0.72 
5.8 2.9 .58 .06 
Oral intake <800mls 67 353.77 83.87 28.34 10.12 0.50 
Males 42 306.6 75.6 26.1 9.1 0.45 
16.4 8.1 .86 <.001 
Females 48 372.2 80.0 29.1 9.7 0.63 
 
V
 The analysis compared differences between the vector means for each category (e.g. mean vectors of ‘less hydrated’ patients were directly compared to those 
‘not-less hydrated’). The p-value is the statistical significance of the difference between the mean vectors.
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Figure 18a: Less-hydrated (red ellipse); 
not less-hydrated (black ellipse). T
2
=6.3, 
p<.001 
 
Figure 18c: Thirst score of ≥50mm (red 
ellipse); <50mm (black ellipse), T
2
=11.2, 
p<.001. 
 
Figure 18d: Morita score ≥2 (red 
ellipse); score <2 (black ellipse), 
T
2
=33.6, p<.001. 
 
Figure 18b: No oedema (red ellipse); 
oedema (black ellipse), T
2
=12.1, p<.001 
 
FIGURE 18:  RXC MEAN GRAPH DEMONSTRATING SIGNIFICANT DIFFERENCES IN 
BIVA FOR CATEGORICAL ANALYSES WITHIN THE SAMPLE (N=90) 
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Figure 18f: females (red ellipse) and 
males (black ellipse), T
2
=16.4, p<.001. 
 
Figure 18e: ECOG stage 4 (red ellipse) 
and <4 (black ellipse), T
2
=6.7, p=.04. 
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4.1.5 GENDER SUB-ANALYSIS (TABLES 25 & 26; 19A-F & 20A-B) 
Statistically significant vector differences were noted when the data was sub-
analysed according to gender. Mean vectors were statistically significantly different 
in both genders (Figures 19a and 20a) according to the presence or absence of less-
hydration (men, T2=56.9, p<.001; females, T2=37.3, p<.001) and the presence or 
absence of oedema (Figures 19b and 20b) (males, T2=15.7, p<0.001; females, T2=3, 
p<0.001). 
The only other significant findings were evident in men. Males with dry mouth VAS 
scores ≥50mm had higher values of R/H and similar Xc/H when compared to those 
with scores <50mm (T2=7.5, p=.04) (Figure 19c). Although the mean vectors for dry 
mouth scores (cut off of 50mm) were significantly different from each other, these 
vectors were in a similar hydration position, according to the parallel divisions of 
the 5-point RXc graph (Figure 19c). Morita dehydration scores of ≥2 (Figure 19d) 
had significantly higher mean R/H (suggesting lower TBW) compared to scores of <2 
(T2=14.1, p<.003).  
 
 
 
105 
 
TABLE 24:  BIVA ANALYSES FOR MALES ACCORDING TO SEVERAL CLINICAL VARIABLES (N=42) 
Variable N 
R/H 
Mean 
R/H SD Xc/H 
Mean 
Xc/H SD RH, XcH 
T
2
 F D P 
Less-hydrated 7 418.46 74.47 40.89 3.03 0.75 
56.9 27.8 3.12 <.001 
Not less-hydrated 35 284.21 53.06 23.12 6.65 0.41 
Oedema 10 240.12 45.86 23.35 6.48 0.67 
15.7 7.7 1.44 <.001 
No oedema 32 327.35 71.22 26.94 9.71 0.64 
Burge-4 ≥222mm (mean) 16 322.40 70.22 26.57 11.24 0.48 
1.4 .7 .38 .5 
Burge-4 <222mm (mean) 26 296.85 78.41 25.79 7.74 0.79 
Thirst ≥50mm 20 330.22 74.07 27.87 10.60 0.54 
4.0 2.0 .62 .16 
Thirst <50mm 22 285.10 71.90 24.46 7.38 0.73 
Unpleasant taste ≥50mm 15 318.60 74.06 26.74 11.57 0.50 
.6 .3 .25 .74 
Unpleasant taste <50mm 27 299.91 76.96 25.72 7.63 0.77 
Dry mouth ≥50mm 24 326.01 67.47 26.00 9.40 0.67 
7.5 3.6 .85 .04 
Dry mouth <50mm 18 280.68 79.81 26.19 8.97 0.68 
Fatigue ≥50mm 27 313.23 65.43 26.93 9.13 0.5 
.8 .4 .29 .69 
Fatigue <50mm 15 294.63 92.38 24.56 9.18 0.81 
Secretions 4 319.61 115.91 24.99 10.63 0.82 
.5 .2 .37 .78 
No secretions 38 305.21 72.24 26.20 9.09 0.61 
Morita dehydration ≥2 23 338.83 78.93 29.72 9.10 0.51 
14.1 6.9 1.16 .003 
Morita dehydration <2 19 267.55 49.57 21.68 7.09 0.60 
Dry axilla 24 324.66 75.13 27.72 9.49 0.51 
3.5 1.7 .58 .20 
Moist axilla 18 282.47 71.12 23.91 8.33 0.77 
 
 
106 
 
 
Variable N 
R/H 
Mean 
R/H SD 
Xc/H 
Mean 
Xc/H SD RH, XcH T2 F D P 
Sunken eyes 10 320.60 68.64 28.33 9.34 0.18 
.8 .4 .32 .68 
Eyes not sunken 32 302.20 78.11 25.38 9.07 0.75 
Ur:Cr ≥100:1 15 328.73 76.44 27.30 8.65 0.32 
2.2 1.1 .48 .36 
Ur:Cr <100:1 27 294.28 73.61 25.41 9.44 0.79 
ECOG ≥2 37 307.4 78.1 25.6 9.3 0.63 
1.8 .9 .64 .42 
ECOG<2 5 300.9 60.3 29.6 7.8 0.90 
ECOG ≥3 24 309.9 71.3 25.2 9.5 0.53 
1.7 .8 .41 .44 
ECOG<3 18 302.1 82.8 27.3 8.6 0.80 
ECOG =4 6 344.0 67.0 27.1 8.3 0.76 
2.3 1.1 .67 .34 
ECOG <4 36 300.3 75.9 25.9 9.3 0.62 
Oral intake ≥800mls 10 261.21 61.75 21.01 4.45 0.60 
6.1 3 .89 .06 
Oral intake <800mls 32 320.76 74.66 27.67 9.64 0.60 
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TABLE 25: BIVA ANALYSES FOR FEMALES ACCORDING TO SEVERAL CLINICAL VARIABLES (N=48) 
Variable N 
R/H 
Mean 
R/H SD Xc/H 
Mean 
Xc/H SD RH, XcH 
T
2
 F D P 
Less-hydrated 3 482.24 80.23 53.84 17.82 0.99 
37.3 18.3 3.64 <.001 
Not less-hydrated 43 364.86 75.23 27.43 6.42 0.450 
Oedema 17 334.85 89.99 23.88 5.34 0.56 
11.3 5.5 1.01 <.001 
No oedema 31 392.68 66.93 31.94 10.39 0.34 
Burge-4 ≥222mm (mean) 29 374.21 77.04 30.99 11.047 0.43 
3.4 1.6 .54 .20 
Burge-4 <222mm (mean) 19 369.12 86.34 26.18 6.36 0.60 
Thirst ≥50mm 32 382.95 82.73 30.64 10.68 0.42 
3.8 1.9 .60 .17 
Thirst <50mm 16 342.70 67.13 25.98 6.55 0.40 
Unpleasant taste ≥50mm 22 386.83 76.15 30.17 7.65 0.49 
1.4 .7 .34 50 
Unpleasant taste <50mm 26 359.82 82.51 28.16 11.20 0.42 
Dry mouth ≥50mm 34 377.55 74.13 30.32 10.21 0.42 
2.0 1.0 .45 .39 
Dry mouth <50mm 14 359.19 94.46 26.07 7.80 0.54 
Fatigue ≥50mm 36 379.12 73.97 28.42 6.70 0.49 
3.3 1.6 .61 .21 
Fatigue <50mm 12 351.42 96.41 31.08 15.89 0.52 
Secretions 2 451.40 41.98 30.06 6.22 1 
- - - - 
No secretions 46 368.75 79.70 29.04 9.85 0.45 
Morita dehydration ≥2 29 391.06 72.73 30.43 11.25 0.39 
4.5 2.2 .63 .12 
Morita dehydration <2 19 343.41 83.83 27.04 6.40 0.59 
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Variable N 
R/H 
Mean 
R/H SD 
Xc/H 
Mean 
Xc/H SD RH, XcH T2 F D P 
Dry axilla 26 384.10 75.01 31.67 11.31 0.42 
4.4 2.1 .61 .13 
Moist axilla 22 358.13 85.07 26.03 6.30 0.51 
Sunken eyes 17 387.08 68.47 32.16 13.09 0.23 
2.8 1.4 .51 .26 
Eyes not sunken 31 364.04 85.60 27.40 6.88 0.68 
Ur:Cr ≥100:1 22 372.76 93.77 30.68 13.02 0.46 
1.3 .7 .33 .52 
Ur:Cr <100:1 26 371.72 68.12 27.73 5.46 0.51 
ECOG ≥2 38 376.4 87.7 29.0 10.7 0.46 
.8 .4 .32 .68 
ECOG<2 10 356.3 37.6 29.6 4.7 0.49 
ECOG ≥3 29 380.2 96.7 28.9 11.8 0.50 
1.2 .6 .32 .57 
ECOG<3 19 359.9 43.5 29.4 5.3 0.19 
ECOG =4 11 411.5 60.7 31.9 16.6 0.17 
3.7 1.8 .66 .17 
ECOG <4 37 360.5 82.0 28.2 6.5 0.68 
Oral intake ≥800mls 13 340.56 69.61 29.45 6.84 0.61 
4.1 2 .66 .15 
Oral intake <800mls 35 383.95 81.29 28.95 10.64 0.45 
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FIGURE 19:  RXC MEAN GRAPH DEMONSTRATING SIGNIFICANT DIFFERENCES 
IN BIVA FOR CATEGORICAL ANALYSES FOR MALES (N=42) 
 
Figure 19a: Less-hydrated (red ellipse); 
not less-dehydrated (black ellipse). 
T
2
=56.9, p<0.001 
 
Figure 19b: No oedema (red ellipse); 
oedema (black ellipse), T
2
=15.7, p<0.001 
 
Figure 19d: Morita dehydration score ≥2 
(red ellipse); <2 (black ellipse), T
2
=14.1, 
p=0.003. 
 
Figure 19c: Dry mouth score of ≥50mm 
(red ellipse); <50mm (black ellipse), 
T
2
=7.5, p=.04. 
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Figure 20a: Less-hydrated (red ellipse); not 
less-hydrated (black ellipse). T
2
=37.3, 
p<0.001.
vi
 
 
Figure 20b: No oedema (red ellipse); 
oedema (black ellipse), T
2
=12.1, 
p<0.001. 
 
FIGURE 20: RXC MEAN GRAPH DEMONSTRATING SIGNIFICANT DIFFERENCES 
IN BIVA FOR CATEGORICAL ANALYSES FOR FEMALES (N=48) 
 
vi
 The Less-hydrated (red ellipse) extends beyond the parameters of the figure. 
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4.1.6 THE RXC Z-SCORE GRAPH ANALYSIS (TABLE 26 & FIGURE 21) 
Analysis from the RXc Z-score graph demonstrates that participants from this study 
were normally hydrated with a low muscle mass. Male and females were similarly 
placed within the 50% tolerance ellipse. Compared with previous results, our data 
was similar to the lung cancer samples reported by Toso et al; 98 158 however, breast 
cancer patients had more muscle mass297 and those affected by cancers of the head 
and neck cancer were leaner.206 298 The head and neck cancer studies show a slight 
difference in positions on the Z-score graph, with the sample populations 
respectively placed in the 50% and 75% tolerance ellipses.206 298 
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TABLE 26: RXC Z-SCORES FOR PREVIOUS CANCER STUDIES ACCORDING TO THEIR REFERENCE POPULATIONS  
  Study population details  Reference population 
Author Description 
R/H 
Mean 
Xc/H 
Mean 
Z(R) 
score 
Z (Xc) 
score 
 N 
R/H 
mean 
R/H 
SD 
Xc/H 
Mean 
Xc/H 
SD 
Nwosu 2014 
Males, predominantly Caucasian, mixed 
advanced cancer (n=42) 
306.6 26.1 0.19 -0.65  354 298.6 43.2 30.8 7.2 
Nwosu 2014 
Female, predominantly Caucasian, mixed 
advanced cancer (n=48) 
372.2 29.1 0.01 -0.69  372 371.9 49.0 34.4 7.7 
Toso 2000
158
 
Males, Caucasian, lung cancer stage IIIB 
(n=33) 
302.0 25.0 -0.12 -1.00  56 308.0 49.0 31.0 6.0 
Toso 2000
158
 Males, Caucasian, lung cancer stage IV (n=30) 314.0 24.0 0.12 -1.17  56 308.0 49.0 31.0 6.0 
Małecka-Massalska 
2012
297
 
Females, breast cancer (n=34) 377.54 53.58 0.29 0.90  34 341.0 127.2 47.0 7.3 
Toso 2003
98
 
Males, Caucasian, lung cancer, locally 
advanced and disseminated (n=61) 
317 26 0.18 -0.83  56 308.0 49.0 31.0 6.0 
Melecka Massala 
2012
206
 
Males, head and neck cancer (n=56) 342.54 27.62 0.84 -0.56  31 314.52 33.3 30.2 4.6 
Toso 2003
98
 
Males, Caucasian, lung cancer in remission 
(n=31) 
287 25 -0.43 -1.00  56 308.0 49.0 31.0 6.0 
Melecka Massala 
2013
298
 
Males, head and neck cancer (n=67) 327.01 28.04 0.51 -0.23  67 307.4 38.1 29.3 5.4 
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FIGURE 21: RXC Z-SCORE GRAPH ANALYSIS FROM THIS STUDY AND 
PREVIOUS CANCER STUDIES FROM THE LITERATURE PRESENTED WITH 
THEIR REFERENCE POPULATIONS  
 
Symbol Description 
● Males, predominantly Caucasian, mixed advanced cancer (n=42), Nwosu 
et al 2014. 
▲ Female, predominantly Caucasian, mixed advanced cancer (n=48), Nwosu 
et al 2014. 
■ Males, Caucasian, lung cancer stage IIIB (n=33), Toso 2000.158 
○ Males, Caucasian, lung cancer stage IV (n=30), Toso 2000.158 
△ Females, breast cancer (n=34), Małecka-Massalska et al 2012.297 
◆ Males, Caucasian, lung cancer, locally advanced and disseminated (n=61), 
Toso 2003.98 
□ Males, head and neck cancer (n=56), Melecka Massala 2012.206 
x Males, Caucasian, lung cancer in remission (n=31), Toso 2003.98 
♢ Males, head and neck cancer (n=67), Melecka Massala 2013.298 
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4.1.7 SUMMARY OF CHAPTER 
The majority of this sample were normally hydrated (n=43, 47.8%), with more-
hydration (n=37, 41.1%) more prevalent than less-hydration (n=10, 11.1%). 
Comparison between less-hydrated and those without less-hydration demonstrates 
that oral fluid intake was statistically significantly lower in less-hydrated 
participants (p=.048); additionally, axilla dryness (as measured by the Morita 
dehydration score) was significantly higher in less-hydration (p=.02). No other 
statistically significant differences were detected for the current sample. Although 
differences between these groups were not statistically significant, the analysis 
demonstrates that (when compared to those without less-hydration) individuals 
with less-hydration experienced higher values for several variables. This included 
the Burge-4 score (and its constituent items of thirst, dry mouth and unpleasant 
taste), the Morita dehydration score (and its constituent item of mucous 
membrane sub-score), ur:cr, urinary osmolality and ECOG performance status.  
Overall, for the sample (n=90), BIVA demonstrates significant differences between 
mean vectors for those classified by the presence or absence of less-hydration 
(p<.001), oedema (p<.001), thirst VAS cut off of 50mm (p<.001), Morita dehydration 
score cut-off of 2 (p<.001) and ECOG cut off of 4 (p=.04). Women had less TBW 
volume compared to men and other variations in the significance of differences 
were present on account of gender. BIVA comparison with other cancer 
populations demonstrated that patients in this sample were normally hydrated 
(through placement within the normal 50% tolerance ellipse) and had a similar 
body composition to those affected by cancers of the lung and head and neck.  
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CHAPTER 5: SURVIVAL ANALYSIS 
5.1.1 INTRODUCTION 
Survival outcomes for study participants (according to hydration states, H2/R and 
biochemistry) are presented in this chapter. A cox regression analysis is described 
to illustrate the influence of confounding factors on survival. Throughout this 
chapter 95% confidence intervals are presented in square brackets. 
5.1.2 DEMOGRAPHICS OF SURVIVAL DATA (TABLE 27 & 28) 
Survival was recorded from the date of initial BIVA assessment. Each patient was 
followed up for 3 months at the end of data collection. Overall, 76 (84.4%) 
participants died, with 14 (15.6%) alive at the end of the follow-up period (Table 
27). From the date of recruitment, 23 (25.6%) patients died within 30 days and four 
(4.4%) died within seven days.  No patients were lost to follow-up. Median survival 
was 62 days [38.76, 85.24] and ranged between 2 to 410 days (Table 28).  
TABLE 27: NUMBER OF PATIENTS ALIVE OR DECEASED ACCORDING TO 
3-MONTH FOLLOW-UP, 30-DAY SURVIVAL AND 7-DAY SURVIVAL 
PERIODS 
Status N % 
Patients dead at the end of the 3 month 
follow up 
76 84.4 
Patients alive at the end of the 3 month 
follow up  
14 15.6 
   
Patients dead ≤30 days of study 
recruitment 
23 25.6 
Patients dead after ≤7 days of study 
recruitment 
4 4.4 
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TABLE 28: SURVIVAL TIME (DAYS) FOR THE SAMPLE (N=90) FROM THE 
DATE OF THE INITIAL ASSESSMENT 
 
Mean
a
 Median 
Estimate SE 95% Confidence Interval Estimate SE 95% Confidence Interval 
Lower  Upper  Lower  Upper  
108.634 12.264 84.597 132.671 62.000 11.859 38.757 85.243 
a. Estimation is limited to the largest survival time if it is censored. 
 
Metric Survival time (days) 
Mean 94.29 
Median 64.00 
Std. Deviation 86.38 
Minimum 2 
Maximum 410 
 
5.1.3 SURVIVAL ANALYSIS OF PARTICIPANTS BASED ON THEIR 
HYDRATION STATUS CLASSIFICATION (TABLE 29, FIGURE 22) 
Kaplan-Meier analysis of the three hydration states (normal, less-hydrated and 
more-hydrated) demonstrated that median survival was shortest at 44 days [34.7, 
53.29] in less-hydration, followed by 68 days [19.28, 116.72] in normal hydration 
and 70 days [0, 141.8] in more-hydration. Log rank test of these three variables 
failed to demonstrate a statistically significant difference between the three 
categories (p=.09).  
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TABLE 29: MEAN AND MEDIANS FOR SURVIVAL TIME ACCORDING TO 
THE THREE HYDRATION CLASSIFICATIONS  
 Mean
a
 Median 
Hydration classification 
according to BIVA 
Estimate SE 95% Confidence 
Interval 
Estimate SE 95% Confidence 
Interval 
 Lower  Upper  Lower  Upper  
Normal 110.614 18.483 74.388 146.840 68.000 24.858 19.279 116.721 
Less hydrated 50.000 7.967 34.385 65.615 44.000 4.743 34.703 53.297 
More hydrated 123.075 17.935 87.922 158.227 70.000 36.633 .000 141.801 
Overall 108.634 12.264 84.597 132.671 62.000 11.859 38.757 85.243 
 
 
Overall Comparisons 
 Chi-
Square 
df Sig. 
Log Rank (Mantel-Cox) 4.926 2 .085 
Test of equality of survival distributions for the different hydration classification 
according to BIVA. 
 
FIGURE 22: KAPLAN-MEIER GRAPH SHOWING SURVIVAL TIME IN DAYS 
ACCORDING TO THE THREE HYDRATION CLASSIFICATIONS AS 
DETERMINED BY BIVA (P=0.09) 
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5.1.3.1  SURVIVAL ANALYSIS OF LESS HYDRATED VS. NOT LESS 
HYDRATED PATIENTS (TABLE 30, FIGURE 23) 
As the median survival times for the normal and more-hydrated group were similar, 
these categories were combined to facilitate comparison between less-hydrated 
and those without less-hydration. Analysis of this variable demonstrates that 
median survival was statistically shorter in less-hydrated patients compared to 
other patients (44 days [34.7, 53.29] vs 68 days [36.84, 99.16], log-rank p=.04. 
 
TABLE 30: MEAN AND MEDIANS OF SURVIVAL TIMES ACCORDING TO 
THE LESS-HYDRATED BIVA CLASSIFICATION 
 Mean Median 
Is the patient less-
hydrated? 
Estimate SE 95% Confidence 
Interval 
Estimate SE 95% Confidence 
Interval 
 Lower Upper Lower Upper 
No 115.964 13.543 89.419 142.508 68.000 15.896 36.844 99.156 
Yes 50.000 7.967 34.385 65.615 44.000 4.743 34.703 53.297 
Overall 108.634 12.264 84.597 132.671 62.000 11.859 38.757 85.243 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 4.075 1 .044 
 
Test of equality of survival distributions according to dehydration status classification. 
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FIGURE 23: KAPLAN-MEIER GRAPH SHOWING SURVIVAL TIME IN DAYS 
ACCORDING TO THE LESS-HYDRATED CLASSIFICATION AS 
DETERMINED BY BIVA (P=0.04) 
 
 
5.1.3.2  SURVIVAL ANALYSIS OF MORE-HYDRATED VS. NOT MORE-
HYDRATED PATIENTS (TABLE 31, FIGURE 24) 
Median survival was longer in patients classified as more-hydrated compared to 
those who were not (49 days [23.14, 74.86] vs. 70 days [0, 141.8]); however, this 
difference was not statistically significant (p=.16).  
TABLE 31:  MEAN AND MEDIANS FOR SURVIVAL TIMES ACCORDING 
TO THE MORE-HYDRATED BIVA CLASSIFICATION 
 
 Mean Median 
Is the patient over-
hydrated according 
to BIVA? 
Estimate SE 95% Confidence 
Interval 
Estimate SE 95% Confidence 
Interval 
 Lower  Upper  Lower  Upper  
No 99.177 15.411 68.971 129.383 49.00 13.193 23.142 74.858 
Yes 123.075 17.935 87.922 158.227 70.00 36.633 .000 141.801 
Overall 108.634 12.264 84.597 132.671 62.00 11.859 38.757 85.243 
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FIGURE 24: KAPLAN-MEIER GRAPH SHOWNG SURVIVAL TIME IN DAYS 
ACCORDING TO THE MORE-HYDRATED CLASSIFICATION AS 
DETERMINED BY BIVA (P=0.16) 
 
 
 
5.1.3.3  SURVIVAL ANALYSIS ACCORDING TO H2/R (TABLE 32) 
Cox regression analysis was conducted using H2/R as a continuous variable. The 
impedance index was a statically significant predictor of survival, HR=0.98 [.96, .99], 
p=0.01. Each unit m2/Ohm increase of H2/R reduces the probability of death by a 
factor of 1.03 (i.e. 1/Exp[B]). This suggests that a higher H2/R (which indicates 
higher TBW volumes) reduces the likelihood of death.  
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TABLE 32: COX REGRESSION ANALYSIS FOR H2/R 
 
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square 
df Sig. Chi-square df Sig. Chi-square df Sig. 
562.690 5.669 1 .017 6.235 1 .013 6.235 1 .013 
 
 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B) 
Lower Upper 
H
2
/R -.021 .009 5.628 1 .018 .979 .962 .996 
 
 
Covariate Means 
 Mean 
H
2
/R 51.582 
 
5.1.4 SURVIVAL ANALYSIS ACCORDING TO RENAL BIOCHEMISTRY 
(TABLE 33 & 34, FIGURE 25) 
Kaplan-Meier analysis demonstrates that participants with pre-renal failure (ur:cr 
ratio ≥100:1) had significantly shorter median survival compared to those without 
(44 days [32.08, 55.92] vs. 100 days [48.51, 151.49], p=.03). Furthermore, cox 
regression analysis of the ur:cr ratio (as a continuous variable) provided a hazard 
ratio (HR) of 1.009 [1.005, 1.014], p=.003 (Table 34). This suggests that each unit 
increase (mmol:mmol) of the ur:cr ratio causes survival to worsen by a factor of 
1.009. 
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TABLE 33: MEAN AND MEDIANS FOR SURVIVAL TIMES ACCORDING TO 
THE PRESENCE OF PRE-RENAL FAILURE  
 
 
 Mean Median 
Is pre-renal 
failure present? Estimate SE 
95% Confidence 
Interval Estimate SE 
95% Confidence 
Interval 
 Lower  Upper  Lower  Upper  
No 134.353 16.855 101.317 167.390 100.000 26.270 48.512 151.488 
Yes 64.709 10.810 43.523 85.896 44.000 6.081 32.082 55.918 
Overall 108.634 12.264 84.597 132.671 62.000 11.859 38.757 85.243 
 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) 8.987 1 .003 
 
Test of equality of survival distributions according to the presence or absence of pre-renal failure. 
 
 
FIGURE 25: KAPLAN-MEIER GRAPH SHOWING SURVIVAL TIME IN DAYS 
ACCORDING TO THE PRESENCE, OR ABSENCE, OF PRE-RENAL FAILURE 
(P=.003) 
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TABLE 34: COX REGRESSION SURVIVAL ANALYSIS ACCORDING TO THE 
UR:CR RATIO 
 
Omnibus Tests of Model Coefficients
a
 
-2 Log Likelihood Overall (score) Change From Previous Step Change From Previous Block 
Chi-square df Sig. Chi-square df Sig. Chi-square df Sig. 
555.675 15.867 1 .000 13.250 1 .000 13.250 1 .000 
 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 
Ur:Cr ratio .009 .002 15.980 1 .000 1.009 
 
Covariate Means 
 Mean 
Ur:Cr ratio 96.683 
 
5.1.5 ADJUSTMENT FOR POTENTIAL CONFOUNDERS USING COX 
REGRESSION ANALYSIS (TABLE 35) 
Cox regression analysis was undertaken to evaluate the potential influence of 
confounding factors on survival. The equation included age (continuous), sex 
(dichotomous), ECOG performance status (ordinal), presence of metastatic disease 
(dichotomous), ur:cr ratio (continuous), and H2/R (continuous) and the less-
hydrated classification (dichotomous). 
 
Following adjustment, the H2/R (HR=0.97 [.95, .99]; p=0.003) and ur:cr (HR=1.009 
[1.003, 1.015]; p=0.002), remained significant predictors of survival. Other factors 
were found to significantly influence survival. This included performance status, 
which was demonstrated by successive increases in the hazard ratios according to 
the ECOG grades. Comparatively, using ECOG-1 a reference, the risk of death 
increased by twofold for ECOG-2 (HR=2.64 [1.17, 5.94]; p=0.02) and by threefold in 
the ECOG-3 (HR=3.33 [1.50, 7.42]; p=0.003) and ECOG-4 (HR=3.35 [1.37, 8.21]; 
p=.008) grades respectively. Metastatic disease increased the risk of death by 
roughly twofold (HR=1.98 [1.15, 3.43]; p=.014). Following adjustment, the less-
hydrated classification was no longer a statistically significant predictor of survival. 
Age and gender were not significant predictors of survival.   
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TABLE 35: COX REGRESSION SURVIVAL ANALYSIS FOR SEVERAL 
VARIABLES 
 
Omnibus Tests of Model Coefficients 
-2 Log 
Likelihood 
Overall (score) Change From Previous 
Step 
Change From Previous 
Block 
Chi-
square 
df Sig. Chi-square df Sig. Chi-square df Sig. 
530.451 38.282 9 .000 38.474 9 .000 38.474 9 .000 
 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B) 
Lower Upper 
AGE .009 .011 .618 1 .432 1.009 .987 1.030 
FEMALE -.304 .277 1.202 1 .273 .738 .429 1.270 
ECOG   9.374 3 .025    
ECOG (2 vs 1) .970 .414 5.475 1 .019 2.637 1.171 5.942 
ECOG (3 vs 1) 1.204 .408 8.717 1 .003 3.334 1.499 7.417 
ECOG (4 vs 1) 1.209 .457 6.998 1 .008 3.352 1.368 8.212 
METASTASTES .684 .279 5.989 1 .014 1.981 1.146 3.426 
Ur:cr .009 .003 9.904 1 .002 1.009 1.003 1.015 
LESS HYDRATED -.313 .419 .560 1 .454 .731 .322 1.661 
H
2
/R -.031 .011 8.605 1 .003 .969 .949 .990 
 
Covariate Means 
AGE 71.167 
SEX .533 
ECOG (2 vs 1) .244 
ECOG (3 vs 1) .400 
ECOG (4 vs 1) .189 
METASTASES .711 
Ur:Cr  96.683 
LESS HYDRATED .111 
H
2
/R 51.582 
 
5.1.6 SUMMARY OF CHAPTER 
Seventy-six (84.4%) participants died before the end of the follow-up period. Those 
who were classified as less-hydrated had statistically significant shorter survival 
compared to those who did not. Overall, survival was shortest in less-hydrated 
patients, longest in more hydration, with the survival for those normally-hydrated 
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in between those two groups. Those who were classified with pre-renal failure had 
shorter survival compared to those who did not. Increasing H2/R value (suggesting 
higher TBW volume) was associated with longer survival and increasing ur:cr ratio 
(suggesting worsening renal function) was associated with shorter survival.  Cox 
regression analysis identified potential confounding factors of metastatic disease 
and performance status. Following adjustment for these factors H2/R and ur:cr ratio 
still remained statistically significant predictors of survival. However, the less-
hydrated classification was no longer a statistically significant predictor of survival 
following the regression analysis.  
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CHAPTER 6: EVALUATION OF LONGITUDINAL 
CHNAGES IN HYDRATION THROUGH THE 
ANALYSIS OF REPEAT BIO-IMPEDANCE 
ASSESSMENTS 
 
6.1.1 INTRODUCTION 
This chapter presents analysis of participants receiving multiple assessments. The 
assessment frequency is presented in addition to an analysis of the influence of 
time-related changes of bio-impedance on survival. 
6.1.2 NUMBER OF REPEAT ASSESSMENTS (TABLES 10 AND 37; 
FIGURES 26 & 27) 
A total 126 assessments were conducted. Sixty-six (73.3%) patients were evaluated 
at baseline only whereas 24 (26.7%) received multiple assessments. Further 
information of the number of assessments is provided in table 10. 
Of the participants receiving repeat assessments the RXc graph demonstrates that 
15 (62.5%) were normally hydrated, eight (33.3%) were more-hydrated and one 
(4.2%) was less-hydrated. The final hydration classifications for the sample receiving 
repeat assessments were similar to baseline (Table 36). However, when compared 
to the baseline hydration status for all patients, a higher proportion of patients 
receiving repeat assessments were comparatively more likely to be normally 
hydrated (62.5% vs 47.8%) and less likely to be less-hydrated (4.2% vs. 11.1%) (see 
Table 20). 
 
 
 
127 
 
TABLE 36: COMPARISON OF HYDRATION STATUS CHARCTERISTICS OF 
THE BASELINE AND FINAL BIO-IMPEDANCE MEASUREMENTS IN 
PATIENTS RECEIVING MULTIPLE ASSESSMENTS   
 Baseline assessment  Final assessment 
 N %  N % 
Normal 16 66.7  15 62.5 
Less-hydrated 2 8.3  1 4.2 
More-hydrated 6 25.0  8 33.3 
 
6.1.3 PAIRED DATA ANALYSIS OF THE BASELINE AND FINAL BIO-
IMPEDANCE (TABLE 37; FIGURES 28A, 28B & 28C) 
The analysis of participants’ paired vectors analysis demonstrated that, when 
compared to baseline measurements, repeat BIVA assessments had lower 
(negative) Xc/H scores and higher values for R/H. The final vector difference 
position (Figure 28a) had moved down and right and has a 95% confidence ellipse 
that does not cross the origin (i.e. 0,0). Paired Hotelling’s T2 test demonstrated that 
the paired vector difference was statistically significant (T2 = 9.5, <.001). The higher 
dR/H suggested lower TBW on the final assessment compared to the first. The 
lower dXc/R suggested individuals had increased cellular breakdown on the final 
assessment compared to baseline. Sub-analysis by gender (Figure 28b & 28c), 
demonstrated similar results for women (p<.001). However, in men the vector 
difference demonstrated comparatively higher mean values for dR/H and dXc/H, 
which is represented by the mean vector moving upwards and right of the origin on 
the RXc graph (Figure 28b). This paired vector has a larger 95% confidence ellipse 
and is not a statistically significant finding (p=.5). 
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TABLE 37: RESULTS OF THE VECTOR DIFFERENCE ANALYSIS (BASELINE 
AND FINAL BIVA ASSESSMENTS) 
  N dR/H 
Mean 
dR/H 
SD 
dXc/H 
Mean 
dXc/H 
SD 
Correlation    
r (dR/H, 
dXc/H) 
T
2
 F D p 
All 24 14.3 33.4 -1.4 7.7 0.50 9.5 4.5 .63 <.001 
Males 9 17.6 37.5 1.1 8.0 0.47 2 .9 .47 .5 
Females 15 12.4 31.8 -3.0 7.4 0.52 9.8 4.5 .81 <.001 
 
FIGURE 26: RXC GRAPH SHOWING THE BASELINE AND FINAL BIO-
IMPEDANCE VECTOR POSITIONS OF MALES RECEIVING MULTIPLE 
ASSESSMENTS (N= 9) 
Baseline Final 
FIGURE 27:  RXC GRAPH SHOWING THE BASELINE AND FINAL BIO-
IMPEDANCE VECTOR POSITIONS OF FEMALES RECEIVING MULTIPLE 
ASSESSMENTS (N=15) 
Baseline Final 
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FIGURE 28A:  RXC PAIRED GRAPH DEMONSTRATING THE CHANGE IN 
VECTOR POSITION OF THE FIRST AND LAST BIVA ASSESSMENTS IN ALL 
PATIENTS RECEIVING REPEAT ASSESSMENTS (N=24)  
 
FIGURE 28B:  RXC PAIRED GRAPH DEMONSTRATING THE CHANGE IN 
VECTOR POSITION OF THE FIRST AND LAST BIVA ASSESSMENTS IN 
MALES RECEIVING REPEAT ASSESSMENTS (N=9)  
 
FIGURE 28C:  RXC PAIRED GRAPH DEMONSTRATING THE CHANGE IN 
VECTOR POSITION OF THE FIRST AND LAST BIVA ASSESSMENTS IN 
FEMALES RECEIVING REPEAT ASSESSMENTS (N=15)  
 
 
 
130 
 
6.1.4 ANALYSIS OF THE UR:CR RATIO AND H2/R CHANGE FROM 
BASELINE TO FINAL ASSESSMENT (TABLE 38) 
An increase of the ur:cr ratio (from baseline to final assessment) was observed in 
twelve (50%) of the patients receiving repeat assessments, whereas an equal 
number (n=12, 50%) had no change or decrease in ur:cr ratio. The H2/R increased in 
nine (37.5%) patients between baseline and final assessments, with H2/R remaining 
the same or decreasing in 15 (62.5%). 
TABLE 38:  CHANGE IN THE UR:CR RATIO AND H2/R FROM BASELINE 
TO FINAL BIVA ASSESSMENT FOR PATIENTS RECEIVING MULTIPLE 
ASSESSMENTS  
 
 Change in Ur:Cr ratio  Change in H
2
/R 
 N %  N % 
No change or 
decrease 
12 50  15 62.5 
Increase 12 50  9 37.5 
 
6.1.5 SURVIVAL ANALYSIS (TABLE 39 & 40; FIGURES 29 & 30) 
Kaplan Meier survival demonstrated no significant difference based on an increase 
or decrease of H2/R or ur:cr ratio from baseline to the final assessment. 
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TABLE 39: MEAN AND MEDIANS FOR SURVIVAL TIMES BASED ON THE 
CHANGE OF H2/R FROM BASELINE TO THE FINAL ASSESSMENT  
 Mean Median 
Is there an increase in 
H
2
/R? 
Estimate SE 95% Confidence 
Interval 
Estimate SE 95% Confidence 
Interval 
 Lower  Upper  Lower  Upper  
No 111.267 23.494 65.219 157.314 77.000 7.729 61.852 92.148 
Yes 141.222 31.350 79.776 202.668 137.000 1.491 134.078 139.922 
Overall 123.198 19.338 85.296 161.100 78.000 41.641 .000 159.617 
 
Overall Comparisons 
 Chi-Square df Sig. 
Log Rank (Mantel-Cox) .350 1 .554 
Test of equality of survival distributions times based on the change of impedance index from baseline 
to final assessment. 
 
FIGURE 29: KAPLAN-MEIER GRAPH SHOWING SURVIVAL TIME IN DAYS 
ACCORDING TO CHANGE IN H2/R (P=0.55) 
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TABLE 40:  MEAN AND MEDIANS FOR SURVIVAL TIMES BASED ON THE 
CHANGE OF UR:CR RATIO FROM BASELINE TO FINAL ASSESSMENT  
 Mean Median 
Change in Ur:Cr Estimate SE 95% Confidence 
Interval 
Estimate SE 95% Confidence 
Interval 
 Lower  Upper  Lower  Upper  
No change or 
decrease 
112.750 24.753 64.234 161.266 68.000 70.148 .000 205.490 
Increase 135.250 31.317 73.869 196.631 78.000 31.177 16.893 139.107 
Overall 123.198 19.338 85.296 161.100 78.000 41.641 .000 159.617 
 
 
Overall Comparisons 
 Chi-
Square 
df Sig. 
Log Rank (Mantel-Cox) .864 1 .353 
Test of equality of survival distributions for the different levels of Change in Ur:Cr. 
 
FIGURE 30:  KAPLAN-MEIER GRAPH SHOWING SURVIVAL IN DAYS 
ACCORDING TO CHANGE IN UR:CR RATIO (p=0.35) 
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6.1.6 SUMMARY OF CHAPTER 
In total, twenty-four (26.7%) participants received multiple assessments. When 
compared to the baseline assessments for all participants, those receiving repeated 
measurements were more likely to be normally-hydrated and less likely to be less-
hydrated. Compared to baseline, the paired vector analysis demonstrated the dR/H 
was statistically significantly higher (suggesting less hydration) and lower Xc/R 
(suggesting less cellular mass) on the final assessment. This finding remained 
statistically significant in females but not in men which may suggest possible 
variance by gender. An increase or decrease of H2/R or ur:cr ratio did not 
significantly influence survival. 
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CHAPTER 7: DISCUSSION 
 
SECTION 1: OVERVIEW OF RESEARCH PROJECT 
This project was devised to improve the understanding of hydration in advanced 
cancer patients, in order to contribute new knowledge to the evidence base. It is 
hoped that this thesis will lead to further work which will eventually lead to 
improvements in patient care. 
The key results from the study are examined in section 7.2.1 and are discussed in 
relation to the study objectives. The strengths and weaknesses of the study are 
presented in sections 7.2.2 and 7.2.3 respectively. The contribution to the evidence 
base is discussed in section 7.3.2 with the concluding remarks presented in section 
7.3.4. 
7.1.1 RATIONALE FOR THESIS AND GAP IN KNOWLEDGE 
The aims and objectives in this study were developed to add new knowledge about 
the subject of hydration in advanced cancer. The gap in evidence can be 
summarised by the following points: 
- There is limited understanding of how hydration in advanced cancer 
influences symptoms, physical signs and biochemical tests. To date, no 
studies have used bio-impedance measurements in advanced cancer to 
evaluate differences in hydration according to these factors.  
- The difference in body composition and hydration status between different 
types of cancer is not clearly understood. To date, no studies have used the 
BIVA Z-score analysis to synthesize data for cancer studies in order to 
compare for differences in hydration.  
- There is limited data to describe how hydration influences survival in 
advanced cancer. There are no studies to determine whether hydration 
(classified by BIVA or H2/R) is predictive of survival in advanced cancer.  
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- There is a lack of understanding of how hydration may change over time in 
those with advanced cancer. No studies have used the paired RXc BIVA 
analysis to evaluate how hydration in advanced cancer changes between 
time points. 
There is a need for further research about the risks and benefits of CAH for 
palliative cancer patients. However, to achieve this it is important to determine the 
characteristics of cancer hydration and to establish how TBW influences symptoms, 
physical signs and survival. It can be argued that an attempt to evaluate the benefit 
of CAH without knowledge of the association between TBW and symptoms may 
create uncertainty.  
Concerning previous work, differences in the use of the terms ‘hydration’ and 
‘dehydration’ may cause confusion. Many of the studies are small and of varying 
methodological quality. Consequently, previous studies are difficult to synthesise 
on account of differences in diagnostic criteria, evaluation methods, interventions 
and outcomes. BIA has attributes that are favourable for use in frail individuals; 
therefore, it has the potential to be used to improve the understanding about 
hydration states in advanced cancer.  
7.1.2 RATIONALE FOR THE STUDY DESIGN 
This study was designed with acknowledgement of the requirements of the 
advanced cancer patients. The study was built around a non-invasive framework to 
be as simple as possible for the participants. All assessment methods were selected 
with consideration for the welfare of the participant. The Burge and Morita 
assessment tools were selected in light of their simplicity; BIVA was chosen as it 
was non-invasive. The research team did not conduct blood tests (to facilitate study 
eligibility) to reduce the risk of causing distress to the participant. Instead, 
participants were recruited provided that blood tests were done as part of their 
standard clinical care. Urine tests and weight assessments were also not 
compulsory, but were only conducted if the participant was able to comfortably 
complete these assessments. 
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We acknowledge that there is limited data from the literature to facilitate 
comparison of our results; this is the first study to use BIVA to study hydration in 
advanced cancer. The lack of hydration core-outcome created difficulties for the 
sample size calculations. As no hydration core-outcomes were available from the 
literature we chose assessment tools with the most evidence in advanced cancer. 
Several variables (physical, biochemical, symptoms, performance status and 
medications) were included to enable comparison between other hydration 
indicators through regression analysis. The observational analysis was undertaken 
to provide information about TBW (using regression analysis, through its 
association with H2/R) with a provisional recruitment target of 90 patients and 
subsequent statistical analysis based on this number. 
A primary goal of this study was to study hydration characteristics of advanced 
cancer patients to inform further studies using BIVA which may involve analysis at 
certain time points and use clinical interventions. We opportunistically conducted a 
longitudinal BIVA of patients receiving repeated multiple biochemical assessments 
to study BIVA change over time. The outcomes of first and last bio-impedance 
assessments were evaluated. We acknowledge that this analysis would have 
benefited from specified time periods for the assessments with a defined period of 
follow-up. However, this was beyond the scope of this project. 
7.1.3 THEORECTICAL PERSPECTIVE FOR THE THESIS 
A post-positivist approach provided a useful framework to evaluate of the use of 
BIVA in the assessment of hydration in advanced cancer. Post-positivism is a 
contemporary empiricist view that has developed in light of criticisms surrounding 
logical positivism.303 304 Positivism assumes that objective things can be studied as 
fact, with the scientific methods providing the explanation and absolute truth to 
address the posed hypothesis. This approach was thought to be too rigid by many 
(including positivists themselves) who argued that the positivist explanation was 
too narrow to explain reality.305 306 Karl Popper, the famous positivist, argued that it 
was possible that knowledge was an illusion with the potential for an experiment or 
observation to demonstrate that what was previously thought to be true was 
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actually false.307 308 This led to the development of post-positivism, a philosophy 
that assumes that reality is multiple, subjective, and mentally constructed by 
individuals.309 The philosophy assumes the existence of a stable observable reality, 
driven by natural causes that can be measured and observed.309 The two 
approaches differ as whilst the positivist approach claims to absolute truth through 
the establishment of generalisation and laws,310 the post-positivist approach 
acknowledges that it is impossible for humans to truly perceive it due to their 
imperfect mental and sensory capacity.310 311 For Karl Popper, the disproval of 
theories and laws, was much more useful than verification.305 Therefore, the post 
positive approach is concerned with searching for evidence, in order, to provide 
proof of the existence of phenomena.303 Consequently, post positivism enables the 
researcher to critically test, and ascertain the validity of hypotheses whilst 
interacting with the research participants. This approach helps to develop an 
institutive interactive process, which leads to a greater understanding of the 
meaning of the outcomes which results from the subject under examination.312  
The principles of post-positivism have been used in research to describe a learning 
capacity rather than a testing one.313 This means that researcher recognises the 
common humanity that connects researchers and the research participants, rather 
than treating them as ‘subjects’ of an experiment. As a result, the theory has been 
used to acknowledge the ethical interests of research participants and prioritise 
their safety during involvement in research studies. This researcher-participant 
interaction, coupled with the acknowledgement of human complexity, emphasises 
good clinical practice.310 314 
This theoretical perspective provides scientific basis to establish theory, and uses 
repeated empirical measurements to test hypotheses. Furthermore, it 
acknowledges the existence of more than one reality which is experienced and 
influenced by the research participants. A possible example of these phenomena in 
this study was demonstrated by the numerical scoring system that was used to 
measure symptoms. It is acknowledged that symptoms reported by the patient may 
be influenced by various factors (related or unrelated to the item being assessed) 
which are difficult to quantify. Furthermore, as the subject of hydration at the end-
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of-life is an emotive issue, some individuals may have beliefs or concerns based on 
their personal experiences. The acknowledgment of these factors will assist the 
interpretation of the study outcomes. Importantly, the acknowledgement that the 
research participant has freely agreed to take part in this research study, to assist 
the process of learning about reality, prioritises the duty of the research team to 
prevent the individual from harm. 
This thesis accepted that advanced cancer is a pathological process that alters 
normal homeostasis. BIVA was used to measure electrical impedance to tissue 
interfaces. This study accepted that a change in physiological hydration was 
measureable by BIVA. Physiologically, fluid depletion effects the concentration of 
electrolytes and with subsequent modification of serum and urine biochemistry. 
Alteration of normal homeostasis will, in turn, affect symptoms and physical signs 
which will be measureable through objective and subjective assessments.208  In this 
study, several variables reportedly associated with hydration were used as 
independent variables whereas BIA and BIVA acted as the primary (dependent) 
outcome variable. Using the post-positivist framework we expected that the 
primary and secondary outcomes were affected by several factors. This was 
exemplified through the acknowledgment that hydration is an aspect of health, and 
the World Health Organization defines health as an ‘holistic entity, involving 
physical, psychological, social and spiritual domains.315 The subject of hydration 
includes all aspects of this definition, which fits with the theoretical perspective of 
this thesis. Consequently, this thesis was written accepting that reality as perceived 
by the patient and researcher was important for the interpretation of the study 
outcomes. 
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SECTION 2: SUMMARY AND CRITICAL APPRAISAL OF MAIN FINDINGS 
7.2.1 MAIN RESULTS OF THE STUDY 
This study was completed successfully with a recruitment rate of 76.3% and no 
adverse events. Regression analysis demonstrated that H2/R was statistically 
significantly predicted by four variables. Female gender was associated with a 13.85 
reduction in H2/R, suggesting lower TBW (p<.001). Each point increase in the Burge-
4 score caused a .29 reduction in H2/R (p=.04). Similarly, the Morita dehydration 
score corresponded with a 2.55 reduction in the H2/R (p=.02). As H2/R correlates 
with TBW, the findings suggest that lower TBW was associated with females and 
increasing intensities of the Burge-4 symptoms and Morita physical signs. Oedema 
was associated with a 10.94 increase in H2/R, which suggests an increased TBW for 
these patients. The ur:cr ratio and ECOG performance status were not statistically 
significant in the prediction equation. 
The RXc graph classified hydration status as normal in 43 (47.8%), ‘more hydrated’ 
in 37 (41.1%) and ‘less hydrated’ in 10 (11.1%) patients. Direct comparison between 
‘less hydrated’ and ‘not less hydrated’ participants demonstrated that the ‘less 
hydrated’ group had significantly decreased oral fluid intake (p=.04). Although the 
‘less hydrated’ group recorded higher values for the Burge-4 score, Morita 
dehydration score and biochemical variables, these did not reach statistical 
significance. For this cohort, the overall vector position on the RXc Z-score graph 
was within the normal confidence ellipse and towards the cachexia quadrant. These 
findings were similar to the previous cancer studies involving patients with cancers 
of the lung and head and neck. 
Overall, median survival for the sample was 62 days [95%CI =38.76, 85.24)]. Survival 
was significantly shorter in patients who were ‘less hydrated’, those with pre-renal 
failure and those with decreasing values for H2/R. These findings remained 
significant despite adjustment (using cox regression) for various variables.  
A longitudinal analysis was conducted of the twenty-four (26.7%) participants who 
received multiple assessments. Evaluation of their first and last bio-impedance 
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measurements demonstrated that, compared to baseline, the R/H scores were 
higher on the final assessment (suggesting less hydration). This finding remained 
statistically significant in females but not in men which may suggest possible 
variance by gender. Change of H2/R or ur:cr ratio between the first and last 
assessments did not affect survival. 
7.2.2 STRENGTHS OF THE STUDY 
7.2.2.1  STUDY DESIGN 
The non-invasive nature of the study design was successful in the ensuring 
recruitment, retention and the safety of study participants. This was demonstrated 
by the excellent recruitment rate of 76.3% of 90 patients over ten months. This 
study achieved the required sample size and was able to recruit successfully from 
the hospice setting. Furthermore, no adverse events were reported during the 
course of the study and many participants agreed to receive further assessments. 
This bodes well for further research as it may suggest that palliative care patients 
want to be part of appropriately designed studies.  
Our study uses BIVA, a non-invasive, reliable, validated body composition 
assessment tool. We used appropriate statistical methods, such as regression and 
survival analysis, to evaluate associations between the hydration and other factors. 
The assessments used in this study comprised of several clinical variables; this is an 
improvement on previous hydration studies which are limited in their scope. For 
example, this analysis included BIVA, clinical signs, patient self-reported symptoms, 
serum and urine biochemistry, oral fluid intake, performance status, medication 
review and a survival analysis. Consequently, this study provides data of various 
aspects of hydration states, which facilitated an in-depth analysis of several factors 
and identification of potential confounding factors and hypotheses for future work. 
Additionally, this study used BIVA to conduct a longitudinal analysis of hydration, a 
first in advanced cancer. 
All patients were assessed in the morning by one operator using the same protocol. 
Consequently there was no risk of inter-observer error, although intra-observer bias 
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was possible. As all assessments were performed within 72 hours of serum 
biochemistry, which presents a quantifiable time period for the degree of 
association with the ur:cr ratio. This improves on previous work (about hydration in 
advanced cancer) which often does not report blood tests within a specified 
timeframe.  
7.2.2.2   ASSESSMENT METHODS 
This is the first study to use BIA and BIVA to evaluate the relationships of clinical 
observations, biochemistry and self-reported symptoms in advanced cancer. The 
BIA TBW prediction equations are inappropriate in advanced cancer due to a 
violation of the basic assumptions caused by cancer pathophysiology. This study did 
not feature prediction equations but instead used H2/R as the outcome measure. 
Previous cancer studies have demonstrated that H2/R has excellent correlation with 
TBW.83 136 H2/R was not used for the calculation or estimation of TBW volume (using 
subsequent prediction equations), but instead was used as a comparative index to 
determine relationships of the H2/R with other variables. Consequently, in this 
analysis, H2/R was able to evaluate relative differences in TBW although it was 
unable to quantify the fluid volume.  
Hydration-specific signs and symptoms were evaluated (i.e. the Burge 
questionnaire, Morita dehydration score and oral fluid intake assessment). These 
tools potentially provide a standardised assessment method that can be replicated 
in future studies. Our analysis provided a complete assessment of the hydration 
status of the individual enabling statistical comparisons to be analysed.  
This study involved assessments of several factors, which enabled potential 
confounding variables to be analysed to determine potential relationships with 
hydration. This included regression analyses to identify factors associated with the 
H2/R, and an evaluation of whether specific medications influenced the Burge-4 
score. This is an improvement on previous work, which often does not include 
assessment of potential confounding variables. 
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7.2.3 SUMMARY OF LIMITATIONS 
7.2.3.1  METHODOLOGY 
Several limitations are apparent from this analysis. As this study is observational in 
nature, it is not possible to determine causation between associated variables. For 
example, it is not possible to determine whether lower values of H2/R caused 
increased values of the Morita dehydration and Burge-4 score or vice versa. 
Further, this study had no control group, meaning that it is not possible to compare 
data to a non-cancer population. Consequently, the level of symptoms and physical 
signs that could be expected in a non-cancer group compared to this sample is 
unknown. Regarding BIVA, although an adult BIVA reference population was used 
for the RXc graph assessments, this data was based on a general medical Caucasian 
Italian sample which may differ in characteristics to our sample.  
7.2.3.2  BIOCHEMICAL FACTORS 
Concerning the biochemical tests, some patients wished to take part in the study 
but were unable to do so as no blood results were available. It is possible that a 
longer eligibility timeframe for blood tests (i.e. a cut-off of >72 hours) would have 
permitted greater recruitment; however, this would have increased the possibility 
of the blood tests being unrepresentative of the biochemical profile at the time of 
BIVA assessment. A tighter timeframe for recruitment (e.g. ≤24 hours) may have 
provided a more accurate reflection of the participant’s biochemistry at the time of 
BIVA assessment; however, this may have caused many to be ineligible for the 
study. Only four (4.4%) individuals died within seven days of study entry. Therefore, 
this data was not representative of patients in the last week of life. It is possible 
that this finding is the consequence of two methodological factors. First, only 
patients who had biochemical tests taken in the previous last 72 hours were 
included. Although this was to encourage participation it is possible that frailer 
patients were inadvertently excluded as a consequence. This is because dying 
patients are less likely to receive clinical investigations (and hence, were not eligible 
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for the study). Secondly, dying patients may be have been unable to provide 
consent, or deteriorated during the recruitment process.  
7.2.3.3  BIOELECTRICAL IMPEDANCE ASSESSMENTS 
A limitation of BIA and BIVA is that its interpretation is based on the assumption of 
constant resistivity and cross-sectional area of the human body.85 112 316 As 
highlighted earlier in chapter two, SF-BIA is based on a basic two-compartment 
model (fat and fat free mass) and assumes stable states of the hydration, geometry, 
shape, minerals and nutrients of the assessed individual. In terms of body 
composition, our sample was not homogenous; this was illustrated by several 
differences between participants (e.g. in the presence of oedema, albumin level 
and performance status). Consequently, although the H2/R is a simple method to 
compare fluid volume its interpretation was not straightforward due to the 
required consideration of other factors. In this study, the bio-impedance 
assessments were not directly compared to a reference method (e.g. deuterium 
dilution). Although previous validation studies (using 4-C reference models) 
demonstrate that H2/R is a significant predictor of TBW in cancer,136 the absence of 
a comparative reference method (in this study) meant cross-validation was not 
possible. Therefore, it is possible that factors on an atomic, molecular, cellular and 
functional level may have exerted some influence on the findings that we are 
unable to account for in this study. 
The SF-BIA and BIVA methods are unable to distinguish between fluid 
compartments, anatomy or define intracellular and extracellular fluid volumes. 
Consequently, individuals with localised peripheral oedema may have had higher 
H2/R (and subsequently be placed in the more-hydrated RXc group) even if 
intracellular fluid volumes were lower. Therefore, this analysis was unable to 
determine how fluid volume compartments relate to the studied variables. 
Additionally, the anatomical location of oedema and its severity was not recorded. 
Therefore, it was not possible to determine the relationship between the location 
of oedema and the study variables. Clinically, this is important as the location of 
oedema may affect the outcomes of an individual. For example, oedema may be 
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peripheral in cardiac failure but more abdominally placed (ascites) in liver 
problems. In venous obstruction (for example, superior venae caval obstruction) 
the oedema is superior, whereas it is more generalised in the presence of 
hypoalbumineia. These differences of oedema (according to specific diseases and 
conditions) may affect symptoms and survival that cannot be fully evaluated in this 
instance. 
7.2.3.4  TYPE OF CANCER 
This analysis involved many different cancers at various stages of illness. It is well 
documented that certain cancers have known associations with pathological fluid 
disorders. For example, abdominal ascites is prevalent with ovarian and gastric 
cancers,317 lung cancer may cause pleural effusion318 319 and breast cancer is 
associated with upper limb lymphoedema.320 The BIVA Z-score analysis in chapter 4 
demonstrated differences in the vector positions of different types of cancer. 
Consequently, it is possible that there was variation in body composition of 
participants on account of pre-existing differences related to the attributes of the 
specific cancer. Studies included in the comparative analysis were specific to cancer 
type and stage of illness. Therefore, more accuracy may have been achievable 
through sub-classification of cancer type and stage. 
7.2.3.5  ETHNICITY AND GENDER 
The majority of participants (n=89, 98.9%) were Caucasian; therefore, this study is 
only representative of this ethnicity and the data cannot be extrapolated to other 
ethnicities. This study included a pooled analysis of both male and females; 
however, some differences in BIA/BIVA were recorded on account of gender. For 
example, women had lower H2/R than men, suggesting less TBW volume. This may 
suggest this sample was not homogenous. In light of this, our data analysis was 
stratified by gender; however, this reduced the sample size for the statistical 
analysis. The decision to include both male and females in the analysis was 
consistent with the methodology of previous studies.186 188 190 200 However, our data 
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suggests that males and females require separate BIVA analysis using the RXc 
method. 
7.2.3.6  SAMPLE SIZE 
Although this study has achieved its recruitment target, a larger sample would have 
provided greater opportunity to stratify data and conduct sub-analysis. Further 
study according to gender, age, type of cancer and oedema may have been useful 
in the analysis. Only ten participants were identified within the less-hydrated group; 
therefore, a larger sample would have helped identify the characteristics of the 
less-hydrated group, with comparison to the normal and more-hydrated groups. 
This study was not able to determine whether pulmonary oedema was present in 
our patients and whether this was linked to the development of secretions.258 
Unfortunately, it was not possible to evaluate the influence of myoclonus on H2/R 
as this feature was only recorded one patient in the sample. 
7.2.3.7  CLINICAL ASSESSMENTS 
The assessment of oral intake involved subjective assessments that were conducted 
by various members of nursing staff. Consequently, there is the potential for 
discrepancy of evaluations caused by the inter-observer bias. All study assessments 
were conducted at earliest convenience for patients between 9am and 12pm. This 
variation in the timing of assessments meant that some patients received 
medications (including mouth care procedures) prior to the assessments whereas 
others did not. This may have biased the reporting of symptoms. The assessment 
process was conducted in order to maintain the comfort of participants (by tailoring 
the assessment times to the needs of the patient); however, a more standardized 
framework of assessment (including timing and procedural requirements 
concerning medications) may have been useful to reduce the potential for variation 
between assessments.  
Patients were not fasted or required to void their bladder ahead of assessments. 
This was done to reduce the potential for discomfort. However, this meant that the 
optimum assessment conditions of BIA were not achieved.119 Practically, some 
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patients struggled to understand the VAS scoring tool. When asked to grade their 
symptoms using the Burge score some answered using a numerical scoring format. 
It is possible this highlights the familiarity of numerical scoring assessments that are 
commonly used by healthcare professionals during clinical assessments. Some 
patients perceived dry mouth and thirst to be the same and struggled to 
differentiate between these symptoms (a finding that is consistent with previous 
studies269). Others accepted there was a difference between these variables, 
although they acknowledged that one would most likely affect the other. It is 
possible that these factors may have affected how the participants scored these 
items.  
The Burge Dehydration Symptom Questionnaire and the Morita Dehydration 
Assessment score both lack validity and reliability data. These tools have been used 
by other researchers and were chosen for use in this study as they represented the 
best (and only) available hydration assessment tools in advanced cancer. However, 
there is no strong data to prove evidence of the validity, reliability of transferability 
of the tool. This study could have been improved by the incorporation of reliability 
testing into the design. For example, participants could have received repeat study 
measurements (performed by another researcher later in the same day) to 
compare the agreement between assessors. Furthermore, assessment tools with 
evidence of good reliability and validity (e.g. the Edmonton Symptom Assessment 
Scale321 322) could have been used instead of (or in addition to) the chosen 
assessment methods. In this instance, generic symptoms could have been assessed 
to determine their association with hydration which may have facilitated the 
subsequent development of a hydration assessment tool, which could then be 
tested to determine its validity and reliability. 
7.2.3.8  HEIGHT AND WEIGHT ASSESSMENT 
Weight was recorded in only 28 participants. It was not possible to weigh the 
remainder as these individuals were not able to safely transfer. Consequently, the 
BMI was unobtainable in the majority of the sample. It is possible that the BMI of 
immobile patients was different to the rest of the sample (for example, lower BMI if 
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these individuals were more cachectic). In light of the expected variation of body 
mass in our sample, we chose a reference population featuring a BMI range of 16 – 
31 kg/m2. However, a narrower BMI range (relative to the expected BMI our 
sample) may have provided a more reliable estimation of the population.  
Concerning the measurement of height measurement there were some issues with 
using the stadiometer in participants who were unable to stand. There were 
practical difficulties in manoeuvring some patients into the correct position that 
was required to complete the assessment.  
7.2.3.9  CLINICALLY ASSISTED HYDRATION 
This study is unable to provide information about the influence of CAH on BIVA or 
the other study outcomes. No patients received CAH in the 24 hours prior to the 
baseline assessments. Additionally, no information about the use (or non-use) of 
CAH before or after the assessments was collected. Consequently, it is not possible 
to determine whether CAH in the days leading up the assessments may have 
affected the assessments.  
7.2.3.10  LONGITUDINAL ASSESSMENTS 
The repeat (follow-on) assessments were not conducted at pre-defined, set time-
points. This introduced variation in the timing of these assessments. Repeat 
assessments were done in response to blood tests. These tests were done for 
various clinical indications, such as a deterioration of the condition of the patient. It 
is possible that patients receiving follow-up assessments were different to those 
not receiving assessments. For example, they may represent patients who were 
more unwell, or experienced a change in their condition, which needed further 
blood tests for evaluation. Alternatively, they may represent a stable group of 
patients who were considered well enough to warrant routine blood tests for 
monitoring purposes (as opposed to those who were dying and hence, blood tests 
were no longer appropriate). No ongoing clinical information was collected as part 
of this analysis. Therefore, the use (or change in use) of therapies known to 
influence hydration (e.g. CAH, diuretic therapy) is unknown. Regarding the follow 
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up assessments no patients declined these measurements. However, some patients 
(although eligible to receive follow-on assessments) were not approached as they 
were deemed too unwell by the clinical team. Therefore, the repeat assessments 
were not a reflection of all participants; rather, it describes those who required 
additional blood tests and were considered well enough (by the clinical team) to 
provide consent to participate. 
7.2.3.11  SURVIVAL FOLLOW UP  
Due to time-related factors, the follow up period for the last patient of the study 
was only 3 months. Although the majority of the patients had died within this 
timeframe, a longer follow-up period (e.g. 12 months) may have added greater 
accuracy to the survival analysis. 
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SECTION 3: COMPARISON OF STUDY FINDINGS WITH PREVIOUS 
RESEARCH AND WHAT THIS STUDY ADDS TO THE EVIDENCE BASE 
7.3.1 COMPARISON OF FINDINGS WITH PREVIOUS RESEARCH 
7.3.1.1  H2/R ASSOCIATIONS 
The regression analysis demonstrates how H2/R was predicted by gender, oedema, 
symptoms and physical signs. This is consistent with previous literature. In this 
study women had significantly higher R/H compared to men. This suggests that 
women had higher fat mass and were less hydrated compared to men. Women had 
a lower H2/R, which suggests comparatively lower TBW volume. This finding is 
consistent with previous BIA population data144 146 and is consistent with accepted 
human physiology. Women normally have more body fat than men and therefore 
contain less body water than men in proportion to their weight.70 71 Oedematous 
participants had increased H2/R and lower BIA vectors compared to non-
oedematous participants; again, this is consistent with previous work.95 150 204 323 324 
The prevalence of the seven dehydration-related symptoms was similar to original 
data presented by Burge.250 This may suggest consistency of these symptoms in 
advanced cancer hospice inpatients. However, without a control group we are 
unable to compare these symptoms to non-cancer populations. Higher Burge-4 
scores were associated lower H2/R suggesting less TBW. This may provide evidence 
of the association between these symptoms and hydration. It is also consistent with 
the non-cancer studies that were originally done to evaluate these symptoms.283 286-
289 
Regression analysis demonstrated that medications reportedly associated with dry 
mouth325 (comprising of opioids, diuretics, anticholinergics, SNRIs and SSRIs) were 
not predictive of the Burge-4 score. This suggests that the Burge-4 was not 
influenced by these medications. Regression analysis also demonstrated that the 
Morita dehydration score was predictive of H2/R, a finding consistent with non-
cancer studies examining the level of association that the scores’ composite 
variables has with dehydration.225 226 231 250 Consequently, this study provides 
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evidence which adds credibility to the Morita Dehydration Scores’ intended use as 
an assessment tool of assessing fluid status in advanced cancer patients. This 
analysis showed no statistically significant difference in bio-impedance 
measurements between patients with or without respiratory tract secretions; this 
suggests no significant difference in TBW. This finding is consistent with previous 
work which found no association between hydration level and respiratory tract 
secretions.247 258 However, some authors propose a link between respiratory tract 
secretions and pulmonary oedema.326 327  
7.3.1.2  COMPARISONS WITH OTHER CANCERS 
Male and female bio-impedance vectors were similar to previous work involving 
patients affected by head, neck and lung cancer. Our sample data was within the 
normal 50th centile on the BIVA ‘z-score’ graph, but in a position associated with 
lower muscle mass. Analysis of data from the literature demonstrated that female 
breast cancer patients were leaner compared to other cancer populations.297 The 
reason for this difference is not clear; however, it is possible that the patients with 
breast cancer were healthier (possibly due to their evaluation at diagnosis as 
opposed to later in their illness). This is distinct from the other BIVA cancer studies 
which involved patients with more advanced disease.98 158 
7.3.1.3  LONGITUDINAL ASSESSMENTS 
In other disciplines, longitudinal BIVA studies generally evaluate the effects of an 
intervention (for example, dialysis) through pre and post bio-impedance 
assessments. Some studies have also used BIVA to evaluate specific physiological 
situations, such as pregnancy.328 The results of our longitudinal analysis (using 
paired data for BIVA repeat assessments) demonstrated higher R/H on the final 
assessment compared to baseline; this may suggest that patients were less 
hydrated on the final assessment compared to baseline. Concerning the 
longitudinal assessments, the Simons et al study from 1999 is the only research 
which our data can be compared.136 Our data demonstrates that longitudinal 
analysis with BIVA is possible in advanced cancer and can potentially be used to 
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evaluate effects of an intervention, or to evaluate change in hydration in a specified 
time period, such as the dying phase.136 Comparatively, the Simons et al study 
found changes in H2/R and TBW occurred in both directions. It should be noted that 
the Simons et al study only involved patients who were part of a clinical trial 
evaluating the use of progestogen on food intake, a medication known to cause 
fluid retention.329 Therefore, this affects our ability to compare the results to our 
analysis as patients may have been more prone to fluid retention in the Simons et 
al study.  
7.3.1.4  RENAL BIOCHEMISTRY 
The prevalence of pre-renal failure (as defined by ur:cr ≥100:1) was (41.1%, 
n=37/90); this was similar to that reported in cancer patients receiving inpatient 
rehabilitation (44%; n=27/62).248 Our study demonstrated a lack of association 
between ur:cr ratio and H2/R through linear regression; however, no data for 
comparison was identified from the literature. Related work included a study by 
Valdespino-Trejo et al,330  in which  MF-BIA was used to predict worsening renal 
function in patients with decompensated heart failure. This analysis demonstrated 
that a whole body impedance ratio (200kHz compared to 5 kHz) of >.85 (suggesting 
fluid overload) was a significant risk factor for worsening renal function (RR=5.3, 
p=0.05). The authors conclude that this association was likely attributable to 
worsening hypoalbuminaemia, through its propensity to cause decreased renal 
perfusion through fluid loss from the vascular space, resulting in worsening renal 
function and oedema.   
Our work supports the findings of previous studies which find little association 
between renal biochemistry and the symptoms of dry mouth, thirst and respiratory 
tract secretions in advanced cancer patients.247 249 250 No statistically significant 
difference in the Burge-4 and Morita Dehydration scores were evident between 
‘less hydrated’ and ‘not less hydrated’ participants. This may provide further 
evidence that biochemistry lacks sensitivity to predict hydration-related symptoms 
in advanced cancer patients.228 247 
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7.3.1.5  SURVIVAL ANALYSIS 
Regarding the survival analysis, the association of pre-renal failure with shorter 
survival is in-keeping with previous work in cancer patients.331 The cox regression 
survival analysis in this study was consistent with the Prognosis in Palliative care 
Study (PiPS) predictor models for palliative care patients. The presence of 
metastases and lower performance status were predictors of shorter survival, the 
same finding as the PiPs.332 Another similar finding with our study and the PiPs was 
the association between high urea and shorter survival. However, the ur:cr ratio 
was used in our analysis rather than urea alone.  
Previous studies have demonstrated that haemodialysis patients classified as ‘more 
hydrated’ (on the RXc graph) had shorter survival compared to those normally 
hydrated.95 Similarly, survival was shorter in patients assessed with MF-BIA who 
were deemed to be overhydrated (relative to their ECW).333 334 Our findings differ 
from these studies as the individuals classified as ‘more hydrated’ lived longer than 
‘normally hydrated’ and ‘less hydrated’ participants respectively. Further, shorter 
survival was associated with lower H2/R. This may potentially highlight differences 
in hydration according to its relationship with disease. A possible cause for this 
difference is that in haemodialysis studies, ‘more-hydration’ was a consequence of 
adverse fluid haemostasis caused by poor renal function. This is in contrast to our 
cohort; where ‘more-hydration’ did not necessarily imply that patients were over-
hydrated (as a consequence of renal failure). It is not possible to determine the 
direct causal relationship of these factors. We are unable to determine the exact 
reason for the shorter survival suggested by lower H2/R and classification as ‘less-
dehydration’. However, we can postulate that in the advanced cancer patient, the 
presence of ‘less hydration’ may suggest clinical deterioration or was associated 
with disease states with shorter survival (e.g. the anorexia cachexia syndrome). 
Further work is therefore necessary to determine why this difference exists.   
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7.3.2 CONTRIBUTION TO THE EVIDENCE BASE 
This study was the first to use BIVA in advanced cancer patients to evaluate how 
symptoms, physical signs, and serum biochemistry are related to hydration. 
Concerning hydration in advanced cancer, this is the first study to report an 
association between clinical symptoms and hydration (measured by H2/R) through 
the use of an objective, validated body composition measurement tool. Our unique 
findings showed how H2/R was statistically significantly associated with the Burge-4 
score, a composite measure of four symptoms (dry mouth, thirst, unpleasant taste 
and fatigue) and the Morita Dehydration Score, a composite measure of three 
clinical signs (dry mucous membranes, sunken eyes and dry axilla). These findings 
suggest that fluid volume is associated with symptoms and clinical signs. In this 
instance, lower fluid volumes were associated with higher scores for physical 
symptoms and physical signs.  
This is the first study to use the RXc graph to report the characteristics of a hospice-
based, mixed cancer sample. It is also the first to use the Z-score graph to evaluate 
differences between other cancer reference groups. Further, this research is the 
first to use longitudinal BIVA assessments in advanced cancer and the first to report 
that patients were apparently less hydrated on their final assessment compared to 
baseline.   
This thesis adds new understanding to various aspects concerning the influence of 
hydration on survival in advanced cancer. The analysis of survival according to BIVA 
hydration classification is original. Further, the finding of the association between 
H2/R and survival has not previously been reported. This analysis describes how 
individuals with pre-renal failure experienced significantly shorter survival. 
Although the association between poor renal function and survival has previously 
been reported, this is the first study to report this using ur:cr ratio of >100:1  as a 
definition of renal failure in advanced cancer. Additionally, the discovery of no 
statistically significant difference in survival based on the change of H2/R or ur:cr 
ratio over time is unique. 
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Our study was the first to report the prevalence of less-hydration related symptoms 
in a UK hospice population and to compare this to the original analysis conducted 
by Burge in 1991.269  This study is the first to demonstrate the similarities of 
symptom prevalence across the two palliative care samples. This study had 
recruitment rate of 76.3% with no adverse events and consequently supports 
existing evidence of the safety and tolerability of BIVA. Researchers, funders and 
policy makers should be encouraged by our findings as this will facilitate more 
research in similar settings. 
This analysis demonstrates that hydration in advanced cancer is complex. Research 
in this area requires care. Furthermore, study outcomes need to be interpreted well 
and communicated sensitively. This thesis used a quantitative methodology; 
however, this subject is complex and requires consideration of qualitative factors in 
order to determine how the outcomes relate to clinical practice. This analysis 
suggests that less hydration was associated with increased symptom intensity, 
higher dehydration scores and shorter survival. This may cause some to question 
whether CAH should have been administered; however, we are unable to comment 
about the role of CAH as this was not the aim of this research study.  
It is important to acknowledge how language can be used to ascribe ‘value’ to 
certain statements about the fluid status of an individual. This can be done either 
intentionally or unintentionally and can add emotion to discussions (and decisions) 
regarding CAH. The term ‘dehydration’ has acquired a variety of subjective 
meanings, which differ from the original physiological definition. It can be argued 
that the term ‘dehydration’ now suggests inadequate hydration and hence, 
requires intervention (e.g. with CAH).  In this study, when discussing hydration we 
used the phrases ‘normally hydrated’, ‘more hydrated’ and ‘less hydrated’ as we 
felt these were less emotive than the terms ‘over-hydrated’, ‘under-hydrated’ and 
‘dehydrated’. Additionally, survival was described using the terms ‘longer’ and 
‘shorter’ as these were felt to be less emotive that the comparative terms ‘better’ 
or ‘worse’. 
 
 
 
155 
 
7.3.3 FUTURE WORK AND UNANSWERED QUESTIONS 
Researchers can use our experience to improve the methodology and conduct of 
future studies. Several questions arise from the outcomes of this study. Firstly, as 
this study describes a mixed cancer, hospice-based, Caucasian sample, it is unclear 
how these findings relate to other individuals of different ethnicities and those 
without cancer in non-hospice settings. Consequently, future studies can potentially 
use BIA/BIVA to evaluate hydration according to different conditions, stratified by 
performance status and stage of illness. 
It is possible that a statistically significant difference between certain variables 
(Burge-4 score, ur:cr ratio, urine osmolality, ECOG and the Morita Dehydration 
Score) will be detected if a larger sample is studied. In this analysis ‘less hydration’ 
was only detected in ten patients.  Although this study demonstrated an association 
between hydration with symptoms, physical signs and survival, it is unable to 
conclude whether CAH is beneficial. Future studies can use BIVA to evaluate 
outcomes of CAH therapy. Such studies can involve CAH as the intervention, with 
assessments conducted at specified time points to evaluate outcomes of BIVA (as 
an objective measure of hydration), physical signs, symptoms, survival and quality 
of life.  
Our study was not representative of dying patients. Consequently, it is not possible 
to extrapolate our results to patients in the last hours to days of life. Future 
research can seek to evaluate hydration states of the dying. This approach will 
require innovative methodology, such as advanced consent procedures, in order, to 
recruit and maintain involvement of patients who are expected to lose the capacity 
to provide ongoing consent due to deterioration clinical condition. 
This analysis shows that H2/R, BIVA and pre-renal failure were predictive of survival. 
Consequently, there is the potential that BIA and the ur:cr ratio can be incorporated 
into existing assessment tools to aide prognostication in advanced cancer patients. 
Additionally, BIVA could be used to evaluate non-hydration factors in the palliative 
cohort (for example, to assess muscle mass in the evaluation of cachexia). 
Furthermore, BIVA could be used to evaluate body composition changes in 
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response to clinical treatments such as radiotherapy and chemotherapy, in order, 
to predict outcome. Future studies can use H2/R and BIVA to evaluate survival for 
various diagnoses at different stages of disease, particularly the last hours to days 
of life. Additionally, the marker of phase angle (which has been found to be 
associated with survival in previous studies) can be further evaluated to assess to 
test its usefulness and its relationship with hydration. 
7.3.4 CONCLUDING REMARKS 
This study is the first to demonstrate how fluid status is associated with symptoms, 
survival and physical signs in advanced cancer. This sheds new light on the subject 
of hydration in palliative care. Our data suggest that a good level of recruitment to 
studies involving palliative patients is possible. This is noteworthy, as patients in 
specialist palliative care units are more likely to have more advanced disease and 
symptom burden compared to those within general medical and oncology units. 
Researchers, funders and policy makers should be encouraged by our findings as 
patient participation in research will help to identify and address patient-centred 
priorities at the end of life. This thesis demonstrates that the subject of hydration in 
advanced cancer is complex, under-researched and methodologically challenging. 
Rather than a simple question of whether CAH should be administered or not, it 
represents a multi-faceted issue that requires a careful decision making. Several 
factors need to be considered, which include diagnosis, stage of disease, gender, 
ethnicity, symptoms, use of medications, performance status, quality of life, 
oedema and the potential risks and benefits of CAH.  
Further work is essential to learn more about hydration according to different types 
of cancer, at specified disease stages and whether medical interventions are of 
benefit in these scenarios. Consequently, this study provides the first step of 
journey which will hopefully improve the care of advanced cancer patients 
throughout the world. 
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Appendix 1 - Mathematical Formulas 
Formulas used in the development of the BIVA method are presented in this 
section. 
Equation 1: Development of the impedance index formula (see 
introduction 1.3.4 Use of BIA to predict fluid volumes) 
The impedance (Z, Ω) of a human body is a function of the specific electrical 
resistivity (p, Ω•cm2) of the adilipidic tissue (a good conductor of electrical current) 
and is obtained by its section (A, cm2) and length (L, cm): 
Z = 𝜌( L/A)335 
Considering the lean body mass as a cylinder, the equation can be rewritten by 
multiplying by L/L: 
Z = 𝜌(L2/A•L)93 
Replacement of A(L) with volume (V, cm3) and adapting the equation e will obtain: 
V= 𝜌(L2/Z)119 
Consequently, the use of an alternating current and cylindrical electrical conductor 
will allow: 
V= 𝜌(L2/R)336 
Therefore, if 𝜌 is constant, L2/R is directly proportional to the volume of the lean 
body mass. The fundamental laws of the impedance measurement are in Nyboer J’s 
book.92 In the human subject, height is used as a measure of the conductor length. 
Therefore the final equation is: 
Volume = height2/impedance.92 
Parameters of tolerance ellipses of bivariate Z-scores (RXc-score graph) can be 
calculated accordingly, using equations 2 and 3.144 
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Equations 2 and 3: Formulas for the calculation of the bio-impedance 
confidence and tolerance ellipses  
The following section has been adapted (with permission) from Piccoli A , Pastori: 
BIVA software.101 
Geometrical parameters for drawing the RXc Graph and the RXc-score Graph 
Confidence and tolerance intervals can be calculated for the bivariate normal 
distribution.148 337-340 A simple linear correlation analysis can be used for calculation 
following appropriate modification of the equations.142 144  
Given n pairs of observations x and y, with standard deviation sx and sy, and 
correlation coefficient r, for a fixed 𝛼 probability level, the Snedecor's Fα value is 
taken with 2 and n-2 degrees of freedom. 
RXc Graph 
The RXc graph semi-axes (L1 and L2) and the slopes (b1 and b2 = -1/b1), of the axes of 
the 100(1-α)% confidence and tolerance ellipses (e.g. α= 0.05, 0.25, and 0.50 for the 
95th, 75th, and 50th percentile, respectively) can be calculated using the equations 
2a and 3a, respectively. 
RXc-score graph 
The parameters of tolerance ellipses of bivariate Z-scores (RXc Z-score graph) can 
be calculated accordingly, using equations 2b and 3b.144 
Equation 2 a (See 1.4.3: The RXc graph method in clinical bio-
impedance analysis) 
𝐋𝟏, 𝐋𝟐 =
√𝑲. √(𝑛 − 1)(𝑠𝑥2 +  𝑥𝑦2) ± √[(𝑛 − 1)(𝑠𝑥2 + 𝑠𝑦2)]2 − 4 (𝑛 − 1)2(1 − 𝑟2)𝑠𝑥2  𝑠𝑦2  
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Equation 2 b 
𝑳𝟏, 𝑳𝟐 = √𝑲. √𝟐 (𝒏 − 𝟏) ± 𝟐 𝒓 (𝒏 − 𝟏) 
 
Where 
K = F/n·(n-2) for confidence ellipses 
K = F·(n+1)/n·(n-2) for tolerance ellipses 
Equation 3 a 
𝒃𝟏, 𝒃𝟐 = (𝒃, −
𝟏
𝒃
) = (𝒔𝒚𝟐 − 𝒔𝒙𝟐)/𝟐𝒓𝒔𝒙𝒔𝒚 ± √𝟏 +  [(𝒔𝒚𝟐 − 𝒔𝒙𝟐)/𝟐 𝒓𝒔𝒙𝒔𝒚]
𝟐 
 
Equation 3b 
𝒃𝟏, 𝒃𝟐 = ±𝟏 
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Appendix 2: Details of studies included in the literature review 
Study Purpose Design Participants Exclusions Dehydration 
definition 
Outcome measure Methods Conclusions 
Morita et 
al 2005
227
 
 
To explore 
systematically the 
associations between 
hydration volume and 
dehydration and fluid 
retention symptoms in 
the last 3 weeks of life 
in terminally ill patients 
with abdominal 
malignancies. 
Multicentre, 
prospective, 
observational 
study 
n=226 
 
14 oncology units, 19 
palliative care units, 4 
home-based palliative 
care programs in 
Japan. 
 
- Age≥ 20  
-  Life expectancy ≤ 
3 months 
-  Incurable 
malignancy of lung or 
abdominal 
origin (excluding 
hepatic 
malignancies). 
 
Mean age = 68 
Male/female = 
106/120 
 
n=272 
 
- Death with 3 weeks of 
initial assessment 
(n=200) 
- Survival beyond 
observation period 
(n=35) 
- Medical complication 
(n=17) 
- Prior communication 
difficulty (n=15) 
- Discharge (n=5) 
 
liver 
cirrhosis, renal failure, 
nephritis syndrome, 
protein-losing 
enteropathy, intra-
abdominal 
shunt for ascites, 
hypercalcaemia, 
endocrine 
disorders, and vital 
organ complications 
unrelated 
to underlying 
malignancies;  surgical, 
radiological, or 
oncological treatments 
in the 3 
weeks prior to study 
inclusion;  existing 
communication 
Degree of 
dehydration 
defined on 
basis of three 
physical 
findings. 
1. Ad Hoc dehydration score 
(0-5) 
2. The peripheral oedema 
score (0-21) 
3. Pleural effusion score (0-2) 
4. Ascites score (0-2) 
5.  Delirium (evaluated by the 
Memorial Delirium 
Assessment Scale) 
 
Analysis of data 
collected:  
 
Patients 
classified into 2 
groups; the 
hydration group 
(n=59) who 
received  ≥1 L or 
more of 
artificial 
hydration 
per day both 1 
and 3 weeks 
before death, 
and the non-
hydration group 
(n= 167) who 
did not. 
 
Percentage of patients 
with deterioration in 
dehydration score in 
final 3 weeks of life 
significantly higher in 
non-hydration group 
compared to hydration 
group (35% versus 14%, 
p=0.002). 
 
Fluid retention 
symptoms increased 
significantly in 
hydration group 
compared to non-
hydration group: 
oedema (44 versus 
29%, p=0.039) ascites 
(29% versus 8.4%, 
p<0.001), pleural 
effusion (15% versus 
5.4%, p=0.016). 
 
No significant 
difference in degree of 
bronchial secretion, 
hyperactive delirium, 
communication 
capacity, agitation, 
myoclonus or bedsores. 
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difficulty; and  the use 
of 
artificial enteral 
nutrition. 
 
Morita et 
al 
2006
228
  
To explore 
the association 
between (1) hydration 
volume 
and laboratory findings 
and (2) calculated 
fluid balance and the 
changes in clinical signs 
of 
dehydration and fluid 
retention during the 
last 
3 weeks of life in 
terminally ill cancer 
patients. 
Multicentre, 
prospective, 
observational 
study 
n= 125 
 
14 oncology units, 19 
palliative care units, 4 
home-based palliative 
care programs in 
Japan. 
 
- Age≥ 20  
- Life expectancy ≤ 
3 months 
-  Incurable 
malignancy of lung or 
abdominal 
origin (excluding 
hepatic 
malignancies). 
 
Mean age = 67 
Male/female = 61/64 
Number not given 
 
liver 
cirrhosis, renal failure, 
nephritis syndrome, 
protein-losing 
enteropathy, intra-
abdominal 
shunt for ascites, 
hypercalcaemia, 
endocrine 
disorders, and vital 
organ complications 
unrelated 
to underlying 
malignancies;  surgical, 
radiological, or 
oncological treatments 
in the 3 
weeks prior to study 
inclusion;  existing 
communication 
difficulty; and  the use 
of 
artificial enteral 
nutrition. 
Degree of 
dehydration 
defined on 
basis of three 
physical 
findings. 
1. Ad Hoc dehydration score 
(0-5) 
2. The peripheral oedema 
score (0-21) 
3.Pleural effusion score (0-2) 
4. Ascites score (0-2) 
 
Scores developed by the 
authors.  
Secondary 
analysis of data 
collected:  
Laboratory 
data; 
Clinical 
assessment 
data; 
Fluid balance; 
Oral intake. 
 
Patients 
classified into 
two groups: the 
hydration group 
(n= 44), who 
received  ≥1 L or 
more of 
artificial 
hydration 
per day both 1 
and 3 weeks 
before death, 
and the non-
hydration group 
(n= 81) who did 
not. 
 
 
 
The mean 
albumin level 1 week 
before death was 
significantly lower in 
the hydration group 
than in the 
non-hydration group, 
and the interaction 
between hydration 
group and decrease in 
the 
albumin level 
 
There was no significant 
difference between the 
groups in the mean 
blood 
urea 
nitrogen/creatinine, 
sodium, or potassium 
levels 1 week before 
death. 
 
The calculated fluid 
balance was not 
significantly 
different between the 
patients with 
deterioration 
in scores of 
dehydration, oedema, 
ascites, and pleural 
effusion during the last 
3weeks and those 
without. 
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Bruera et 
al 
2005
229
 
To determine the effect 
of clinically assisted 
hydration on overall 
symptom control in 
terminally ill cancer 
patients with 
dehydration. 
Randomised, 
controlled, 
double-blind 
trail. 
n= 51 
 
NB: sample size 
calculation 54 per 
group (i.e. total 
n=108) 
 
- A palliative diagnosis 
of advanced cancer 
with no further 
treatment planned. 
-  Oral intake ≤ 
1000 mL/day; 
-decreased skin 
turgor≥ 2 
seconds. 
- One or more of: dry 
mouth; thirst; 
decreased volume of 
urine 
output; a darker 
colour of urine than 
usual 
-  Laboratory values 
consistent with 
dehydration 
 obtained within 24 
hours of admission to 
the 
study. 
- Age ≥16   
- Able to tolerate  
subcutaneous or 
intravenous fluids. 
 
Demographics not 
given 
n= 13 
 
patient’s refusal to 
participate; the 
presence of severe 
dehydration, defined as 
a decreased systolic 
resting blood pressure 
of 30 mmHg or lower 
from the patient’s 
baseline value; low 
perfusion of the limbs; 
no urine output for 12 
hours or longer; 
a decreased level of 
consciousness; or 
evidence of severe 
renal failure or bilateral 
hydronephrosis. 
Oral intake ≤ 
1000 mL/day; 
-decreased 
skin turgor≥ 2 
seconds. 
- one or more 
of 
: dry mouth; 
thirst; 
decreased 
volume of 
urine 
output; a 
darker colour 
of urine than 
usual 
laboratory 
values 
consistent 
with 
dehydration, 
such as an 
elevated 
blood urea 
nitrogen to 
creatinine 
[BUN/Cr ) 
ratio of ≥20:1. 
Target symptoms 
(hallucinations, myoclonus, 
fatigue, and sedation) 
assessed with 0-10 numeric 
rating scale. 
 
Mini Mental State 
Examination (MMSE). 
 
 
 
Patients  
were randomly 
assigned to 
receive either 
1,000 
mL (treatment 
group) or 100 
mL (placebo) 
normal saline 
administered 
over 4 hours for 
2 days. 
 
Patients 
evaluated for 
target 
symptoms 
global well-
being, and 
overall benefit. 
The administration of 
artificial fluids 
improved sedation and 
myoclonus in the 
intervention group.  
Bruera et 
al 2013
230
 
To determine whether 
parenteral hydration 
was superior to placebo 
Randomised, 
placebo-
controlled, 
n=129 
 
NB: Sample size 
n=776 
 
- Declined to participate 
Defined by 
decreased 
skin turgor in 
Target symptoms 
(hallucinations, myoclonus, 
fatigue, delirium and 
Patients were 
randomly 
assigned to 
Hydration at 1L per day 
did not improve 
symptoms, quality of 
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in improving symptoms 
associated with 
dehydration, delayed 
the onset and severity 
of delirium, and had an 
effect on quality of life 
(QoL) and survival in 
patients with advanced 
cancer receiving 
hospice care. 
double-blind, 
multicentre 
trial. 
calculation was 75 
per group (i.e. total 
n=150) 
 
- Diagnosis of 
advanced cancer  
- Age ≥ 18 years 
- An admission to 
Hospice 
- A reduced oral 
intake of fluids with 
evidence of 
dehydration (see 
dehydration 
definition)  
- A life expectancy ≥1 
Week 
- Availability of a 
primary caregiver 
-  A Memorial 
Delirium Assessment 
Scale (MDAS) score 
less than 13 
- Able to give written 
informed consent 
- Lives within 60 miles 
of The University of 
Texas MD 
Anderson Cancer 
Center. 
(=205) 
- Did not meet inclusion 
criteria (n=387) 
- Delirium/actively 
dying (n=110) 
- No dehydration (n=26) 
- Non-English speaking 
(n=25) 
-Brain metastases (=22) 
- Other (n=204) 
- Died (n=154) 
- Unable to contact 
(n=30) 
subclavicular 
region (>2 
seconds) and 
a score of >2 
of 5 in the 
clinical 
dehydration 
assessment
228
 
an intensity of 
≥1 on a 0 to 
10 scale (0=no 
symptom, 
10=the worst 
possible 
symptom) for 
fatigue and 
two of the 
three other 
target 
symptoms 
(hallucination
s, sedation, 
and 
myoclonus) 
 
sedation) assessed with 0-10 
numeric rating scale. 
 
- Edmonton Symptom 
Assessment Scale 
- Unified Myoclonus Rating 
Scale (UMRS) 
- Memorial Delirium 
Assessment Scale (MDAS) 
- Richmond Agitation Sedition 
Scale (RASS) 
- Nursing Delirium Screening 
Scale (NuDESC) 
- Functional Assessment of 
Chronic Illness Therapy-
Fatigue (FACIT-F) 
 
receive either 
1,000 
mL/day 
(treatment 
group) or 100 
mL/day 
(placebo) 
normal saline 
administered 
over 4 hours 
until patient 
was 
unresponsive, 
developed 
progressive 
coma or died. 
 
Global symptom 
evaluation was 
used to 
estimate 
minimal 
importance 
difference in 
target 
symptoms pre 
and post 
treatment. 
life, or survival 
compared to placebo. 
Guo et al 
2007
248
 
To determine the 
prevalence of pre-renal 
azotaemia in a cancer 
rehabilitation patient 
population. 
 
To evaluate the 
relationship of pre-
renal azotaemia to 
rehabilitation outcome, 
Retrospective 
chart review 
n= 62 
 
Cancer patients 
admitted to the acute 
inpatient 
rehabilitation unit: 
Demographics not 
given. 
n= 8 
 
Patients considered to 
have renal insufficiency 
BUN/Cr ratio 
≥ 20 (pre-
renal 
azotaemia) 
1. Pre-renal azotaemia 
prevalence 
 
2. Length of rehabilitation 
stay of pre-renal azotaemia 
group compared to non pre-
renal azotaemia group. 
 
3.  Discharge destiny of pre-
renal azotaemia group 
Patients 
classified into 2 
groups: The 
pre-renal 
azotaemia 
group (n= 27) 
and the non 
pre-renal 
azotaemia 
group (n= 35). 
Pre-renal azotaemia 
prevalence = 44% 
[n=27/62) 
 
No significant 
association between 
pre-renal azotaemia on 
length of rehabilitation 
stay or discharge 
destiny. 
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specifically length of 
stay and discharge 
destiny in these 
patients. 
compared to non-pre-renal 
azotaemia group. 
 
Secondary 
analysis of 
collected data: 
- Demographics 
-  Laboratory 
data 
- Length of stay 
- Discharge 
destiny 
 
Waller et 
al 
1994
249
 
Are cancer patients 
dehydrated when close 
to death? 
 
Does the provision of 
intravenous fluids 
influence the state of 
hydration of such 
patients or their level of 
consciousness? 
Cross-
sectional 
n= 68 
 
Hospice inpatients: 
- Terminal cancer 
- Laboratory tests 
done within 48 hours 
of death (patients 
selected after death) 
 
Demographics not 
given 
Number and details not 
given 
Elevated 
sodium, 
specific cut-
off was not 
defined. 
Differences between urea, 
sodium, serum osmolality, 
urine osmolality, urine/serum 
osmolality ratio, blood urea 
nitrogen (BUN)/creatinine 
ratio. 
 
Alertness scale: 
1. Fully conscious 
2. Responsive to visual or 
vocal stimuli 
3. Responsive to only painful 
stimuli 
4. Comatose 
The Early Warning Score 
(EWS) is validated for the 
identification of medical 
patients at risk general 
deterioration. 
Comparison of 
biochemical 
measurements 
and alertness 
scale 
measurements 
between 
groups. 
87% [n= 59/68) of 
patients classified as 
dehydrated. 
 
State of consciousness 
correlated inversely 
with serum sodium and 
urine osmolality. 
 
Patients receiving 
intravenous fluids were 
not better hydrated 
than those without IV 
therapy. 
 
State of consciousness 
was not improved for 
those hydrated 
compare to those 
without IV therapy. 
Burge et 
al 
1993
250
 
To determine the 
severity and 
distribution of 
symptoms associated 
with dehydration in 
inpatient palliative care 
patients. 
 
To determine the 
Cross 
sectional 
survey  
n= 52 
 
Palliative care unit 
(PCU) patients: 
- Age ≥18 
- Advanced cancer 
- Prognosis ≤6 weeks 
- Ability to speak 
English or French 
n= 71 
 
- Confusion (n=20) 
- Weak (n= 7) 
- Drowsy/coma (n=13) 
- Language (n=7) 
- Died (n=5) 
- Refused (n=5) 
- Aphasia (n=2) 
Dehydration 
not defined 
Visual analogue score (VAS) 
for following symptoms: 
- Thirst 
- Pain 
- Dry mouth 
- Nausea 
- Bad taste 
- Fatigue 
- Pleasure to drink 
Cross sectional 
survey of 
palliative care 
inpatients 
across to 
hospitals. 
 
Associations 
between 
No association between 
severity of symptoms 
and fluid intake. 
 
No association between 
biochemical measures 
and thirst. 
 
Fatigue, dry mouth and 
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association between 
these objective 
measures of 
dehydration. 
- Ability to 
understand, consent 
to, and take part in 
study. 
 
Mean age 64.4 
Male/female = 26/26 
27% died within 2 
weeks of study 
- Anxiety/agitation 
(n=2) 
 
 
symptoms and 
predictor 
variables (fluid 
intake, plasma 
osmolality, 
sodium, and 
urea). 
thirst are highly 
prevalent. 
Cerchietti 
et al 
2000
251
 
 
To assess the 
usefulness of 
hypodermoclysis 
hydration in the relief 
of thirst, chronic 
nausea and delirium. 
Randomised 
controlled 
trail 
n= 42 
 
NB sample size = 50 
 
Terminal stage 
advanced cancer 
patients with one or 
more of the 
following: 
- Thirst 
-Chronic nausea or 
delirium 
-Dehydration 
diagnosed on physical 
examination (with or 
without renal failure) 
-Inability to maintain 
adequate water 
intake ≤50mls/day 
 
Mean age= 55.8 
(intervention), 51.7 
(control) 
Male/female = 17/25 
Number not given 
 
Dehydration 
diagnosed on 
physical 
examination 
(with or 
without renal 
failure). 
Visual analogue score (VAS) 
for following symptoms: 
- Thirst 
- Chronic nausea 
- Delirium 
- MMSE 
 
 
20 patients 
received 1000 
lm 5% dextrose 
in water with 
addition of 
140mEq/l 
sodium chloride 
per day, at an 
infusion rate of 
42ml/hr via the 
subcutaneous 
route. 
 
22 received no 
fluids. 
 
VAS scores and 
MMSE used to 
compare 
hydrated and 
non-hydrated 
group. 
Both groups showed 
significant and equal 
improvements in relief 
of thirst and nausea at 
24 hours, but this 
improvement was only 
maintained in the 
hydration group at 
48hours. 
 
Delirium did not 
improve significantly in 
either group. 
Ellershaw 
et al 
1995
247
 
To investigate the 
relationship that 
respiratory tract 
secretions, thirst and 
dry mouth have with 
level of hydration as 
measured by 
Prospective 
cohort  
n= 82 
 
Palliative care 
inpatients: 
- Advanced cancer 
- Dying and taking just 
sips of fluid or unable 
Patients were excluded 
if a doctor or nurse 
involved in the care of 
the patient felt it was 
inappropriate for the 
patient to be included 
in the study. 
Dehydration 
definition 
based on the 
presence of 
one or more 
of the 
following: 
Self-reported symptoms (dry 
mouth and thirst) by patient. 
Clinical assessment of 
respiratory tract secretions. 
 
Biochemical definitions 
 
Based on 
dehydration 
definition: 61 
patients defined 
biochemically 
dehydrated, 21 
not 
No statistically 
significant relationship 
between respiratory 
tract secretions, dry 
mouth, thirst and the 
level of hydration. 
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biochemical 
parameters, in the 
terminally-ill patients. 
to take moral 
medications 
 
Median age = 73 
Male/female = not 
given 
All died within 5 days 
of entry to study 
 
No other details given. 
-Serum 
osmolality 
>295 
mOsmol/kg 
-Creatinine 
≥130 µmol/L 
-Urea ≤12 
mmol/L 
 
. biochemically 
dehydrated. 
Comparisons 
made between 
groups. 
Morita et 
al 
2001
246
 
To identify the 
association between 
sensation of thirst in 
hospice inpatients and 
various medical factors, 
especially dehydration. 
Cross-
sectional 
study 
n= 88 
 
Palliative care 
inpatients: 
- Age ≥18 or older 
- Diagnosis of 
incurable advanced 
cancer 
- Physicians’ estimate 
of 6 months life 
expectancy or less. 
 
Demographics not 
given. 
n= 96 
 
- Cognitive impairment  
- Diabetes insipidus 
and/or thyroid or 
adrenal dysfunction 
- Delirium/dementia 
(n=52) 
- Past history of heart 
failure, COPD or 
hypertension (n=17) 
- Palliative Performance 
Scale (PPS) of ≥60 
(n=11) 
- Lack of laboratory 
examinations (n=6) 
- Unable to understand 
VAS (n=5) 
- Faulty blood sampling 
(n=5) 
Two 
definitions 
used: 
 
1. Atrial 
natriuretic 
peptide (ANP) 
≤15pg/ml 
2. Ellershaw’s 
definition(54): 
- Serum 
osmolality 
>295 
mOsmol/kg 
- Creatinine 
≥130 µmol/L 
- Urea ≤12 
mmol/L 
 
Visual Analogue Score (VAS) 
score for thirst. 
 
ANP ≤15pg/ml. 
 
Ellershaw’s definition. 
 
 
Patients 
grouped 
dehydrated or 
not-dehydrated.  
 
VAS scores 
analysed: 
- Continuously 
used as a 
dependent 
variable 
-Logistic 
regression 
analysis where 
patients with 
VAS ≥8 
compared with 
each other. 
 
Comparison of 
biochemical 
measurements 
between 
groups. 
No significant 
correlations observed 
between the VAS score 
for thirst and 
biochemical measures 
based on the 
Ellershaw’s definition. 
 
Dehydration defined by 
ANP level ≤15pg/ml 
showed severity of 
thirst to be significantly 
associated with: 
- Hyperosmolality 
≥300mosmol/kg 
- Gastrointestinal 
cancer 
- Survival 
- Performance status 
- Oral intake 
- Vomiting 
- Stomatitis 
 
Mouth breathing and 
opioids potential causes 
of severe thirst as 
identified from 
retrospective chart 
review. 
Galanakis 
et al 
To estimate the extent 
to which hydration and 
Retrospective 
analysis of 
n=1125 
Patients with 
n=1390 
 
Dehydration 
not defined 
Relationship of hydration risk 
factors to delirium groups. 
Data extracted 
from a clinical 
Patients classified into 
six different groups 
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2010
256
 related risk factors 
influence the course of 
delirium over time. 
 
 
clinical trial 
data 
advanced cancer 
surviving at least 3 
days, receiving care 
palliative care at   
centres in Quebec 
and Ontario as part of 
a clinical trial for the 
prevention of 
delirium. 
Data unavailable  
Details of measures 
unavailable. 
trial database. 
 
Group based 
trajectory 
modelling and 
multivariate 
linear 
regression were 
used to identify 
subgroups of 
individuals with 
similar delirium 
trajectories 
during the first 
30 days of 
admission and 
to determine 
what factors 
influence 
membership to 
these 
trajectories. 
based on 
presence/absence and 
course of delirium. 
 
Hydration was not 
predictive of delirium 
or group membership. 
Yamaguch
i et al 
2012
253
 
To clarify the 
longitudinal changes in 
patient reported global 
quality of life (QoL), 
observational 
discomfort, symptoms 
and fluid retention 
signs in patients with 
advanced cancer 
receiving guideline-
based parenteral 
hydration therapy. 
Prospective, 
observational 
study 
n=161 
 
- >20 years 
- Incurable 
abdominal 
malignancy 
- Severely reduced 
oral intake (< 
 100 kcal/day and 100 
mL/day); 
- Available for follow-
up 
 
 
- Hepatic, prostate, or 
oesophageal 
malignancy 
- Renal (creatinine> 2 
mg/dL), 
- Heart (NYHA 
classification >II), or 
liver failure 
(total bilirubin > 2 
mg/dL) unrelated to 
malignancy 
- Liver cirrhosis, 
nephrotic 
syndrome, or protein-
losing enteropathy of 
any aetiology 
- Intra-abdominal shunt 
for ascites; 
Dehydration 
not defined 
1. Patient-reported global 
quality of life (using item 30 
of the European Organization 
for Research Treatment of 
Cancer Quality of Life 
Questionnaire-C30). 
2. Observational discomfort 
(using the Discomfort Scale). 
3.Patient reported benefit 
and satisfaction with CAH 
4. Physical symptoms 
5. Psychiatric symptoms 
Patients 
completed 
questionnaires 
weekly (weeks 
1-4) and then 
two-weekly (up 
until week 12 or 
death). 
 
Patients 
received CAH 
accordingly to 
national 
Japanese 
guideline. CAH 
reduced to 
<1L/day in 
patients with 
No significant 
difference of QoL, 
Discomfort Score and 
symptoms between low 
and high volume 
groups. 
 
More than 80% of 
patients maintained all 
fluid retention signs. 
 
Hyperactive delirium 
significantly higher in 
small-volume hydration 
group in last 48 hours 
of life (5.3% versus 
17.3%, p=0.009). 
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-Hypothyroidism, 
adrenal insufficiency, 
SIADH requiring 
intervention; 
- Cognitive impairment; 
- Antitumor therapy 
(surgical, radiological, 
or chemotherapy) 
within 
2 weeks prior to study  
- Use of artificial enteral 
nutrition. 
fluid retention 
signs. 
 
Patients 
grouped as low 
volume 
(<1l/day) and 
high volume 
(>1L/day) 
 
Nakajima 
et al 
2013
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To explore the 
influences of hydration 
volume toward the 
symptoms during the 
last 3 weeks of life in 
these patients. 
Prospective, 
observational 
study 
n=75 
 
- Age > 20 years 
-  Life expectancy 
estimated by a 
physician to be < 3 
months 
- Incurable 
malignancy of 
abdominal origin. 
 
Number not given. 
 
- Liver cirrhosis 
- Renal failure 
- Nephrotic syndrome 
- Protein-losing 
enteropathy 
- Intra-abdominal shunt 
for ascites 
- Hypercalcaemia 
- Adrenalopathy 
- Thyroid diseases 
- Other complications 
of the circulatory, 
respiratory, hepatic, or 
renal system unrelated 
to 
underlying 
malignancies 
- Surgical, radiological, 
or oncological 
treatments with the 
primary intent of 
tumour reduction in 
the three weeks prior 
to study inclusion 
- Communication 
difficulty  
Degree of 
dehydration 
defined on 
basis of three 
physical 
findings. 
1. Dehydration score[35] 
2. The peripheral oedema 
score  
3.Ascites and pleural effusion 
score 
4. Bronchial secretion 
5. Delirium (evaluated by the 
Memorial Delirium 
Assessment Scale) 
 
Assessment schedule based 
on work of Morita 2005.
227
  
Analysis of data 
collected:  
 
Patients 
classified into 2 
groups; the 
hydration group 
(n=32) who 
received  ≥1 L or 
more of 
artificial 
hydration 
per day both 1 
and 3 weeks 
before death, 
and the non-
hydration group 
(n= 43) who did 
not. 
 
The percentages of 
patients with 
deterioration in 
dehydration score in 
the last 3 weeks were 
significantly higher in 
the non-hydration 
group than in the 
hydration group (35% 
versus 13%; p=0.027). 
 
Significantly higher fluid 
retention symptoms 
reported in the 
hydration group 
compared to the non-
hydration group: 
oedema (57% versus 
33%, p=0.040), ascites 
(34% vs. 14%, p=0.037) 
and bronchial secretion 
(44% vs. 19%, p=0.036). 
 
No significant 
differences in the 
degree of pleural 
effusion and delirium. 
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- Artificial enteral 
nutrition.  
Musgrave 
et al 
1995
252
 
To evaluate the effects 
of intravenous fluids in 
a group of dying 
patients. 
Cross-
sectional 
study 
n= 19 
 
Inpatients on adult 
oncology unit: 
-Terminally ill 
- Receiving IV fluids 
- Prognosis of ≤10 
days  
 
Demographics not 
given 
n= 19 
 
- Survival > 10 days 
(n=5) 
- Died without IV (n=1) 
- Transferred (n=2) 
- (Semi)unconscious 
(n=11) 
Dehydration 
not defined 
Structured questionnaire 
developed by the 
researchers. 
 
Questionnaire was reviewed 
for content validity by an 
oncologist, two specialists in 
oncology nursing and two 
statisticians. 
 
 
Patients asked 
to complete a 
questionnaire 
recording 
severity of 
thirst. Serum 
biochemistry 
and fluid intake 
and output 
volumes 
recorded. 
Comparisons 
made between 
variables. 
95% (n= 18/19) of 
patients reported thirst. 
 
No association between 
level of thirst with the 
amount of IV fluids 
received, blood urea 
nitrogen, sodium levels. 
 
Little association 
between fluid retention 
signs and volume of 
fluid received. 
Davis et al 
2009
200
 
To determine whether 
bioelectrical impedance 
analysis (BIA) correlates 
with hydration changes 
during clinically assisted 
hydration and to 
determine if these 
changes were of 
prognostic importance. 
Prospective 
observational 
study 
n= 50 
 
Inpatient palliative 
care unit: 
- Active cancer 
- Undergoing 
continuous hydration 
- Able to give consent 
 
Mean age = 63 
Male/female = 30/20 
n= 29 
 
- Delirious 
- Actively dying 
- Unable to 
communicate 
- Deferred participation  
- Patients with 
defibrillators 
Dehydration 
not defined 
Phase angle. 
 
 
Patients 
underwent BIA 
measurements 
for 3 
consecutive 
days. 
Laboratory 
studies, patient 
weight and vital 
signs recorded. 
Patient survival 
calculated. 
Higher phase angle 
before hydration 
predicts longer survival. 
 
Increase in phase 
angles during hydration 
predicted poorer 
survival and pre-
existing intracellular 
dehydration, cachexia 
or poor membrane 
function. 
Crawford 
et al 
2009
259
  
To investigate whether 
bioimpedance 
spectroscopy (BIS) has 
the potential to 
improve 
prognostication in an 
outpatient clinic for 
patients with cancer 
receiving palliative care. 
Observational n= 84 
 
Outpatient oncology 
and palliative care 
clinics: 
- Advanced cancer 
- Fluency in English 
- Age ≥18 
- Judged by their 
primary medial 
specialist to be in the 
palliative phase of 
n= 19 
 
- Declined participation 
(n=4) 
- Physical decline (n=15) 
 
Dehydration 
not defined 
BIS measures and survival 
time. 
 
 
Survival time 
and BIS 
measurements 
of basal 
metabolic rate 
and 
measurement 
11 body 
composition 
parameters 
(extracellular 
fluid (ECF), 
Metabolic rate and 
accumulation of body 
fluid are indicators of 
poor prognosis in 
palliative cancer 
patients. 
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their illness 
- No severe cognitive 
impairment 
 
Mean age = 65.9 
Male/female = not 
given. 
 
intracellular 
fluid 
(ICF),ECF/ICF 
ratio, fluid in 
trunk and arm 
and leg, protein 
mass, mineral 
mass, and 
percent of body 
fat) were 
recorded. 
Fritzson 
et al 
2013
258
 
Association between 
parenteral fluids and 
symptoms in hospital 
end-of-life care: an 
observational study of 
280 patients. 
To investigate 
whether dying 
patients 
receiving CAH 
suffer from 
more or less 
symptoms 
than patients 
who do not 
receive CAH. 
n=251 
 
- Patients who were 
reported to Swedish 
Register of Palliative 
Care to have 
died expectedly in a 
hospital in the 
Västerbotten 
county (Sweden) 
between 1 January 
2011 and 30 
June 2012. 
 
n=279 
 
- Case notes not 
selected (n=250) 
- No data available 
(n=1) 
- Sedation in last 24 
hours of life (n=6) 
- Length of stay <24 
hours (n=22) 
Dehydration 
not defined. 
Documented presence of 
dyspnoea, respiratory 
secretions, anxiety, nausea 
and confusion in the last 24 
hours of life. 
Patients 
classified into 
two groups 
using stratified 
random 
sampling: 
(i) CAH group 
(n=140) 
(ii) non-CAH 
group (n=140). 
 
Patients 
matched by 
age, sex and 
disease. 
 
Higher dyspnoea 
prevalence in the CAH 
group vs. non-CAH 
group (51% vs 22% last 
24 h, p<0.0001; 70% vs 
45% last 7 days, 
p<0.001). Increasing 
prevalence of dyspnoea 
was associated with 
larger CAH volumes. No 
clinically significant 
differences in anxiety, 
nausea or confusion 
were found. 
 
 
Simons et 
al 1995
83
 
The use of bioelectrical 
impedance analysis to 
predict total body 
water in patients with 
cancer cachexia 
To investigate 
the 
applicability 
of 
BIA to 
determine 
TBW by using 
deuterium 
dilution as a 
reference 
method in 
end-stage 
cancer 
n=41 
 
- Ambulatory 
- Cancer diagnosis 
 
Number not given. 
 
Dehydration 
not defined. 
H
2
/R, body weight and ∆-
TBWdeu. 
Assessment of 
16 underweight 
and 25 normal-
weight cancer 
patients. 
 
Correlations 
between H
2
/R, 
∆-TBWdeu and 
TBW as 
estimated by 
prediction 
equations were 
H
2
/R was a strong 
predictor of ∆-TBWdeu 
in both normal-weight 
patients (r
2
 = 0.85, 
p<.0001) and 
underweight patients 
(r
2
 = 0.86, p<.0001). SF-
BIA overestimates TBW 
in underweight patients 
when prediction 
formulas are used that 
have been developed in 
normal-weight subjects. 
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patients with 
and without 
cachexia. 
evaluated.  
Simons et 
al 1999
136
 
Bioelectrical impedance 
analysis to assess 
changes in total body 
water in patients with 
cancer. 
To compare 
changes in 
H
2
/R 
with changes 
in ∆-TBWdeu 
in cancer 
patients over 
12 weeks. 
n=33 
 
- Advanced-stage 
cancer patients who 
participated 
in a randomized 
placebo-controlled 
trial investigating the 
effects of a synthetic 
progestogen on food 
intake and body 
composition. 
n=21 
 
- No repeat assessment 
(n=16) 
- Death or physical 
deterioration (n=6) 
- Side effects (n=4) 
- Refusal to continue 
(n=2) 
- Protocol violation 
(n=2)  
- Mechanical gastric 
obstruction (n=1) 
- Peritonitis (n=1) 
Dehydration 
not defined. 
H
2
/R, body weight and ∆-
TBWdeu. 
Study 
assessments 
undertaken at 
baseline, 6 
and 12 weeks. 
 
Correlations 
between H
2
/R, 
∆-TBWdeu and 
TBW as 
estimated by 
prediction 
equations were 
evaluated. 
Changes in TBWdeu 
occurred in both 
directions (mean +0.2 
+/- 1.6 L, range -3.3 to 
+3.1 L). Changes were 
significantly predicted 
by changes in H
2
/R (r
2 
=0.43, P <.0001, SEE 
1.22 L), although 
precision was poor 
(residual SD = 1.2 L). 
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Appendix 3: Study advertisement poster 
 
HYDRATION IN PALLIATIVE CANCER PATIENTS: THE TESTING OF A NEW 
ASSESSMENT METHOD 
 
 
Marie Curie Hospice Liverpool is currently participating in a study to improve the 
knowledge of hydration in people with advanced cancer 
 
Inclusion criteria Exclusion criteria 
 Admitted to the Marie Curie Hospice 
Liverpool. 
 Patients with implantable 
defibrillator devices or 
pacemakers. 
 
 Over 18 years of age.  Patients unable to provide fully 
informed consent. 
 Known diagnosis of cancer (proven 
by histology or radiological imaging). 
 
 No further curative treatment 
possible. 
 
 Able to understand the study 
protocol in English or through the 
use of communication aides or 
interpreter services. 
 
 
IF YOU BECOME AWARE OF PATIENTS WHO YOU BELIEVE FIT THE ABOVE CRITERIA 
AND MAY BE WILLING TO PARTICIPATE IN THE STUDY PLEASE CONTACT: 
Dr Ami Nwosu 
Email: anwosu@liv.ac.uk 
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Appendix 4: Healthcare professionals’ factsheet 
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Appendix 5: Letter to General Practitioner 
 
Version 1; July 2012 
 
Patient details: 
 
Date: XX-XX-XX 
 
Dear Doctor, 
 
This letter is to inform you that the above patient is currently enrolled on the 
‘Hydration in palliative cancer patients: the evaluation of a novel assessment 
technique’ study. This study is taking place at the Marie Curie Palliative Care 
Institute Liverpool between August 2012 and July 2013. This study will not affect 
their day-to-day treatment and will not affect their medication therapy. Therefore, 
this patient’s management of should not be influenced or altered by their 
participation in this study. 
 
If you require any further information please do not hesitate to contact me. 
 
Yours sincerely, 
 
 
Dr Amara Nwosu 
Academic Research Fellow in Palliative Medicine 
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MARIE CURIE HOSPICE LIVERPOOL 
Generic information available for patients, relatives, staff introducing the research study and offering contact details for further information for those 
interested 
 
Yes 
APPENDIX 6: Consent process 
 
Screening questions 
Sign Consent form 
Patient agrees to enter study 
Assessment schedule 
No 
Yes 
Yes 
Yes 
Researcher makes initial approach to patient to introduce the study and will provide information sheets. The researcher will explain they will return 24 
hours later to further discuss the study. 
No further action unless 
patient becomes eligible 
at a later date 
Eligible for entry into study? 
Case note 
review 
No further action – 
unless requested by 
patient at a later date 
The researcher will arrange another meeting at a 
convenient date and time for the patient 
Patient becomes eligible 
for study entry 
Patient does not want to 
participate in study 
Patient needs more time/information before 
making decision 
Clinical team gain permission from patient to allow approach from the research team, in order to provide them with further study information 
Clinical team informs patient about the research project. Provides information sheet 1 (APPENDIX 5) if necessary. 
 New admissions to hospice? 
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Appendix 7: Participant information sheet - Part 1 
Title of Project:  Hydration in palliative cancer patients: the testing of a new assessment 
method 
 
Contact for further information: 
Dr Amara Nwosu 
Research co-ordinator 
 Marie Curie Palliative Care Institute Liverpool (MCPCIL) 
University of Liverpool, Cancer Research Centre 
200 London Rd 
Liverpool, L3 9TA  
Tel: 0151 794 8972 
Email: ami.nwosu@mariecurie.org.uk 
 
Introduction 
We would like to invite you to take part in our research study. Before you decide we would 
like you to understand why the research is being done and what it will involve for you. One 
of our team will go through the information sheet with you and answer any questions you 
have. Ask us if there is anything that is not clear. 
 
What is the purpose of the study? 
The aim of this study is to improve the understanding of how advanced cancer affects 
hydration. Hydration levels may be different in people with cancer, when compared, to 
people who do not have cancer; however, little is known about this. Sometimes people 
may receive fluids by ‘a drip’ for various reasons, including dehydration. Fluids can be given 
by a small needle, into a vein or alternatively, to the tissue beneath the skin. However, 
research is limited, and we currently know little about when fluids may be helpful or 
harmful.   
We plan to measure the hydration levels in people affected by cancer. We will do this by 
using a simple, safe, hand-held machine called a ‘body analyser’. The machine is quick and 
simple to use and is similar to technology currently used in gyms. The whole process will be 
similar to have an electrocardiogram (ECG) done. The hope is in the future, doctors will be 
able to make better decisions when deciding to start a fluid drip in people with cancer. 
 
 
 
 
 
 
 
177 
 
 
Why have I been invited? 
We are offering all people admitted to the hospice from October 2012 the opportunity to 
take part in our study. If you have cancer we are interested in learning more about how 
your body regulates your water content.  
 
Do I have to take part? 
It is up to you to decide to join the study. We will explain the study and go through this 
information sheet with you. If you agree to take part, we will then ask you to sign a consent 
form once you have had time to read the information. Your participation in the study will 
be confidential. The clinical care you receive in the hospice will not be affected by you 
decide to participate or not. 
 
What will happen to me if I take part? 
1. Interview – we will ask a few questions about your health and will review your medical 
records. 
2. Hydration symptom questionnaire – we will ask you to mark one point on a line to 
indicate the average intensity of seven symptoms over the past 24 hours. 
3. Clinical examination – a doctor will visually inspect your eyes your eyes and check your 
mouth and armpits for moisture. 
4. Hydration assessment – we will use the body analyser to measure your hydration. 
5. Blood and urine tests – To participate you will need to have had a blood test measuring 
your kidney function, taken in the past 3 days, as part of your clinical care. We may also ask 
you to provide a urine sample 
The whole process listed above should take 30 minutes. You will be invited to have the 
above repeated if you have any more blood tests done( as part of your clinical care) whilst 
you are in the hospice.  
 
What will I have to do? 
To take part in the study you should further discuss with Dr Amara Nwosu, the research 
coordinator. You will be provided with the additional information in part 2 of the 
information sheet for you to read. If you agree to participate you will be asked to sign a 
consent form. 
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Appendix 8: Participant information sheet – Part 2 
What will happen to me if I take part? 
1. Interview 
If you take part a member of the research team will initially ask you some questions 
about your medical history. This will include details of your age, current (and 
previous medical) conditions and any problems you may have experienced in the 
past week. We will look at your clinical records to note the medications you are 
taking. We will also record the amount of fluid your have either drank, or received 
through a drip or a feeding tube (if you have one). 
 
2. Hydration symptom questionnaire 
 If you agree to take part in the study we will ask you to complete a short written 
questionnaire. You will be asked to mark one point on the line to indicate the 
average intensity of seven symptoms over the past 24 hours. 
 
3. Clinical examination 
The researcher will complete a brief clinical examination to look at your eyes, 
mouth and armpits to assess the dryness of these areas. We will measure your 
height may record your weight. 
 
4. Hydration assessment  
We will use a machine called a body analyser to assess your water content. This is a 
small machine with three leads which will be placed on your skin. The leads will 
have a small sticky pad which will attach lightly to your skin, it will not hurt you. 
Leads will be placed on your right hand and right foot, once activated the machine 
will then collect the information. Similar technology is currently used in gyms. The 
whole process is similar to having an electrocardiogram (ECG) done. Information 
from the assessments will be analysed at the end of the study to learn about the 
hydration status of participants. It is not possible to give you results at the bedside. 
The testing process is completely safe and pain free. 
 
5. Blood and urine tests 
The results of blood and urine results you have had taken whilst in the hospice will 
also be recorded. In order to learn more about your water content, we may add 
additional tests to the blood sample you have already had taken. We may also ask 
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you to provide a urine sample if this has not been done during your stay in the 
hospice. 
The whole process listed above should take 30 minutes. You will be invited to have 
these steps repeated if you have any more blood tests taken by your doctor whilst 
you are in the hospice 
 
What are the possible disadvantages and risks of taking part? 
There are no known side effects associated with the analyser. However, body 
analyser may interfere with medically inserted electric devices such as pacemakers 
and implantable cardiac devices. If you have such devices you will not be able to 
participate in the study. 
 
What are the possible benefits of taking part? 
The study will not help you directly. However, in the future the outcomes of study 
may enable clinicians to make better treatment decisions managing hydration in 
people with advanced cancer.  
 
Expenses and payments 
There will be no expenses or payments available for participants in this study. 
 
What happens when the research study stops? 
The clinical care received by participants would not be affected by the completion 
of the research study. At the end of the study a summary of the main research 
outcomes will be available for interested participants. 
 
What will happen if I don’t want to carry on with the study? 
If you do not feel that you are able to continue in the study you are free to change 
your mind and you will receive no further assessments. You can withdraw your 
consent at any time without giving a reason and without your clinical care being 
affected in any way.  
 
Complaints and harm 
If you have a concern about any aspect of this study, you should speak to the 
researcher who will do their best to answer your questions 0151 794 8972. If you 
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remain unhappy, please contact the hospice manager, Diane Barker on 0151 801 
1400. In the event that something does go wrong and you feel you are harmed 
during the research you may have grounds for a legal action. Please contact the 
research sponsor, the University of Liverpool for further information. 
 
Will my taking part in this study be kept confidential? 
All information collected about you during the research will be kept confidential. 
Recorded information will be made anonymous and coded so you will be 
unidentifiable from the research documents. No personal information will be stored 
as part of the research study. All study information will be kept in a secure locked 
cabinet in the research offices of Marie Curie Palliative Care Institute Liverpool and 
will only be accessible to members of the research team. During the analysis phase, 
written information will be transferred to electronic records and will be encrypted 
to ensure confidentiality.  
 
Involvement of General Practitioner (GP) 
If you decide to participate in the study we will seek permission from you to notify 
your General Practitioner (GP). We will explain that your participation in this study 
will not alter your medical therapy and that no further treatment or monitoring is 
required on completion of the study.  
 
What will happen to the results of the research study? 
We hope to learn more about how water is regulated in people with advanced 
cancer and if this shows any association with their symptoms. We intend to publish 
the results in medical journals and present the findings to national and 
international research conferences in order to make sure that the message from 
this study are shared widely and appropriately. We will produce a summary of the 
research findings which will be circulated to interested participants. This study may 
lead to other research studies using a ‘fluid drip’ to see if this helps improve 
symptoms in advanced cancer. 
 
Who is organising and funding the research? 
The Marie Curie Palliative Care Institute Liverpool, University of Liverpool (MCPCIL) 
is responsible for organising the research. 
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Who has reviewed this study? 
This proposal has been reviewed and approved by the North Wales Research Ethics 
Committee - West, which is a committee whose task it is to make that research 
participants are protected from harm. You can find out more about the work of 
Research Ethics Committees by visiting the National Research Ethics Service website 
at http://www.nres.npsa.nhs.uk. 
 
If you would like any further information about this study please contact: 
 
Dr Amara Nwosu 
Research co-ordinator 
 Marie Curie Palliative Care Institute Liverpool (MCPCIL) 
Dept of Molecular & Clinical Cancer Medicine 
University of Liverpool 
Cancer Research Centre 
200 London Rd 
Liverpool, L3 9TA  
Tel: 0151 794 8972 
Email: ami.nwosu@mariecurie.org.uk 
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Appendix 9: Screening questions to determine eligibility for study 
entry 
 
1. Do you have cancer? 
Yes  No  
If NO ineligible for study  
 
2. (a) Are you still receiving treatment for this cancer or is further treatment or 
investigation planned (e.g. surgical, radiotherapy, chemotherapy, 
procedures)? 
Yes  No  
 
If YES proceed to question 2(b) 
If NO proceed to question 3 
 
(b) If you are receiving treatment or you are due to receive treatment in the 
future, is the intention of this treatment palliative? 
Yes  No  
If NO ineligible for study  
 
3. Do you have a pacemaker or an implantable cardiac device? 
Yes  No  
If YES ineligible for study  
 
NOTE: Participants will be asked the above questions and medical records will be 
screened in order to confirm eligibility for study participation. 
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Appendix 10: Consent form 
 
Centre: Marie Curie Hospice Liverpool 
Study Number: RD 025 
Patient Identification Number for this study: 
 
CONSENT FORM 
 
Title of project: Hydration in palliative cancer patients: the testing of a new assessment 
method  
Name of Researcher: Dr Amara Nwosu 
  Please 
tick box 
1 I confirm I have read and understand the information sheet date 19/08/13 
(version 1) for the above study. I have had opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
2 I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or 
legal rights being affected. 
 
3 I agree to take part in the above study.  
 
Name of patient     Signature   
 Date   
 
Name of witness     Signature   
 Date  
    
When completed: 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes. 
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APPENDIX 11: Assessment schedule 
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APPENDIX 12: Flowchart summary of research protocol  
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Appendix 13: Data collection sheet for study assessments 
Participant number: _________________________________ 
 
 BASELINE SUBSEQUENT ASSESSMENTS 
Date 
 
      
Serum urea 
(mmol/l) 
      
Serum 
creatinine 
(µmol/l) 
      
Serum 
sodium 
(mmol/l) 
      
Serum 
calcium 
(mmol/l) 
      
Serum 
albumin (g/l) 
      
Serum 
osmolarity 
(mosm/kg) 
      
Urine 
osmolarity 
(mosm/kg) 
      
Weight (kg)  
 
     
Height (m)  
 
     
Resistance (R 
- Ohm) 
 
 
 
     
Reactance 
(Xc) 
 
 
     
R/H Ohm/m  
 
     
Xc/H Ohm/m  
 
     
Phase angle 
(PA) 
 
 
     
Body Mass 
Index - BMI 
(kg/m2) 
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Appendix 14: Demographic details collection sheet 
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Appendix 15: The Anticholinergic Burden (ACB) scale 
 
(A total ACB scale score of three or more is considered clinically relevant) 
 
 
 
References:  
1. Boustani MA, Campbell NL, Munger S, Maidment I, Fox GC. Impact of anticholinergics on the aging brain: a 
review and practical application. Aging Health. 2008;4(3):311-20.  
2. Campbell N, Boustani M, Limbil T, Ott C, et al. The cognitive impact of anticholinergics: a clinical 
review. Clinical Interventions in Aging. 2009;4(1):225-33  
  
 ACB Score 1 (mild) ACB Score 2 (moderate) ACB Score 3 (severe) 
 Alimemazine Amantadine Amitriptyline 
 Alprazolam Belladonna alkaloids Amoxapine 
 Alverine Carbamazepine Atropine 
 Atenolol Cyclobenzaprine Benztropine 
 Beclometasone dipropionate Cyproheptadine Chlorpheniramine 
 Bupropion hydrochloride Loxapine Chlorpromazine 
 Captopril Meperidine Clemastine 
 Chlorthalidone Methotrimeprazine Clomipramine 
 Cimetidine hydrochloride Molindone Clozapine 
 Clorazepate Oxcarbazepine Darifenacin 
 Codeine Pethidine hydrochloride Desipramine 
 Colchicine Pimozide Dicyclomine 
 Dextropropoxyphene  Diphenhydramine 
 Diazepam  Doxepin 
 Digoxin  Flavoxate 
 Dipyridamole  Hydroxyzine 
 Disopyramide phosphate  Hyoscyamine 
 Fentanyl  Imipramine 
 Fluvoxamine  Meclizine 
 Furosemide  Nortriptyline 
 Haloperidol  Orphenadrine 
 Hydralazine  Oxybutynin 
 Hydrocortisone  Paroxetine 
 Isosorbide preparations  Perphenazine 
 Loperamide  Procyclidine 
 Metoprolol  Promazine 
 Morphine  Promethazine 
 Nifedipine  Propentheline 
 Prednisone/Prednisolone  Pyrilamine 
 Quinidine  Scopolamine 
 Ranitidine  Thioridazine (withdrawn) 
 Theophylline  Tolterodine 
 Timolol maleate  Trifluoperazine 
 Trazodone  Trihexyphenidyl 
 Triamterene  Trimipramine 
 Warfarin   
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Appendix 16: Symptoms of Dehydration Questionnaire – adapted 
from Burge 1991 
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Appendix 17: Clinical examination scoring system – adapted from 
Morita 2005 
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Appendix 18: Oral health assessment chart 
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Appendix 19: Bioelectrical Impedance Analysis (BIA) testing procedure 
Testing Procedure 
 The subject should not have exercised or taken a sauna within 8 hours of the study.  
 The subject should refrain from alcohol intake for 12 hours prior to the study.  
 The subject's height and weight should be accurately measured and recorded.  
 The subject should lie quietly during the entire test.  
 The subject should remove the right shoe and sock and lie supine with the arms 30 
degrees from the body and legs not touching.  
 The electrode sites may need to be cleaned with alcohol, particularly if the skin is 
dry or covered with lotion.  
 Attach the electrodes and patient cables as shown in the illustration.  
Diagram showing electrode placement require for the bioelectrical 
impedance analysis test 
 
 
Picture to show the appearance of bioelectrical impedance analysis in 
clinical practice 
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Appendix 22: Accepted conference abstracts 
Oral Presentations 
Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw J. Hydration in advanced 
cancer: the testing of a new assessment 
method 
Palliative Care Congress, Harrogate. 12-
14th March 2014. 
Background: Current hydration assessments methods are limited in cancer patients 
approaching death. Bioelectrical impedance analysis (BIA) is an accurate validated 
method of assessing body composition; however its clinical use in advanced cancer 
is uncertain. 
 
Aim: To measure hydration in advanced cancer patients using BIA, in order to 
determine the relationship between symptoms, biochemistry and performance 
status. 
 
Methods:  A cross-sectional prospective analysis of advanced cancer patients within 
a specialist palliative care unit in Liverpool, UK.  
 
BIA raw measurements, Resistance (R – Ohm), Reactance, (Xc – Ohm), total body 
water (TBW – through proxy measurement using height/resistance [Ht2/R]), Phase 
angle (PA) and BIA vector analysis (BIVA) were used to compare for differences in 
hydration based on WHO performance status (0= asymptomatic, 4=bedbound), 
symptoms, physical examination and biochemistry. 
 
Results: From a possible 97 patients, 78 (80%) provided consent to participate. 
Ht2/R was lower in patients with a WHO performance status of 4 compared to 
those with a performance status <4 (mean 42.1 [SD 9.0] vs. 52.3 [14.6], p=0.002), 
and greater in those with clinically detectable oedema (mean 57 [SD 17.4] vs. 47.7 
[12.4], p=0.027). Ht2/R correlated negatively with thirst [r= -0.31, p=0.006], dry 
mouth [r= -0.294, p=0.009] and fatigue [r= -0.285, p=0.011). BIVA showed 
significant difference in hydration between groups classified by the presence or 
absence of oedema (p=0.03) and dry mouth (p=0.04).There was no significant 
relationship between hydration (Ht2/R and BIVA) vs. biochemical tests or between 
symptoms vs. biochemistry or performance status. 
 
Conclusion:  In advanced cancer, hydration (as measured by Ht2/R and BIVA) relates 
to clinically measureable signs and symptoms. Further work is needed to determine 
whether BIA can be used to guide the management of fluid states in advanced 
cancer. 
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Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw J. Hydration status in 
advanced cancer patients: assessment 
of a novel evaluation technique 
Sue Ryder Care Centre for the Study of 
Supportive, Palliative and End of Life 
Care, University of Nottingham, 31st 
October 2012 
Background 
There is limited scientific understanding of (de)hydration in advanced cancer. 
Consequently, decisions surrounding the administration of clinically assisted 
hydration (CAH) to dying cancer patients are challenging. Bioelectrical impedance 
analysis (BIA) has shown promise in assessing (de)hydration in various patient 
groupings, but evidence for its use in advanced cancer is limited. 
 
Aim: To critically appraise existing methods of hydration status assessment and 
review the potential for BIA to assess (de)hydration in advanced cancer patients. 
 
Method: A systematic review of literature was conducted. Searches were carried 
out on four electronic databases; conference abstracts and gray literature were 
searched by hand. Studies reporting (de)hydration assessment (biochemical tests, 
physical examination, symptom assessment, and bioelectrical impedance) in 
advanced cancer patients were included. 
 
Results: Fifteen articles were identified. Clinical examination and biochemical tests 
are standard methods of assessing (de)hydration; however, limitations exist with 
these in advanced cancer. There is disagreement over the evidence for commonly 
associated dehydration symptoms in advanced cancer. BIA may have a role in 
evaluating (de)hydration; however, no studies of using this technology to assess 
hydration in advanced cancer have been conducted. 
 
Conclusions: The benefits and burdens of providing CAH in dying cancer patients 
are unclear. BIA shows promise as a hydration assessment tool but requires further 
study in advanced cancer. Innovative research methodologies using BIA, combined 
with regression analyses of biochemical and symptom indications, may potentially 
improve scientific knowledge of (de)hydration and patient care. 
 
Poster Presentations 
  
Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw J. The use of bioelectrical 
impedance vector analysis to assess 
hydration in patients with advanced 
cancer.  
European Association of Palliative Care 
8th International World Congress, Lleida, 
Spain, 5-7th June 2014. 
Background: Current hydration assessments methods are limited in cancer patients 
approaching death. Bioelectrical impedance analysis (BIA) is an accurate validated 
method of assessing body composition; however its clinical use in advanced cancer 
is uncertain. 
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Aim: This study aims to measure hydration in advanced cancer patients using BIA, in 
order to determine the relationship between symptoms, biochemistry, and 
performance status. 
 
Methods: A cross-sectional prospective analysis of advanced cancer patients within 
a specialist palliative care unit in Liverpool, UK. BIA measurements: Resistance (R – 
Ohm), Reactance, (Xc – Ohm), total body water (TBW – through proxy 
measurement using height/resistance [Ht2/R]), Phase angle (PA) and BIA vector 
analysis (BIVA) were used to compare for differences in hydration based on WHO 
performance status (0= asymptomatic, 4=bedbound), symptoms, physical 
examination and biochemistry. 
 
Results: From a possible 118 patients, 90 (76.3%) provided consent. Ht2/R was 
lower in patients with a WHO performance status of 4 compared to those with a 
performance status <4 (mean 43.0 [SD 9.0] vs. 53.6 [SD 15.9], p=0.001), and greater 
in those with clinically detectable oedema (mean 60.37 [SD 19.2] vs. 47.8 [11.8], 
p=0.004). Ht2/R correlated negatively with thirst [r= -0.29, p=0.006], dry mouth [r= -
0.336, p=0.001], nausea [r= -0.226, p=0.032], unpleasant taste [r= -0.282, p=0.007], 
fatigue [r= -0.315, p=0.002]. BIVA showed significant difference in hydration 
between groups classified by the presence or absence of oedema (p=0.0036), and 
dry mouth (p=0.01). There was no significant relationship between hydration (Ht2/R 
and BIVA) vs. biochemical tests or between symptoms vs. biochemistry or 
performance status. 
 
Conclusion: In advanced cancer, hydration status (as measured by Ht2/R and BIVA) 
relates to clinically measureable signs and symptoms. Further work is needed to 
determine whether BIA can be used to guide the management of fluid states in 
advanced cancer. 
 
Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw J. Assessment of hydration 
states in advanced cancer using 
bioelectrical impedance analysis: 
preliminary analysis of a prospective 
observational study.  
National Cancer Research Institute 
(NCRI) Conference, Liverpool. 4-6th 
November 2013. 
Background: There is limited understanding of hydration states in advanced cancer, 
and little evidence to inform management. Consequently, inappropriate 
management may cause patient harm and carer distress. Current hydration 
assessments methods are limited in cancer, partly due to patho-physiological 
differences compared to non-cancer. Bioelectrical impedance analysis (BIA) is a 
novel, accurate method of assessing body composition; however its use in 
advanced cancer is uncertain. 
 
Methods: This study will determine the feasibility of BIA in the assessment of 
cellular hydration in advanced cancer, in order, to explore relationships between 
physical symptoms; biochemical and physiological parameters of hydration. This 
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will involve a longitudinal observational analysis of hospice in-patients with 
advanced cancer.  
 
Results: Since December 2012, of the 74 eligible patients, 71 (95.9%) agreed to 
discuss the study with the researcher, with 58 (78.3%) providing consent for study 
participation. ten (13.5%) patients agreed to take part initially, but were too ill at 
time of assessment; two patients (2.7%) were discharged before an assessment 
could take place. Four patients (5.4%) declined participation in the study.  
 
The results demonstrate significant correlations between Resistance and creatinine 
[ r=0.272, n=58, p=0.039]; Resistance and eGFR [rho= -0.289, n=58, p<0.028]; 
Reactance and creatinine [r=0.267, n=58, p=0.043]. Intracellular water was found to 
be linked with thirst [rho= -0.470, n=20, p=0.037] and mucous membrane moisture 
[rho= -0.488, n=20, p=0.029]. Biochemical dehydration was associated with 
significantly worse survival compared to non-dehydrated patients. 
 
Conclusions: BIA may be useful in exploring associations between physiological 
measurements of hydration and symptoms. Vector transformation of BIA data 
(BIVA) will be undertaken to compare this data with other populations. 
Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw. Hydration status in 
advanced cancer patients: assessment of 
a novel evaluation technique.  
Liverpool Cancer Research UK Centre 
Annual General Meeting, University of 
Liverpool. 21st May 2013. 
Background: There is limited understanding of hydration states in advanced cancer, 
and little evidence to inform management. Consequently, inappropriate 
management may cause patient harm and carer distress. Current hydration 
assessments methods are limited in cancer, partly due to patho-physiological 
differences compared to non-cancer. Bioelectrical impedance vector analysis (BIVA) 
is a novel, accurate method of assessing body composition. 
 
Aim: To determine the feasibility of BIVA, as a method, of assessing cellular 
hydration in advanced cancer. 
 
Methods: Longitudinal observational cohort analysis of advanced cancer hospice 
patients. Hydration status evaluated through: biochemical measures, BIVA, physical 
examination and self-reported symptoms.  
 
Results: Preliminary analysis of 29 patients demonstrates significant correlations 
between intracellular water and various symptoms clusters. 
 
Conclusions: BIVA may be useful in exploring associations between physiological 
measurements of hydration and symptoms. Future analyses will explore 
associations between bio-impedance assessments and survival. 
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Nwosu AC, Mayland C, Mason S, Varro 
A, Ellershaw J. Hydration status in 
advanced cancer patients: assessment of 
a novel evaluation technique. 
National Cancer Research Institute, 
Liverpool. 4-7th November 2012 
Background: There is limited scientific understanding of (de)hydration in advanced 
cancer. Consequently, decisions surrounding the administration of clinically assisted 
hydration (CAH) to dying cancer patients are challenging. Bioelectrical impedance 
analysis (BIA) has shown promise in assessing (de)hydration in various patient 
groupings, but evidence for its use in advanced cancer is limited. 
 
Aim: To critically appraise existing methods of hydration status assessment and 
review the potential for BIA to assess (de)hydration in advanced cancer patients. 
 
Methods: Systematically structured review of literature. Searches were carried out 
on four electronic databases. Studies reporting (de)hydration assessment 
(biochemical tests, physical examination, symptom assessment, bio-electrical 
impedance) in advanced cancer patients were included. 
 
Results: Eleven articles were identified. Clinical examination and biochemical tests 
are standard methods of assessing (de)hydration; however, limitations exist with 
these in advanced cancer. There is disagreement over the evidence for commonly 
associated dehydration symptoms in advanced cancer. BIA may have a role in 
evaluating (de)hydration; however, no studies of using this technology to assess 
hydration in advanced cancer have been conducted. 
Conclusions: The benefits and burdens of providing CAH in dying cancer patients 
are unclear. BIA shows promise as a hydration assessment tool but requires further 
study in advanced cancer. Innovative research methodologies using BIA, combined 
with regression analyses of biochemical and symptom indications, may potentially 
improve scientific knowledge of (de)hydration and patient care. 
Nwosu AC, Mayland C, Williams E, 
Mason S, Ellershaw J. Hydration status in 
advanced cancer patients: assessment of 
a novel evaluation technique.  
Liverpool Cancer Research UK Centre 
Annual General Meeting, University of 
Liverpool. May 2012. 
Background: There is limited scientific understanding of (de)hydration in advanced 
cancer. Consequently, decisions surrounding the administration of clinically assisted 
hydration (CAH) to dying cancer patients are challenging. Bioelectrical impedance 
analysis (BIA) has shown promise in assessing (de)hydration. 
 
 Aim: To critically appraise existing methods of hydration status assessment and 
review the potential for BIA to assess (de)hydration in advanced cancer patients. 
 
Methods: Systematic review of literature. 
  
Results: Eleven articles were identified. Clinical examination and biochemical tests 
are standard methods of assessing (de)hydration; however, limitations exist with 
these in advanced cancer. There is disagreement over the evidence for commonly 
associated dehydration symptoms in cancer. Bioelectrical impedance vector 
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analysis (BIVA) may have a role in evaluating (de)hydration but evidence for its use 
in cancer is limited. 
 
Conclusions: BIVA but requires further study in advanced cancer. Innovative 
research methodologies using BIVA may potentially improve scientific knowledge of 
(de)hydration in cancer patients. 
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Appendix 23: Publications 
 
Nwosu AC, Mayland CR, Mason S, Khodabukus AF, Varro A, Ellershaw JE. Hydration 
in advanced cancer: can bioelectrical impedance analysis improve the evidence 
base? A systematic review of literature. Journal of Pain and Symptom 
Management 2013; Sep;46(3):433-446.e6. 
 
Nwosu AC, Mayland CR, Mason SR, Varro A, Ellershaw JE. Patients want to be 
involved in end-of-life care research. BMJ Support Palliat Care 2013, 
doi:10.1136/bmjspcare-2013-000537. 
 
 
 
 
 
Patients want to be
involved in end-of-life care
research
Advances in multimodal cancer-
directed treatment have improved
survival for metastatic cancer
patients. In the Western world the
combination of various demo-
graphic, health-related and socio-
logical factors will contribute to
increased comorbidities and mortal-
ity over the next decade. A careful,
evidence-based approach is neces-
sary to address the inevitable chal-
lenges, which will be posed by an
increasingly aged population that
will require supportive care towards
the end of their lives.1 Further
investment in palliative care
research is required to generate the
evidence which will improve the
care delivered to patients approach-
ing death.2 Currently, funding for
end-of-life and palliative care
research is inadequate. Data on UK
research funding by National
Cancer Research Institute partners
in 2010 show that just 0.24% was
allocated to palliative and
end-of-life care research. Similarly,
in 2010 the US National Cancer
Institute only awarded 1% its
funding to palliative care research.2
Research involving patients who
are approaching death is methodo-
logically and ethically challenging.
This group of patients often have a
significant symptomatic burden,
including pain, fatigue and psycho-
logical distress. Researchers may
struggle to engage and recruit partici-
pants due to concerns about the
ability of patients to comply with
assessments and provide consent.
Consequently, low levels of recruit-
ment, small sample sizes and high
attrition rates often have a deleteri-
ous impact on the methodological
quality of research.3 However, there
is developing evidence which
demonstrates that patients are keen
to be involved in palliative care
research.4
In light of these issues, we
report the preliminary results of a
pilot study using bioelectrical
impedance analysis to assess hydra-
tion states in advanced cancer
inpatients based within a specialist
palliative care unit within
Liverpool, UK. Participating
patients are assessed using bioelec-
trical impedance analysis, undergo
a clinical examination and com-
plete a self-reported symptom
questionnaire. Since December
2012, of the 80 eligible patients,
78 (97.5%) agreed to discuss the
study with the researcher, with 61
(76.3%) providing consent for
study participation. Eleven
(13.7%) patients agreed to take
part initially but were too ill at
time of assessment. Two (2.5%)
were discharged prior to study
assessments; so far, only six
patients (7.5%) have declined to
participate in the study. As in other
published research, all enrolled
patients stated a desire to help
others as a motivating factor for
participating in the research
study.4
In line with the published litera-
ture, our experience within this
study suggests that palliative care
patients are keen to be involved in
research and that their experience
is positive.5 Our data suggest that a
good level of recruitment to studies
involving palliative patients is pos-
sible. This is noteworthy, as
patients in specialist palliative care
units are more likely to have more
advanced disease and symptom
burden compared to those within
general medical and oncology
units. Researchers, funders and
policy makers should be encour-
aged, as patient participation in
research will help to identify and
address patient-centred priorities at
the end of life.
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Hydration in Advanced Cancer:
Can Bioelectrical Impedance Analysis
Improve the Evidence Base? A Systematic
Review of the Literature
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Abstract
Context. Decisions surrounding the administration of clinically assisted
hydration to patients dying of cancer can be challenging because of the limited
understanding of hydration in advanced cancer and a lack of evidence to guide
health care professionals. Bioelectrical impedance analysis (BIA) has been used to
assess hydration in various patient groupings, but evidence for its use in advanced
cancer is limited.
Objectives. To critically appraise existing methods of hydration status
assessment in advanced cancer and review the potential for BIA to assess
hydration in advanced cancer.
Methods. Searches were carried out in four electronic databases. A hand search
of selected peer-reviewed journals and conference abstracts also was conducted.
Studies reporting (de)hydration assessment (physical examination, biochemical
measures, symptom assessment, and BIA) in patients with advanced cancer were
included.
Results. The results highlight how clinical examination and biochemical tests
are standard methods of assessing hydration, but limitations exist with these
methods in advanced cancer. Furthermore, there is disagreement over the
evidence for some commonly associated symptoms with dehydration in cancer.
Although there are limitations with using BIA alone to assess hydration in
advanced cancer, analysis of BIA raw measurements through the method of
bioelectrical impedance vector analysis may have a role in this population.
Conclusion. The benefits and burdens of providing clinically assisted hydration
to patients dying of cancer are unclear. Bioelectrical impedance vector analysis
shows promise as a hydration assessment tool but requires further study in
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advanced cancer. Innovative methodologies for research are required to add to
the evidence base and ultimately improve the care for the dying. J Pain Symptom
Manage 2013;46:433e446.  2013 U.S. Cancer Pain Relief Committee. Published by
Elsevier Inc. All rights reserved.
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Introduction
The role of hydration in causing or alleviat-
ing suffering in patients with advanced cancer
is poorly understood and remains controver-
sial.1 Most patients dying of cancer have re-
duced oral intake in their last days of life.2
This may be related to either cancer or its
treatment, and reasons include dysphagia,
anorexia, nausea or vomiting, or mechanical
problems such as bowel obstruction.3,4 Accord-
ingly, the subject of clinically assisted hydra-
tion (CAH) is emotive among patients and
their carers,3,5e7 with the omission or with-
drawal of CAH potentially viewed as hastening
death in some instances.3 Decisions surround-
ing the administration of CAH to patients at
the end of life can be challenging, with many
health care professionals, patients, and carers
presenting differing opinions on appropriate
management.3,8e11 The General Medical
Council of the U.K. has released guidance con-
cerning the administration of CAH at the end
of life for patients who are expected to die
within hours or days, and those who are not
expected to die within this time frame. Clini-
cians are required to assess hydration status
in both circumstances.12 However, decisions
about appropriate management are often diffi-
cult because of a limited understanding of hy-
dration mechanisms in advanced cancer and
a lack of evidence to guide health care
professionals.1,8
Dehydration
Physiologically, dehydration has been de-
fined as deficit of total body water (TBW)
that is predominantly intracellular.13 This pro-
cess is associated with hypernatremia, an ele-
vated serum osmolarity, which in turn
stimulates the sensation of thirst from the
thirst center.14 Patients with advanced cancer
may not fit this pattern because of differences
in their fluid requirements and disease patho-
physiology, when compared with noncancer
populations.15,16 In cancer, intracellular dehy-
dration is associated with proteolysis and ca-
chexia17,18 and leads to an increase in
antidiuretic hormone (ADH) level through
stimulation of osmoreceptors or from direct
release from the tumor.19,20 Furthermore,
weight loss, decreased renal perfusion, and ca-
chexia are associated with a loss of intracellular
water and solutes affecting hypothalamic os-
moreceptors, which in turn stimulates ADH re-
lease.21 ADH increases the water permeability
of the distal tubule and collecting duct in the
kidney, promoting water absorption and the
maintenance of serum osmolarity and sodium
at subnormal levels.14 Consequently, an abnor-
mally low osmolarity may cause symptoms such
as nausea and confusion, which have been as-
sociated with dehydration.16
Most patients with cancer suffer from hypo-
natremia rather thanhypernatremia.14,15Hypo-
natremia results from sodium loss in excess of
free water, resulting in a low sodium and serum
osmolarity.14 Furthermore, certainmedications
such as selective serotonin reuptake inhibitors
and nonsteroidal anti-inflammatory drugs also
are associated with hyponatremia and are fre-
quently given to patients with cancer for symp-
tom management.22,23
Clinical studies suggest that patients dying
of cancer may achieve adequate hydration
with much lower volumes of water than those
recommended for the average medical or sur-
gical patient.16 This may result from differ-
ences in body composition, such as decreased
body weight because of cachexia and de-
creased clearance of free water caused by a vari-
ety of mechanisms. For example, patients with
advanced cancer may have reduced insensible
water losses resulting from a reduction in their
434 Vol. 46 No. 3 September 2013Nwosu et al.
physical activity. Typically, hydration studies
are based on noncancer populations and sub-
sequent research findings may not extrapolate
to patients with cancer.24 Consequently, prof-
fered definitions of dehydration in patients
with cancer vary throughout the literature,
with authors using different combinations of
clinical parameters as diagnostic criteria.13,14,25
The lack of uniformity in definitions compli-
cates study comparisons24 and makes decisions
regarding the use of CAH difficult for clini-
cians. There is a need for further study in
this area to address the limited research base.
Novel methods of hydration assessment,
such as bioelectrical impedance analysis
(BIA), have been used in some areas (e.g., in
the assessment of the fluid states of edematous
patients with renal failure receiving dialysis),26
but evidence for its use in advanced cancer is
limited. BIA is a safe, noninvasive, bedside
method of assessing hydration.27
Aims
The aims of this review are:
1. To critically appraise the existing methods
of assessing hydration status in patients
with advanced cancer, namely physical ex-
amination and biochemical measures;
2. To identify dehydration-related symptoms
in patients with advanced cancer; and
3. To review the use of BIA in the assessment
of hydration and to discuss its potential
use in patients with advanced cancer.
Methods
A search strategy was developed for finding
relevant publications in electronic literature
databases. In January 2012, four electronic da-
tabases were searched (MEDLINE, Cochrane
Database of Systematic Reviews, Cochrane
Central Register of Controlled Trials, and Sco-
pus) using combinations of the key words: pal-
liative care, terminally ill, hospice, terminal
care, dehydration, water-fluid balance, fluid
balance, bioelectrical impedance, cancer, tu-
mor, carcinoma, and malignancy. The search
was limited to English language literature pub-
lished between 1960 and 2012. The search
strategy for MEDLINE is shown in Table 1
and was adapted for the other databases.
Bibliographies of relevant articles were man-
ually searched to identify more articles for po-
tential inclusion. Additionally, a hand search
of the most recent issues (January 2010 to
July 2012) of 12 relevant peer-reviewed jour-
nals was conducted: Journal of Pain and Symptom
Management, Journal of Palliative Care, Palliative
Medicine, Journal of Palliative Medicine, New En-
gland Journal of Medicine, Lancet Oncology, British
Medical Journal (BMJ), BMJ Supportive and Palli-
ative Care, The Journal of the American Medical As-
sociation, Annals of Internal Medicine, Nutrition,
and American Journal of Clinical Nutrition. The
gray literature was searched; this literature
comprised abstracts from the American Academy
of Hospice and Palliative Medicine conferences
(2010e2012), the European Association of Pallia-
tive Care conferences (2010e2012), the Pallia-
tive Care Congress (2012), the International
Congress of Palliative Care (2010), and the Marie
Curie Research Conferences (2011e2012). To ob-
tain further information about the gray litera-
ture abstracts that were selected for inclusion
in this study, the authors of these studies
were contacted (by e-mail) and asked to pro-
vide more information about the research.
Further details of studies included in this re-
view are presented in Table 2 (available on
jpsmjournal.com).
Selection Criteria
One reviewer (A. C.N.) used a stepwise proce-
dure to identify relevant studies. Studies ad-
dressing (de)hydration assessment (physical
examination, biochemical measures, symptom
assessment, and BIA) in patients with advanced
cancer were eligible for inclusion in the review.
Table 1
Search Strategy Applied in MEDLINE
Query
Number Query Content
#1 (((palliative care) OR hospice) OR terminally
ill) OR terminal care
#2 ((((cancer) OR neoplasms) OR tumor) OR
carcinoma) OR malignancy
#3 dehydration
#4 (water-electrolyte balance) OR fluid balance
#5 bioelectrical impedance
#6 #1 AND #2
#7 #3 OR #4
#8 #5 AND #6
#9 #6 AND #7
#10 #8 OR #9
#11 Limit #10 to Humans and English language
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For the purposes of this study, advanced cancer
was defined as a diagnosis of cancer where no
further curative treatment is possible, which
may be associated with metastases (histological
or radiological). Articles were excluded if the
studies were not in English or if they primarily
reported on pediatric populations.
Data Extraction
Data were extracted using a standard form to
record the following themes: purpose of study,
study design, participants, exclusions, sample
size and statistics, dehydration definition(s),
outcomemeasure, and studymethods. The first
author extracted the data from studies and
discussed the results with A. F. K., S. R. M., and
C. R.M. Reviewers were not blinded for authors,
institutions, or journals of publication.
Quality Assessment
Because the review included studies with
both quantitative and qualitative elements,
a multimethods assessment tool, devised by
Hawker et al.,28 was used to evaluate the study
quality. This assessment tool comprises nine
areas; each area was rated on a four-point scale
from one (very poor) to four (good). The areas
covered were abstract and title, introduction
and aims, methods and data, sampling, data
analysis, ethics and bias, results, transferability
or generalizability, and implications and useful-
ness. Consequently, each article was given a total
score (maximum of 36¼ good and a minimum
of 9¼ very poor) based on the methodological
rigor. The methodological quality was assessed
independently by A. C. N. and A. F. K. Both au-
thors agreed on the quality assessment of all
studies. Data were stored and analyzed using
Statistical Software Package for the Social Sci-
ences (SPSS version 20.0; IBM SPSS Inc., Chica-
go, IL). The methodological quality score is
ordinal in nature; consequently, Spearman’s
rank correlation coefficient was chosen to mea-
sure pairwise correlations of scores between
assessors.
Results
Results of the literature search are summa-
rized in Fig. 1. The initial literature search us-
ing the keywords outlined in the Methods
section returned 334 articles. A total of 316
of these articles were rejected after the review
of the abstract as not relevant. The remaining
18 articles were examined by our inclusion and
exclusion criteria. Three articles were ex-
cluded as they primarily reported noncancer
populations, resulting in the inclusion of 15
studies in the review. The methodological
quality of the selected studies ranged between
22 and 36. Spearman’s rank correlation coeffi-
cient demonstrated a statistically significant
level of agreement between assessors (rs¼
0.846, P< 0.0001). Commonly, sample size
calculations were not conducted and some
studies lacked descriptive information about
the context, setting, and characteristics of
the included (and excluded) patients. Conse-
quently, several studies received lower scores
regarding their potential transferability and
generalizability. However, no study made any
claim that its data could be generalized beyond
the particular population of interest.
Physical Examination
The clinical assessment of hydration,
through the process of physical examination,
is a measure of the extracellular fluid compart-
ment (i.e., extracellular water content, skin tur-
gor, jugular venous pressure, and pulse).15
However, as dehydration prominently describes
an intracellular process, clinical assessment is
unable to diagnose intracellular dehydration.14
There are no routine bedside technologies that
measure fluid in the intracellular space.29
Aware of this problem, authors have attempted
to address the issue by creating a distinction be-
tween dehydration defined physiologically
from that derived from subjective clinical as-
sessment.30,31 In these instances, the term clini-
cal dehydration is generally used to encompass all
types of deficit fluid as they appear in the clini-
cal setting.24 This highlights the possible con-
flict between the clinical experience of
dehydration compared with the biochemical
and physiological definitions of dehydration
commonly found in the literature.32
Some authors have attempted to clarify
which signs are clinically relevant in the assess-
ment of dehydration in elderly and cancer
populations. Noncancer studies have found
certain variables to correlate with dehydration
in elderly populations; these include tongue
dryness, longitudinal tongue furrows, dry mu-
cousmembranes, upper bodymuscle weakness,
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confusion, speech difficulty, sunken eyes,33 dry
axilla,34 a fall in systolic blood pressure, re-
duced laxity of sternal skin turgor, and low
body mass index.24
Based on the outcomes of these studies,
Morita et al.35 subsequently developed a dehy-
dration score consisting of three variables (dry-
ness of oral mucous membranes, axillary
moisture, and sunkenness of eyes). This score
was used to assess dehydration, in addition to
assessments of delirium and peripheral edema,
in a study of CAH volume and its association
with symptoms in terminally ill cancer patients
with abdominal malignancies.35 Dehydration
scores were significantly lower in the patients
receiving CAH in the last three weeks of life
compared with the non-CAH group; however,
use of CAH was associated with increases in pe-
ripheral edema. No significant difference in
hyperactive delirium, communication capacity,
bronchial secretions, agitation, myoclonus, or
serum biochemistry was evident between the
two groups. A similar study by the same au-
thors examined the relationship between
laboratory findings, artificial fluids, fluid bal-
ance, and clinical measures of dehydration in
terminally ill patients with abdominal cancer.36
The authors found no statistically significant
difference in the fluid balance in patients
with an increased clinical dehydration score
compared with those without.36 Myoclonus
and sedation have been associated with dehy-
dration in a study by Bruera et al.,37 who dem-
onstrated improvements in these variables
during a randomized, controlled, double-
blind trial involving dehydrated patients with
cancer receiving CAH. However, these findings
have not been replicated in other studies.35
There is conflict over the accuracy of physi-
cal findings in assessing hydration in advanced
cancer. Skin turgor has been shown to poorly
correlate with dehydration as patients with
cancer are prone to changes in subcutaneous
tissue, which may create inaccuracy in its
interpretation14,33 Postural hypotension is
identified as a feature of hypovolemia (low
blood volume), but lacks sensitivity as a test
for dehydration.38e40 This highlights how
Fig. 1. Overall selection process for clinical studies included in the review.
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different definitions of dehydration may create
difficulty in interpreting study outcomes. Fur-
thermore, postural hypotension may not be
suitable in assessing some patients with ad-
vanced cancer at risk for poor mobility, falls,
and taking medications known to cause hypo-
tension, for example opioids and diuretics.41,42
Variations in body mass caused by cachexia
and edema may make body mass index mea-
surements unsuitable.14,15,43,44 Although part
of a standard medical examination, capillary
refill is only able to detect hypovolemia in chil-
dren and lacks sensitivity in adults.38,45e47
Biochemical Measures
Biochemical tests include the analysis of
blood (obtained from venipuncture) and
urine samples. A change in urine and blood
chemistry provides clues to the underlying
cause of hydration disturbances and helps
the clinician identify potential treatments.
Measures such as serum urea:creatinine ratio
and urine:plasma osmolality ratio have be
used to assess hydration status, with ratios of
$100 (mmol/mmol) and $1.2, respectively,
suggesting dehydration.13,14,24,48,49 Biochemi-
cal dehydration occurs when intracellular wa-
ter is lost, leading to transmembrane water
migration from the intravascular compartment
under osmotic pressure and increased relative
plasma sodium concentration.14,50,51 Electro-
lyte abnormalities, such as hyperkalemia, may
suggest underlying causative factors of dehy-
dration and may be useful prognostic indica-
tors.52 Atrial natriuretic peptide (ANP) level
lower than 15 pg/mL has been used to define
dehydration in palliative care patients;53 how-
ever, the validity and reliability of this measure
has not yet been determined. Observational
studies have found that biochemical measures
of dehydration poorly correlate with symp-
toms, such as thirst and dry mouth.54
Biochemical investigations are performed
for various reasons, including clinical monitor-
ing, in advance of medical procedures, and as-
sessment in response to change in the clinical
condition of a patient. In these circumstances,
abnormal renal function may prompt the clini-
cian to consider the initiation of CAH; how-
ever, studies have shown that patients with
advanced cancer may be prone to renal impair-
ment at the end of life. The prevalence of pre-
renal failure in cancer inpatients was 44%
(n¼ 27/62) in a study by Guo et al.;55 no dif-
ference in length of stay was evident between
patients with renal failure compared with
those with normal renal function. Biochemical
measures alone may not be able to detect clin-
ically meaningful hydration changes in pa-
tients with cancer, especially if measurements
are performed without a record of the pa-
tient’s baseline renal function for comparison.
Authors have demonstrated a worsening in re-
nal function in patients with cancer approach-
ing death, irrespective of whether CAH is
administered or not.35,36,56 Therefore, in ad-
vanced cancer, static abnormal renal function
measurements may provide incomplete assess-
ments of hydration status.31 A prospective
study by Waller et al.56 examining hydration in-
dicators in patients found 87% (n¼ 59/68) of
dying patients to be biochemically dehydrated.
No difference in serum biochemistry or con-
sciousness was found between patients receiv-
ing intravenous fluids compared with those
who received no fluids. The authors conclude
that there is no clinical benefit to the adminis-
tration of intravenous fluids in terminally ill
patients with cancer.
Symptoms of Dehydration
Previous research has attempted to deter-
mine if symptom burden is related to dehydra-
tion and, consequently, whether the use of
CAH improves these symptoms. The first quan-
titative estimate of dehydration symptoms in
advanced cancer was conducted by Burge57
in 1993. This study was a cross-sectional analy-
sis of the symptoms of dehydration in 52 palli-
ative care patients with cancer. A series of
100 mm visual analogue scale scores were
used to evaluate the severity of seven symptoms
(thirst, dry mouth, bad taste, nausea, pleasure
in drinking, fatigue, and pain) experienced by
patients. Fatigue was the most severe symptom
(65% rated greater than 50 mm); dry mouth
and thirst also were very prevalent (53.8%
and 60% rated greater than 50 mm, respec-
tively). There was no association between
symptom severity and fluid intake, or between
biochemical measures and thirst, a finding
consistent with other studies.33 However, Cer-
chietti et al.2 demonstrated improvements in
thirst and chronic nausea in symptomatic palli-
ative care cancer patients with limited oral in-
take, randomized to receive either CAH or
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standard medical therapy. Significant improve-
ments in relief of thirst and chronic nausea
were present in both groups at 24 hours; how-
ever, this effect was only maintained in the hy-
dration group at 48 hours. There is little
evidence to support the role of CAH in the
management of delirium in advanced can-
cer.58,59 A statistical analysis of hospital inpa-
tient data of 1125 patients with advanced
cancer failed to demonstrate a relationship be-
tween hydration and delirium;60 this is a similar
finding in other studies.2,35,61 However, hyper-
active delirium was found to be more prevalent
in patients with advanced abdominal cancers
receiving small volumes of CAH (<1 L/d)
compared with patients receiving larger vol-
umes (>1 L/d).61
Studies assessing oral symptoms and dehy-
dration have found mixed results. Dry mouth
and thirst were highly prevalent in a study of
82 patients with cancer receiving palliative
care at risk for dehydration.54 Of the 23
(28%) patients able to respond to the ques-
tions, 20 (87%) reported dry mouth and 19
(83%) complained of thirst. No association be-
tween thirst, dry mouth, respiratory tract secre-
tions, and biochemical dehydration was found.
Similarly, in a cohort of 88 palliative care pa-
tients, Morita et al.53 found thirst to be highly
prevalent, but poorly associated with dehydra-
tion. Interestingly, the authors found that
thirst was associated with water depletion (de-
fined by ANP). However, a lack of validity
and reliability of ANP and the arbitrary cutoff
level defined by the authors may indicate
that this area requires further study before de-
finitive conclusions are drawn. The effect of
CAH on sensation of thirst in 30 terminal can-
cer patients was evaluated by Musgrave et al.62
Nineteen patients were able to communicate
thirst intensity, but no association between
level of thirst, intravenous fluids, and biochem-
ical parameters was demonstrated. Nakajima63
explored the influence of hydration on symp-
toms in a series of 75 patients with advanced
abdominal cancer. The study found that CAH
improved oral membranous signs of dehydra-
tion but worsened peripheral edema, ascites,
and chest secretions. Yamaguchi et al.61 found
no significant difference in symptom burden
between patients receiving high volumes
(>1 L/24 h) and low volumes (<1 L/24 h)
of fluid in a multicenter, prospective,
observational study of 161 patients with ad-
vanced cancer receiving CAH.
Bioelectrical Impedance Analysis
BIA is based on the flow of electrical current
through the body, measured through the ap-
plication of superficial skin electrodes.64 BIA
is not a direct method of monitoring body
composition and TBW requires prediction
equations for analysis.27 Prediction equations
have been developed using linear regression
and adherence to some basic assumptions, in-
cluding the shape of the body, the relationship
between trunk and leg lengths, and the level of
hydration (as lean body mass hydration is con-
sidered 73%) and fat fraction.27 No universal
equation exists to accommodate different pop-
ulations; therefore, specific validated equa-
tions need to be selected depending on age,
ethnic group, and the clinical situation being
studied.27 However, cancer (and other wasting
diseases) reduces intracellular water through
cachexia, such that the TBW derived from
equations for normal populations will become
less accurate.15
The limitations of BIA have been addressed
by Piccoli65 by using an alternative method of
interpreting the BIA information. Use of raw
BIA measures can provide direct measure-
ments of tissue cell hydration and integrity.
These approaches are independent of regres-
sion equations or weight, and can be carried
out even in situations where BIA assump-
tions are not met (e.g., in advanced cancer).
These raw measurements comprise resistance
(Rdthe restriction to the flow of electrical cur-
rent through the body, primarily related to the
amount of water present in tissue) and reac-
tance (Xcdresistive effect produced by the
tissue interfaces and cell membranes) mea-
surements (Fig. 2). Two indicators of clinical
significance can be derived from the raw mea-
surement; one is phase angle and the other is
a plot of the impedance vector against a known
distribution (bioelectrical impedance vector
analysiseBIVA).27,66,67
Phase Angle. Phase angle is a derived measure
obtained for the relation between the direct
measures of resistance and reactance and can
be calculated from raw BIA measurements
(Fig. 2).68 Part of the measured electrical cur-
rent is stored by the cell membranes, which act
Vol. 46 No. 3 September 2013 439Hydration in Advanced Cancer
as capacitors, creating a phase shift, quantified
geometrically as phase angle.27 Phase angle
has been used as a prognostic marker in various
patient groups, including human immunodefi-
ciency virus,69,70 dialysis patients,71e73 breast
cancer,74 lung cancer,75 colorectal cancer,76
and pancreatic cancer.77 Recently, studies have
used the technology to evaluate hydration in ad-
vanced cancer; for example, Davis et al.15 per-
formed a prospective observational study
using BIA in patients with advanced cancer re-
ceiving CAH. BIA was done for three consecu-
tive days from initiation of CAH. The authors
found that a greater phase angle on Day 1 of
CAH predicted better survival; however, a rise
in phase angle (indicating increased reactance
and the distribution of fluid to the intracellular
compartment) during CAH predicted shorter
survival. The authors propose that an increase
in phase angle during CAH reflects pre-
existing intracellular dehydration, whichoccurs
in patients who aremore likely to have cachexia-
anorexia syndrome, andhence, a worse progno-
sis compared with those without a phase angle
rise during CAH. This may suggest that phase
angle may be able to assist in prognostication
andmay highlight underlying physiological dif-
ferences among patients with cancer receiving
CAH. Crawford et al.78 used BIA to show that el-
evatedmetabolic rate andaccumulationof body
fluids were indicators of poor prognosis in a se-
ries of palliative care patients with cancer. Al-
though interesting, these studies focus on
survival and do not explore issues regarding hy-
dration assessment or the appropriateness of us-
ing CAH in these patients.
Bioelectrical Impedance Vector Analysis. BIVA, in
a fashion similar to the electrocardiogram,
uses graphical vectors to provide a visual
analysis of BIA data.67 Using this method, im-
pedance (Z) is plotted as a vector from its com-
ponents R (x-axis) and Xc (y-axis), after being
standardized by height (H) (Fig. 3). Confi-
dence interval of the mean vector can be plot-
ted to allow statistical analysis and comparison
in (and between) population groups (Fig. 4).
The advantage of this method is that it allows
information to be obtained simultaneously
about changes in tissue hydration or soft tissue
mass, independent of regression equations, or
body weight. Therefore, BIVA readings can be
interpreted accurately even if patients are at
extremes of weight or volume distribution.
BIVA measurements can be compared with ref-
erence populations to enable comparisons
with healthy populations and other diseases.
Changes in the shape and direction of plotted
vectors (vector migration) on repeated mea-
surements in the same individual allow change
in hydration status over time to be recorded.27
BIVA has previously been used to monitor hy-
dration change in edematous patients receiv-
ing hemodialysis and may provide a way to
monitor change in hydration over time in pa-
tients with advanced cancer (e.g., during the
dying phase). Although BIVA has been used
to study hydration in different diseases (e.g., re-
nal failure, cholera, and congestive cardiac
failure),26,79e86 and to undertake general body
composition assessments in lung cancer85,86
Fig. 2. Graphical representation of bioelectrical im-
pedance analysis raw measurements: impedance, re-
actance, resistance, and phase angle.
Fig. 3. Example of a bioelectrical impedance vector
analysis plotted on the RXc graph with 95%, 75%,
and 50% tolerance ellipses. Reproduced with per-
mission from Piccoli et al.67
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and cancers of the head and neck,87 it has yet to
be used to specifically assess hydration in ad-
vanced cancer.
Discussion
Clinical examination and biochemical tests
are standard methods of assessing hydration,
but limitations exist with these methods in ad-
vanced cancer. For example, physical examina-
tion has a low sensitivity and specificity for
identifying fluid deficit.14,88 Study outcomes
are often conflicting and many variables lack
evidence for their inclusion in assessing hydra-
tion status in adult patients with cancer. Histor-
ically, evidence regarding hydration assessment
originates from studies in noncancer popula-
tions, and particular components of a physical
examination (e.g., capillary refill and skin tur-
gor) appear to have less significance in ad-
vanced cancer. Equally, there is disagreement
about the most appropriate biochemical tests
and the diagnostic criteria to diagnose bio-
chemical dehydration. Thedifferences between
local, national, and international definitions of
dehydration may cause clinicians to be unsure
about the significance of biochemical results
in patients with advanced cancer.
Other challenges limit the viability of clini-
cal and biochemical assessment techniques.
For example, the elderly (who comprise the
majority of cancer patients) may have abnor-
mal biochemical profiles secondary to nonhy-
dration related factors, such as altered muscle
mass and preexisting renal or metabolic con-
ditions.16 Repeated venipuncture may cause
pain, discomfort, and be viewed as inappropri-
ate for use in the assessment of patients with
cancer in certain circumstances (e.g., in the
dying phase).89,90 Consequently, clinicians
may avoid performing venipuncture in situa-
tions where the risks of causing harm may out-
weigh the benefits of obtaining biochemical
tests. In this review, we highlighted the con-
cept of clinical dehydration defined by bedside
physician assessment. Clinicians may argue
that there is little utility in identifying bio-
chemical dehydration in a patient without
symptoms; hence, only clinically relevant signs
and symptoms of (de)hydration will be man-
aged. However, in this population, there is
a lack of agreement of which signs and symp-
toms are clinically relevant. Additionally, with-
out an understanding of the pathophysiology
of disease and its resultant symptoms, there
is a risk that features of dehydration may be in-
accurately interpreted and, hence, inappropri-
ately managed. Therefore, it is important for
dehydration in cancer to be appropriately de-
fined to enable associated signs and symptoms
to be identified, thus allowing appropriate
management to be initiated. For example, var-
ious symptoms have been used as indicators
for dehydration, but there is disagreement
about the accuracy of these. Although there
is some evidence to suggest that nausea is im-
proved through the administration of CAH,37
the association of nausea with other variables
(in this study) has not been clarified. Despite
a high prevalence of fatigue,57 the use of
CAH does not appear to improve this
Fig. 4. Data drawn from the literature and plotted
on the RXc-score graph after transformation of im-
pedance measurements from several disease groups
into bivariate Z-scores (with respect to their refer-
ence population). Solid and open circles represent
male and female, respectively. A forward or back-
ward displacement of vectors parallel to the major
axis of ellipses was associated with dehydration or
fluid overloading, respectively, reaching extremes
out of the poles. Vectors above or below the major
axis (meaning upper left or lower right half of ellip-
ses) were associated with more or less cell mass in
soft tissues, respectively, with extremes along the mi-
nor axis. CRF¼ chronic renal failure; HD¼ hemo-
dialysis; HDo¼ obese hemodialysis patients;
HIV¼ human immunodeficiency virus Stages 1e6;
Ob/1e3¼ obese subjects of Classes IeIII;
WR¼Walter Reed Stages 1e6. Reproduced with
permission from Piccoli et al.67
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symptom in patients with cancer.37 Dry mouth
and thirst are common in cancer; however,
these variables may be unreliable indicators
of (de)hydration as a result of their associa-
tion with other factors.54,57,62,91,92 One study
suggests the significance of thirst when serum
ANP is used to define dehydration, but the val-
idity and reliability of this measure has not yet
been determined.53 Despite a greater preva-
lence of hyperactive delirium in patients receiv-
ing reduced volumes of CAH compared with
larger volumes,61 the evidence is poor for the
influence of hydration ondelirium in advanced
cancer.58,60 Overall there is a lack of clinical as-
sessment tools to evaluate hydration in ad-
vanced cancer and unclear data about which
symptoms are most related to dehydration.
These findings, combined with the unclear
benefits and burdens of CAH, make decisions
about the use of CAH challenging for health
care professionals.
BIA is able to assess body composition and
has been used as a prognostic marker in can-
cer studies.74e77 One study demonstrated
that phase angle increase in patients receiving
CAH was associated with increased mortality.15
This may suggest that patients with cancer dif-
fer physiologically in their ability to handle
fluids, with some more prone to adverse ef-
fects than others. The study is limited by small
numbers of patients and a lack of standardiza-
tion of the type of fluid prescribed and the
rate of volume replacement. If a true differ-
ence exists, this may highlight the importance
for clinicians to consider these factors when
administering CAH. Furthermore, studies us-
ing BIA may potentially be a tool to enable cli-
nicians to better understand hydration in
advanced cancer. BIA alone is limited in its
ability to assess hydration in advanced can-
cer;27 however, interpretation using BIVA im-
proves the accuracy of measuring static and
dynamic hydration states.26,67,80 The noninva-
sive nature of the technology may be popular
for researchers keen to use novel methodolo-
gies for assessing hydration in advanced can-
cer. Consequently, BIVA shows promise as
a method for assessing hydration and could
be potentially used to further scientific study
into the relationship between hydration and
related symptoms. However, further study is
required to establish whether measurements
of fluid distribution in advanced cancer, as
determined by BIA and BIVA, are clinically
relevant.
This review is unique in highlighting the po-
tential of BIVA to assess hydration in patients
with advanced cancer. We have identified
a lack of evidence relating to the assessment
and symptomatic treatment of dehydration in
cancer, a finding consistent with similar studies
in this area.
We recognize that there are several limita-
tions with this review. Although hand search-
ing of relevant journals and gray literature
took place, this was limited to the past two
years, and the abstract lists were unavailable
for some conferences; consequently, there is
the potential that data were excluded from
this review. Although a structured process for
identification and inclusion of articles was
adopted, the reviewers were not blinded to
the authors and institutions of the reviewed ar-
ticles. Consequently, there is risk of the re-
viewers’ own bias relating to articles included
or excluded from the review. Many of the in-
cluded studies were small, descriptive, and un-
powered studies with differing definitions of
dehydration. These diagnostic definitions
may have been based on biochemical criteria,
clinical markers, or a combination of both;
therefore, comparisons between the studies
are difficult. Studies involving patients with ad-
vanced cancer present ethical and methodo-
logical challenges that are compounded by
the difficult issue of (de)hydration. Conse-
quently, researchers and ethics committees
may still be learning about suitable approaches
for this subject, which may currently limit the
number of research studies that were available
for inclusion in this review. BIA and BIVA have
been used to assess body composition in sev-
eral populations; however, there is a lack of
studies using this technology to report on clin-
ically relevant outcomes (e.g., symptom bur-
den, survival, and the effect of CAH on these
parameters) in advanced cancer. Additionally,
we were unable to identify any literature re-
porting on the use of BIVA to evaluate hydra-
tion in advanced cancer. The intervention
studies involving CAH used various routes of
administration and different fluid prepara-
tions over differing time periods at different
stages of the subjects’ illness. Although the
outcomes of these studies are interesting, the
lack of harmony between methodology and
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outcomes limits the ability of this review to syn-
thesize data.
A lack of consensus as to how to assess hydra-
tion in advanced cancer makes decisions re-
garding the use of CAH difficult for the
clinician. Further complexity is added because
of the limited number of high quality studies
assessing the benefits and burdens of CAH
for this population. This review has high-
lighted how patients with advanced cancer
may experience some benefits from receiving
CAH, such as improvements in sedation, myo-
clonus, and nausea.2,37 However, there is the
potential to cause harm, in terms of worsening
symptoms of fluid retention (e.g., peripheral
edema, pleural effusion, and ascites).8,61 On
the basis of insufficient evidence, we are lim-
ited in our ability to draw definitive recom-
mendations. Clinicians, therefore, are advised
to make assessments based on the perceived
benefits, risks, and burdens to the individual.12
The clinician should be familiar with existing
methods of hydration assessment and be aware
of their limitations.
Further research to clarify the symptoms as-
sociated with dehydration and to highlight the
benefits and burdens of CAH in patients with
advanced cancer is required. Future studies
need be appropriately powered, with clear def-
initions of (de)hydration. These studies will re-
quire innovative methodologies, for example,
using advance consent of patients. Core out-
come sets for hydration studies should be
agreed to enable clinicians to compare, con-
trast, and synthesize the results of the studies
more effectively. The assessment of (de)hydra-
tion should be conducted in a variety of termi-
nal diagnoses at different stages of the illness
trajectory.
Currently, no studies have used BIVA for the
assessment of hydration in the advanced can-
cer population. Pilot studies using BIVA are re-
quired to determine its feasibility and efficacy
before conclusions may be drawn. If feasible,
BIVA may have a role in evaluating hydration
in advanced cancer and improving knowledge
of hydration in dying patients. BIVA could be
used in combination with other hydration as-
sessment methods to determine the scientific
association of symptoms with dehydration, fa-
cilitating the creation of core outcome mea-
sures for hydration, which can further
support intervention studies using CAH.
Consequently, future studies could use BIA
and BIVA to determine its usefulness in pre-
dicting and monitoring clinical response to
treatments (such as CAH) and survival
through static and longitudinal assessments.
Conclusions
Hydration is an important area of care for
patients with advanced cancer. Limitations ex-
ist with current hydration assessment methods
and there is a lack of consensus of the symp-
toms associated with dehydration. The benefits
and burdens of providing CAH to patients dy-
ing of cancer are unclear. BIVA shows promise
as a hydration assessment tool but requires fur-
ther study in advanced cancer. Innovative
methodologies for research are required to
add to the evidence base and ultimately im-
prove the care for the dying.
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Table 2
Characteristics of Reviewed Studies
Study Purpose Design Participants Exclusions Dehydration Definition Outcome Measure Methods Appraisal Total Score Conclusions
Morita et al.35 To explore
systematically the
associations between
hydration volume
and dehydration
and fluid retention
symptoms in the last
3 wk of life in
terminally ill
patients with
abdominal
malignancies.
Multicenter,
prospective,
observational study
n¼ 226
Fourteen oncology
units, 19
palliative care
units (PCUs),
and four home-
based palliative
care programs in
Japan.
- Age $20 y
- Life expectancy #3
mo
- Incurable malignancy
of lung or abdominal
origin (excluding
hepatic malignancies)
Mean age¼ 68 y
Male/female¼ 106/
120
n¼ 272
- Death within 3 wk of
initial assessment
(n¼ 200)
- Survival beyond
observation period
(n¼ 35)
- Medical complication
(n¼ 17)
- Prior communication
difficulty (n¼ 15)
- Discharge (n¼ 5)
Liver cirrhosis, renal
failure, nephritis
syndrome, protein-
losing enteropathy,
intra-abdominal
shunt for ascites,
hypercalcemia,
endocrine disorders,
and vital organ
complications
unrelated to
underlying
malignancies;
surgical,
radiological, or
oncological
treatments in the 3
wk before study
inclusion; existing
communication
difficulty; and the
use of artificial
enteral nutrition.
Degree of dehydration
defined on basis of
three physical
findings
1. Ad hoc dehydration
score (0e5)
2. Peripheral edema
score (0e21)
3. Pleural effusion
score (0e2)
4. Ascites score (0e2)
5. Delirium (evaluated
by the Memorial
Delirium Assessment
Scale [MDAS])
Analyses of data
collected:
Patients classified into
two groups; the
hydration group
(n¼ 59) who
received $1 L or
more of artificial
hydration per day
both 1 and 3 wk
before death, and
the nonhydration
group (n¼ 167)
who did not.
33 Percentage of patients
with deterioration in
dehydration score in
final 3 wk of life
significantly higher
in nonhydration
group compared
with hydration
group (35% vs. 14%,
P¼ 0.002).
Fluid retention
symptoms increased
significantly in
hydration group
compared with
nonhydration
group: edema (44%
vs. 29%, P¼ 0.039)
ascites (29% vs.
8.4%, P< 0.001),
pleural effusion
(15% vs. 5.4%,
P¼ 0.016).
No significant
difference in degree
of bronchial
secretion,
hyperactive
delirium,
communication
capacity, agitation,
myoclonus, or
bedsores.
Morita et al.36 To explore the
association between
1) hydration volume
and laboratory
findings and 2)
calculated fluid
balance and the
changes in clinical
signs of dehydration
and fluid retention
during the last 3 wk
of life in terminally
ill patients with
cancer.
Multicenter,
prospective,
observational study
n¼ 125
Fourteen oncology
units, 19 PCUs,
and four home-
based palliative
care programs in
Japan.
- Age $20 y
- Life expectancy #3
mo
- Incurable malignancy
of lung or abdominal
origin (excluding
hepatic malignancies)
Mean age¼ 67 y
Male/female¼ 61/64
Number not given
Liver cirrhosis, renal
failure, nephritis
syndrome, protein-
losing enteropathy,
intra-abdominal
shunt for ascites,
hypercalcemia,
endocrine disorders,
and vital organ
complications
unrelated to
underlying
malignancies;
surgical,
radiological, or
oncological
treatments in the 3
wk before study
inclusion; existing
communication
Degree of dehydration
defined on basis of
three physical
findings
1. Ad hoc dehydration
score (0e5)
2. Peripheral edema
score (0e21)
3. Pleural effusion
score (0e2)
4. Ascites score (0e2)
Scores developed by
the authors.
Secondary analyses of
data collected:
laboratory data,
clinical assessment
data, fluid balance,
and oral intake.
Patients classified into
two groups: the
hydration group
(n¼ 44), who
received $1 L or
more of artificial
hydration per day
both 1 and 3 wk
before death, and
the nonhydration
group (n¼ 81) who
did not.
30 The mean albumin
level 1 wk before
death was
significantly lower in
the hydration group
than in the
nonhydration
group, and the
interaction between
hydration group and
decrease in the
albumin level
There was no
significant
difference between
the groups in the
mean blood urea
nitrogen/creatinine
(BUN/Cr), sodium,
or potassium levels 1
wk before death.
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Continued
Study Purpose Design Participants Exclusions Dehydration Definition Outcome Measure Methods Appraisal Total Score Conclusions
difficulty; and the
use of artificial
enteral nutrition.
The calculated fluid
balance was not
significantly
different between
the patients with
deterioration in
scores of
dehydration, edema,
ascites, and pleural
effusion during the
last 3 wk and those
without.
Bruera et al.37 To determine the effect
of clinically assisted
hydration (CAH) on
overall symptom
control in terminally
ill cancer patients
with dehydration.
Randomized,
controlled, double-
blind trial
n¼ 51
NB: Sample size
calculation 54
per group
- A palliative diagnosis
of advanced cancer
with no further
treatment planned
- Oral intake
#1000 mL/d
- Decreased skin turgor
$2 s
- One or more of dry
mouth, thirst,
decreased volume of
urine output, and
a darker color of urine
than usual
- Laboratory values
consistent with
dehydration obtained
within 24 hours of
admission to the
study.
- Age $16 y
- Able to tolerate
subcutaneous or
intravenous (IV)
fluids
Demographics not
given.
n¼ 13
Patient’s refusal to
participate; the
presence of
severe
dehydration,
defined as
a decreased
systolic resting
blood pressure of
30 mmHg or
lower from the
patient’s baseline
value; low
perfusion of the
limbs; no urine
output for 12 h
or longer;
a decreased level
of consciousness;
or evidence of
severe renal
failure or
bilateral
hydronephrosis.
Oral intake#1000 mL/
d
- Decreased skin turgor
$2 s
- One or more of dry
mouth; thirst;
decreased volume of
urine output; a darker
color of urine than
usual; laboratory
values consistent with
dehydration, such as
an elevated BUN/Cr
ratio of $20:1
Target symptoms
(hallucinations,
myoclonus, fatigue,
and sedation)
assessed with 0e10
numeric rating
scale.
Mini Mental State
Examination
(MMSE)
Patients were randomly
assigned to receive
either 1000 mL
(treatment group)
or 100 mL (placebo)
normal saline
administered over
4 h for 2 d.
Patients evaluated for
target symptoms,
global well-being,
and overall benefit.
32 The administration of
artificial fluids
improved sedation
and myoclonus in
the intervention
group.
Guo et al.55 To determine the
prevalence of pre-
renal azotemia in a
cancer
rehabilitation
patient population.
To evaluate the
relationship of pre-
renal azotemia to
rehabilitation
outcome, specifically
length of stay and
discharge destiny in
these patients.
Retrospective chart
review
n¼ 62
Cancer patients
admitted to the
acute inpatient
rehabilitation
unit:
Demographics not
given
n¼ 8
Patients considered
to have renal
insufficiency.
BUN/Cr ratio $20
(pre-renal azotemia)
1. Pre-renal azotemia
prevalence
2. Length of
rehabilitation stay of
pre-renal azotemia
group compared
with nonepre-renal
azotemia group
3. Discharge destiny of
pre-renal azotemia
group compared
with nonepre-renal
azotemia group
Patients classified into
two groups: The pre-
renal azotemia
group (n¼ 27) and
the nonepre-renal
azotemia group
(n¼ 35).
Secondary analyses of
collected data:
- Demographics
- Laboratory data
- Length of stay
- Discharge destiny
26 Pre-renal azotemia
prevalence¼ 44%
(n¼ 27/62)
No significant
association between
pre-renal azotemia
on length of
rehabilitation stay or
discharge destiny.
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Waller et al.56 Are patients with
cancer dehydrated
when close to death?
Does the provision of
IV fluids influence
the state of
hydration of such
patients or their
level of
consciousness?
Cross-sectional n¼ 68Hospice
inpatients:
- Terminal cancer
- Laboratory tests done
within 48 h of death
(patients selected
after death)
Demographics not
given
Number and details not
given.
Elevated sodium,
specific cutoff was
not defined
Differences between
urea, sodium, serum
osmolality, urine
osmolality, urine/
serum osmolality
ratio, BUN/Cr
ratio.Alertness scale:
1. Fully conscious
2. Responsive to visual
or vocal stimuli
3. Responsive to only
painful stimuli
4. Comatose
The Early Warning
Score is validated for
the identification of
medical patients at
risk general
deterioration.
Comparison of
biochemical
measurements and
alertness scale
measurements
between groups.
26 87% (n¼ 59/68) of
Patients classified as
dehydrated.
State of consciousness
correlated inversely
with serum sodium
and urine
osmolality.
Patients receiving IV
fluids were not
better hydrated than
those without IV
therapy.
State of consciousness
was not improved
for those hydrated
compare with those
without IV therapy.
Burge57 To determine the
severity and
distribution of
symptoms associated
with dehydration in
inpatient palliative
care patients.
To determine the
association between
these objective
measures of
dehydration.
Cross-sectional survey n¼ 52
PCU patients:
- Age $18 y
- Advanced cancer
- Prognosis #6 wk
- Ability to speak
English or French
- Ability to understand,
consent to, and take
part in study.
Mean age¼ 64.4 y
Male/female¼ 26/26
27% Died within 2 wk
of study
n¼ 71
- Confusion (n¼ 20)
- Weak (n¼ 7)
- Drowsy/coma
(n¼ 13)
- Language (n¼ 7)
- Died (n¼ 5)
- Refused (n¼ 5)
- Aphasia (n¼ 2)
- Anxiety/agitation
(n¼ 2)
Dehydration not
defined
Visual analogue scale
(VAS) score for
following symptoms:
- Thirst
- Pain
- Dry mouth
- Nausea
- Bad taste
- Fatigue
- Pleasure to drink
Cross-sectional survey
of palliative care
inpatients across two
hospitals.
Associations between
symptoms and
predictor variables
(fluid intake, plasma
osmolality, sodium,
and urea).
36 No association between
severity of symptoms
and fluid intake.
No association between
biochemical
measures and thirst.
Fatigue, dry mouth,
and thirst are highly
prevalent.
Cerchietti et al.2 To assess the usefulness
of hypodermoclysis
hydration in the
relief of thirst,
chronic nausea, and
delirium.
Randomized controlled
trial
n¼ 42
NB sample size¼ 50
Terminal stage
patients with
advanced cancer
with one or more
of the following:
- Thirst
- Chronic nausea or
delirium
- Dehydration
diagnosed on physical
examination (with or
without renal failure)
- Inability to maintain
adequate water intake
#50 mL/d
Mean age¼ 55.8 y
(intervention), 51.7 y
(control)
Male/female¼ 17/25
Number not given Dehydration diagnosed
on physical
examination (with
or without renal
failure)
VAS for following
symptoms:
- Thirst
- Chronic nausea
- Delirium
- MMSE
Twenty patients
received 1000 mL
5% dextrose in
water with addition
of 140 mEq/L
sodium chloride per
day, at an infusion
rate of 42 mL/h via
the subcutaneous
route.
Twenty-two received no
fluids.
VAS scores and MMSE
used to compare
hydrated and
nonhydrated
groups.
28 Both groups showed
significant and equal
improvements in
relief of thirst and
nausea at 24 h, but
this improvement
was only maintained
in the hydration
group at 48 h.
Delirium did not
improve significantly
in either group.
Ellershaw et al.54 To investigate the
relationship that
respiratory tract
secretions, thirst,
and dry mouth have
with level of
Prospective cohort n¼ 82
Palliative care
inpatients:
- Advanced cancer
- Dying and taking just
sips of fluid or unable
Patients were excluded
if a doctor or nurse
involved in the care
of the patient felt
that it was
inappropriate for
Dehydration definition
based on the
presence of one or
more of the
following:
Self-reported symptoms
(dry mouth and
thirst) by patient
Clinical assessment of
respiratory tract
secretions
Based on dehydration
definition: 61
patients defined
biochemically
dehydrated, 21 not
biochemically
34 No statistically
significant
relationship
between respiratory
tract secretions, dry
mouth, thirst, and
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Continued
Study Purpose Design Participants Exclusions Dehydration Definition Outcome Measure Methods Appraisal Total Score Conclusions
hydration as
measured by
biochemical
parameters, in
terminally ill
patients.
to take oral
medications
Median age¼ 73 y
Male/female¼ not
given
All died within 5 d of
entry to study.
the patient to be
included in the
study.
No other details given.
- Serum osmolality
>295 mOsmol/kg
- Creatinine
$130 mmol/L
- Urea #12 mmol/L
Biochemical definitions dehydrated.
Comparisons made
between groups.
the level of
hydration.
Morita et al.53 To identify the
association between
sensation of thirst in
hospice inpatients
and various medical
factors, especially
dehydration.
Cross-sectional study n¼ 88
Palliative care
inpatients:
- Age $18 y or older
- Diagnosis of incurable
advanced cancer
- Physicians’ estimate of
6 mo life expectancy
or less.
Demographics not
given
n¼ 96
1. Cognitive
impairment
2. Diabetes insipidus
and/or thyroid or
adrenal dysfunction
3. Delirium/dementia
(n¼ 52)
4. Past history of heart
failure, chronic
obstructive
pulmonary disease,
or hypertension
(n¼ 17)
5. Palliative
Performance Scale of
$60 (n¼ 11)
6. Lack of laboratory
examinations (n¼ 6)
7. Unable to
understand VAS
(n¼ 5)
8. Faulty blood
sampling (n¼ 5)
Two definitions used:
1. Atrial natriuretic
peptide (ANP)
#15 pg/mL
2. Definition of
Ellershaw et al54:
- Serum osmolality
>295 mOsmol/kg
- Creatinine
$130 mmol/L
- Urea #12 mmol/L
VAS score for thirst.
ANP #15 pg/mL.
Ellershaw et al.’s
definition.
Patients grouped
dehydrated or
nondehydratedVAS
scores analyzed:
- Continuously used as
a dependent variable
- Logistic regression
analysis where patients
with VAS $8
compared with each
other.
Comparison of
biochemical
measurements
between groups.
32 No significant
correlations
observed between
the VAS score for
thirst and
biochemical
measures based on
the Ellershaw
definition.
Dehydration defined by
ANP level #15 pg/
mL showed severity
of thirst to be
significantly
associated with:
- Hyperosmolality
$300 mosmol/kg
- Gastrointestinal
cancer
- Survival
- Performance status
- Oral intake
- Vomiting
- stomatitis
Mouth breathing and
opioids potential
causes of severe
thirst as identified
from retrospective
chart review.
Galanakis et al.60 To estimate the extent
to which hydration
and related risk
factors influence the
course of delirium
over time.
Retrospective analysis
of clinical trial data
n¼ 1125
Patients with
advanced cancer
surviving at least
3 d, receiving
palliative care at
centers in
Quebec and
Ontario as part of
a clinical trial for
the prevention of
delirium.
n¼ 1390
Data unavailable.
Dehydration not
defined
Relationship of
hydration risk
factors to delirium
groups.
Details of measures
unavailable.
Data extracted from a
clinical trial
database.
Group-based trajectory
modeling and
multivariate linear
regression were used
to identify
subgroups of
individuals with
similar delirium
trajectories during
the first 30 d of
admission and to
determine what
factors influence
membership to
these trajectories
22 Patients classified into
six different groups
based on presence/
absence and course
of delirium.
Hydration was not
predictive of
delirium or group
membership.
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Yamaguchi et al.61 To clarify the
longitudinal
changes in patient-
reported global
quality of life (QoL),
observational
discomfort,
symptoms, and fluid
retention signs in
patients with
advanced cancer
receiving guideline-
based parenteral
hydration therapy.
Prospective,
observational study
n¼ 161
- Age >20 y
- Incurable abdominal
malignancy
- Severely reduced oral
intake (<100 kcal/
d and 10 mL/d)
- Available for follow-up
- Hepatic, prostate, or
esophageal
malignancy
- Renal (creatinine
>2 mg/dL)
- Heart (NYHA
classification >II), or
liver failure (total
bilirubin >2 mg/dL)
unrelated to
malignancy
- Liver cirrhosis,
nephrotic syndrome,
or protein-losing
enteropathy of any
etiology
- Intra-abdominal shunt
for ascites
- Hypothyroidism,
adrenal insufficiency,
SIADH requiring
intervention
- Cognitive impairment
- Antitumor therapy
(surgical, radiological,
or chemotherapy)
within 2 wk before
study
- Use of artificial
enteral nutrition
Dehydration not
defined
1. Patient-reported
global QoL (using
Item 30 of the
European
Organization for
Research Treatment
of Cancer Quality of
Life Questionnaire-
C30).
2. Observational
discomfort (using
the Discomfort
Scale).
3. Patient reported
benefit and
satisfaction with
CAH
4. Physical symptoms
5. Psychiatric symptoms
Patients completed
questionnaires
weekly (Weeks 1e4)
and then every 2 wk
(up until Week 12 or
death).
Patients received CAH
accordingly to
national Japanese
guideline. CAH
reduced to <1 L/
d in patients with
fluid retention signs.
Patients grouped as low
volume (<1 L/d)
and high volume
(>1 L/d)
31 No significant
difference of QoL,
Discomfort Score
and symptoms
between low- and
high-volume groups.
More than 80% of
patients maintained
all fluid retention
signs.
Hyperactive delirium
significantly higher
in small-volume
hydration group in
last 48 h of life
(5.3% vs. 17.3%,
P¼ 0.009).
Nakajima63 To explore the
influences of
hydration volume
toward the
symptoms during
the last 3 wk of life
in these patients.
Prospective,
observational study
n¼ 75 Number not given Degree of dehydration
defined on basis of
three physical
findings
1. Dehydration score35
2. Peripheral edema
score
3. Ascites and pleural
effusion score
4. Bronchial secretion
5. Delirium (evaluated
by the MDAS)
Assessment schedule
based on work of
Morita et al.35
Analyses of data
collected:
Patients classified into
two groups; the
hydration group
(n¼ 32) who
received $1 L or
more of artificial
hydration per day
both 1 and 3 wk
before death, and
the nonhydration
group (n¼ 43) who
did not.
28 The percentages of
patients with
deterioration in
dehydration score in
the last 3 wk were
significantly higher
in the nonhydration
group than in the
hydration group
(35% vs. 13%;
P¼ 0.027).
Significantly higher
fluid retention
symptoms reported
in the hydration
group compared
with the
nonhydration
group: edema (57%
vs. 33%, P¼ 0.040),
ascites (34% vs.
14%, P¼ 0.037) and
bronchial secretion
(44% vs. 19%,
P¼ 0.036).
No significant
differences in the
degree of pleural
effusion and
delirium.
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Continued
Study Purpose Design Participants Exclusions Dehydration Definition Outcome Measure Methods Appraisal Total Score Conclusions
Musgrave et al.62 To evaluate the effects
of IV fluids in a
group of dying
patients.
Cross-sectional study n¼ 19
Inpatients on adult
oncology unit:
- Terminally ill
- Receiving IV fluids
- Prognosis of #10 d
Demographics not
given.
n¼ 19
- Survival >10 d (n¼ 5)
- Died without IV
(n¼ 1)
- Transferred (n¼ 2)
- (Semi)unconscious
(n¼ 11)
Dehydration not
defined
Structured
questionnaire
developed by the
researchers.
Questionnaire was
reviewed for content
validity by an
oncologist, two
specialists in
oncology nursing,
and two statisticians.
Patients asked to
complete a
questionnaire
recording severity of
thirst. Serum
biochemistry and
fluid intake and
output volumes
recorded.
Comparisons made
between variables.
24 95% (n¼ 18/19) of
Patients reported
thirst.
No association between
level of thirst with
the amount of IV
fluids received,
BUN, and sodium
levels.
Little association
between fluid
retention signs and
volume of fluid
received.
Davis et al.15 To determine whether
bioelectrical
impedance analysis
(BIA) correlates
with hydration
changes during
CAH and to
determine if these
changes were of
prognostic
importance.
Prospective
observational study
n¼ 50
Inpatient PCU:
- Active cancer
- Undergoing
continuous hydration
- Able to give consent
Mean age¼ 63 y
Male/female¼ 30/20
n¼ 29
- Delirious
- Actively dying
- Unable to
communicate
- Deferred participation
- Patients with
defibrillators
Dehydration not
defined
Phase angle Patients underwent BIA
measurements for 3
consecutive days.
Laboratory studies,
patient weight and
vital signs recorded.
Patient survival
calculated.
29 Higher phase angle
before hydration
predicts longer
survival.
Increase in phase
angles during
hydration predicted
poorer survival and
pre-existing
intracellular
dehydration,
cachexia, or poor
membrane function.
Crawford et al.78 To investigate whether
bioimpedance
spectroscopy (BIS)
has the potential to
improve
prognostication in
an outpatient clinic
for patients with
cancer receiving
palliative care.
Observational n¼ 84
Outpatient oncology
and palliative care
clinics:
- Advanced cancer
- Fluency in English
- Age $18 y
- Judged by their
primary medical
specialist to be in the
palliative phase of
their illness
- No severe cognitive
impairment
Mean age¼ 65.9 y
Male/female¼ not
given
n¼ 19
- Declined participation
(n¼ 4)
- Physical decline
(n¼ 15)
Dehydration not
defined
BIS measures and
survival time
Survival time and BIS
measurements of
basal metabolic rate
and measurement of
11 body composition
parameters
(extracellular fluid
(ECF), intracellular
fluid (ICF), ECF/
ICF ratio, fluid in
trunk and arm and
leg, protein mass,
mineral mass, and
percent of body fat)
were recorded.
36 Metabolic rate and
accumulation of
body fluid are
indicators of poor
prognosis in
palliative cancer
patients.
NYHA¼New York Heart Association Functional Classification; SIADH¼ symptom of inappropriate antidiuretic hormone secretion.
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08 August 2012 
Dear Professor Varro,  
 
Study title: Hydration in advanced cancer patients: the testing of a 
new assessment method 
REC reference: 12/WA/0200 
IRAS reference: 48056 
Protocol number: UoL000863 
 
The REC gave a favourable ethical opinion to this study on 23 July 2012. 
Notification(s) have been received from local assessor(s), following site-specific assessment.  
On behalf of the Committee, I am pleased to confirm the extension of the favourable opinion 
to the new site(s) and investigator(s) listed below: 
  
Research Site  Principal Investigator / Local Collaborator  
Marie Curie Hospice Liverpool  Prof John Ellershaw  
 
The favourable opinion is subject to management permission or approval being obtained 
from the host organisation prior to the start of the study at the site concerned.   
Statement of compliance 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
12/WA/0200   Please quote this number on all correspondence 
 
Yours sincerely 
 
 
Mr Derek James Crawford 
Chair 
E-mail: rossela.roberts@wales.nhs.uk  
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gyfer Ymchwil Gofal Cymdeithasol ac Iechyd gan Fwrdd Addysgu Iechyd Powys 
 
The National Institute for Social Care and Health Research Academic Health Science  
Collaboration is hosted by Powys Teaching Health Board 
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Copy to: Sponsor / R&D Office:  
Mrs Lindsay Carter  
University of Liverpool  
Research Support Office,  
2nd Floor, Block D,Waterhouse Bld,  
3 Brownlow Street 
Liverpool 
L69 3GL        lindsay.carter@liverpool.ac.uk  
                                 
Co-Investigator:  
Dr Amarachukwu Nwosu 
Academic Research Fellow in Palliative Medicine 
Marie Curie Palliative Care Institute Liverpool (MCPCIL) 
Dept of Molecular & Clinical Cancer Medicine, University of Liverpool 
Cancer Research Centre 
200 London Rd, Liverpool 
L69 3BX                    anwosu@liv.ac.uk 
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North Wales Research Ethics Committee – West 
 
Betsi Cadwaladr University Health Board 
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Clinical Academic Office 
Bangor, Gwynedd 
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Telephone/ Facsimile: 01248 - 384.877  
Email: Rossela.Roberts@wales.nhs.uk  
Website : www.nres.nhs.uk     
Professor Andrea Varro 
School of Biomedical Sciences, University of Liverpool 
The Physiological Laboratory 
Crown Street, Brownlow Hill 
Liverpool 
L69 3BX    avarro@liv.ac.uk 
   c/o: amaranwosu@doctors.org.uk; anwosu@liv.ac.uk 
 
23 July 2012 
Dear Professor Varro,  
 
Study title: Hydration in advanced cancer patients: the testing of a 
new assessment method 
REC reference: 12/WA/0200 
IRAS reference: 48056 
Protocol number: UoL000863 
 
The Research Ethics Committee reviewed the above application at the meeting held on 19 
July 2012. The Committee wishes to thank the Co-Investigator, Dr Amarachuckwu Nwosu, 
for attending to discuss the study. 
Ethical opinion 
 
Ethical issues raised by the Committee in private discussion, together with responses 
given by Dr Nwosu when invited into the meeting    
 
Scientific design and statistical analysis; conduct of the study; patient involvement in design  
The Committee noted that this is a comparison of a CE marked device with a standard 
technique; the purpose of this clinical investigation is to demonstrate safety and performance 
of the device, not efficacy and therefore a smaller sample size is acceptable for this ‘proof of 
concept' study.  
The Committee raised a query in relation to the outcome measures.  
The Co-Investigator clarified that the aim is to generate reference data which is population 
specific; survival data is required as hydration markers have been used for survival 
prognosis: it is hoped to identify whether readings using Bioelectrical Impedance Vector 
Analysis techniques have the same predictive value.  
The Committee requested a clarification of the level of patient involvement in the design of 
the study, as the Project Management Team and the Project Steering Group are comprised 
solely of experts and the Project Advisory Group lists only two lay members.  
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The National Institute for Social Care and Health Research Academic Health Science  
Collaboration is hosted by Powys Teaching Health Board 
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The Co-Investigator clarified that the project is based on feed-back on previous work by 
patients and their families, who highlighted that they would like to see more work done on 
hydration; the Marie Currie Advisory Board have significant PPI representation and albeit 
they have not had as much input into this project the lay officer has offered to provide advice 
on the study.    
The Committee suggested that the dissemination of results should not be restricted to web-
based applications, and that other methods (such as leaflets in GP surgeries) could be 
considered.  
 
Independent review  
The Committee discussed the review of the project by the Chief Investigator' institution and 
the level of external peer-review. It was noted that one of the reviewers suggested that 
avoiding the recruitment of very ill patients means missing the most valuable information;  
Dr Nwosu clarified that this was discussed at length in the project team and it was 
recognised that very important data could be obtained from patients in the dying phase; the 
team concluded that it was more appropriate to conduct the pilot study in patients able to 
give consent and able to participate in the assessments (such as visual assessment scores).  
 
Recruitment arrangements; fair participant selection  
The Committee was satisfied that the participators will be recruited fairly and the selection of 
potential participants has taken into account their clinical care; there are no incentives and 
payments made to participants. The applicants went to considerable length to avoid a 
potential conflict of interest between the research team and the clinical care team and to avid 
coercion;  Adequate insurance and indemnity/compensation arrangements are in place. The 
Committee queried whether the researcher who is not part of the clinical team has legitimate 
access to the list of admissions required to identify potential participants; the Co-Investigator 
clarified his current role is that of a researcher not a clinician. The Admissions Coordinator 
runs admissions meetings in the morning; these are attended by all doctors and Co-
Investigator is planning to attend in order to identify potential participants, whom he could 
approach during the day.  The Committee advised that – as the Co-Investigator is not part of 
the clinical care team - it is preferable that the PI for the site (Professor Ellershaw), would 
identify eligible patients and introduce Dr Nowsu to potential participants.  
 
Care and protection of research participants; respect for participants' welfare & dignity; data 
protection and participants' confidentiality  
The Committee discussed where and for how long will data be stored, whether information 
about subjects be appropriately handled, and clarified who will have access to the data. The 
Committee queried the answer to question A36 of the REC application form which mentions 
‘electronic transfer of data' . Dr Nwosu clarified that the analyser can send the results 
/readings directly to the computer in a pseudo-anonymised format, coded by identifier rather 
than by any patient identifiable information.  
 
Suitability of the applicant and facilities  
The Committee discussed the suitability of the applicant and concluded that the Chief 
Investigator is excellently qualified to carry out this research. The Committee discussed the 
requirement for Site-Specific Assessment for the non-NHS sites involved (hospices) and 
concluded that the study can be considered SSA exempt as it involves no clinical 
interventions and all study procedures at these sites will be undertaken by the Chief 
Investigator's team. The REC was satisfied that the risk to participants is likely to be 
negligible and the study procedures will not significantly interfere with participant's freedom 
of action or privacy or be unduly invasive or restrictive.  
However, it was noted that the research team have sent a request for a Site Specific 
Assessment to the Liverpool REC and it was decided that the conditions of approval should 
list that activities at non-NHS sites should be initiated only after the receipt of the notification 
of “No Objection”.  No further ethical issues were raised.    
The Chairman thanked Dr Nwosu for attending to speak to this submission and gave an 
opportunity to the applicant to ask questions. Dr Nwosu did not raise any issues.  
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On the basis of the information provided, the Committee was satisfied with the 
following aspects of the research: 
• Social or scientific value; purpose and need 
• Scientific design and statistical analysis; conduct of the study; patient involvement in 
design 
• Independent review  
• Fir participant selection  
• Risks, burdens and benefits to the subject; favourable risk benefit ratio; redress  
• Care and protection of research participants; respect for participants’ welfare & dignity;   
data protection & participant’s confidentiality  
• Informed Consent process; adequacy and completeness of Participant Information  
• Other study procedures (e.g. scans, tissue samples) 
• Other safety issues pertaining to the medical device  
• Suitability of the Applicant and Supporting Staff 
 
The Committee identified issues with the following aspects of the research: 
 
• Recruitment arrangements 
 
The members of the Committee present gave a favourable ethical opinion of the above 
research on the basis described in the application form, protocol and supporting 
documentation, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS Sites 
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” below).  
 
Non NHS sites 
The Committee has not yet been notified of the outcome of any site-specific assessment 
(SSA) for the non-NHS research site(s) taking part in this study. The favourable opinion does 
not therefore apply to any non-NHS site at present. I will write to you again as soon as one 
Research Ethics Committee has notified the outcome of a SSA. In the meantime no study 
procedures should be initiated at non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
 
Management permission or approval must be obtained from each host organisation prior to 
the start of the study at the site concerned. 
 
Management permission (“R&D approval”) should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
Guidance on applying for NHS permission for research is available in the Integrated 
Research Application System or at http://www.rdforum.nhs.uk.   
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
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The favourable opinion is subject to the following conditions being met prior to the 
start of the study:    
 
1. As the researcher is not part of the clinical team he has no legitimate access to the list of 
admissions required to identify potential participants; the Committee requested that the 
recruitment arrangements are clarified in the protocol. 
 
It is responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
You should notify the REC in writing once all conditions have been met (except for 
site approvals from host organisations) and provide copies of any revised 
documentation with updated version numbers. Confirmation should also be provided 
to host organisations together with relevant documentation  
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document    Version    Date    
Covering Letter    04 July 2012  
REC application (48056/341321/1/170)  09 July 2012  
Protocol  1  01 June 2012  
Other: Appendix 1: Bioelectrical impedance analysis testing 
procedure   
1  01 June 2012  
Other: Appendix 2: Bioelectrical impedance vector analysis and RXc 
graph with 95%, 75% and 50% tolerance ellipses  
1  01 June 2012  
Other: Appendix 3: Bioelectrical impedance vector analysis and RXc 
graph: graphical representation of hydration change  
1  01 June 2012  
Summary/Synopsis Appendix 4: Consent Process flowchart  1 01 June 2012  
Participant Information Sheet: Appendix 5: PIS part 1  1  01 June 2012  
Participant Information Sheet: Appendix 6: PIS part 2  1  01 June 2012  
Other: Appendix7: Screening questions for study entry   1  01 June 2012  
Other: Appendix 8: Assessment Schedule  1  01 June 2012  
Questionnaire: Appendix 9: Demographic details collection sheet  1  01 June 2012  
Questionnaire: Appendix:10: Hydration questionnaire Burge 1993      
Questionnaire: Appendix:11: Hydration questionnaire Morita 2006       
Other: Appendix 12: Blood results template       
Summary/Synopsis Appendix 13: Flowchart of research protocol 1  01/06/2012 
Referees or other scientific critique report Appendix 14: Peer-
reviewer comments 
    
Referees or other scientific critique report Appendix 15: Response 
to Peer-reviewer comments 
  
Advertisement  1 July 2012     
Participant Consent Form  1  01 June 2012  
GP/Consultant Information Sheets  1  01 June 2012  
Investigator CV    27 June 2012  
Letter from Sponsor: LCTU trial adoption  30 April 2012  
Letter from Sponsor: confirmation of sponsorship    07 June 2012  
Letter from Statistician    22 February 2012  
Letter of invitation to participant  1  01 June 2012  
Other: Letter form funder     28 June 2012  
Instructions for use of medical device: 
EFG ElectroFluidGraph User Manual  
rev 2 07/08     
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Membership of the Committee 
 
The members of the Ethics Committee who were present at the meeting are listed on the 
attached sheet. 
No conflicts of interest were declared in relation to this application. 
 
Statement of compliance  
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments 
• Adding new sites and investigators 
• Notification of serious breaches of the protocol 
• Progress and safety reports 
• Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views 
known please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
 
12/WA/0200   Please quote this number on all correspondence 
 
 
Yours sincerely 
 
 
 
 
Mr Derek James Crawford 
Chair 
 
E-mail: rossela.roberts@wales.nhs.uk  
 
 
 
Enclosure: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
 
“After ethical review – guidance for researchers” 
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Copy to: Sponsor / R&D Office:  
Mrs Lindsay Carter  
University of Liverpool  
Research Support Office,  
2nd Floor, Block D,Waterhouse Bld,  
3 Brownlow Street 
Liverpool 
L69 3GL        lindsay.carter@liverpool.ac.uk  
                                 
Co-Investigator:  
Dr Amarachukwu Nwosu 
Academic Research Fellow in Palliative Medicine 
Marie Curie Palliative Care Institute Liverpool (MCPCIL) 
Dept of Molecular & Clinical Cancer Medicine, University of Liverpool 
Cancer Research Centre 
200 London Rd, Liverpool 
L69 3BX                    anwosu@liv.ac.uk 
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North Wales Research Ethics Committee - West 
 
Attendance at Committee meeting on 19 July 2012 
 
 
 
Committee Members 
Name   Profession   Capacity   Present 
Dr. Karen Addy Clinical Psychologist Expert Yes  
Dr. Swapna Alexander Consultant Physician Expert  Yes  
Ms Valerie Barcoft Volunteer Worker Lay + Yes  
Mrs. Kathryn Chester  Research Nurse  Expert  Yes 
Dr. Christine Clark Consultant Obstetrician & Gynaecologist Expert Yes  
Mr. Derek James Crawford Consultant Surgeon (Chairman) Expert Yes 
Mrs. Gwen Dale-Jones    Retired Personal Assistant    Lay + Yes 
Mr. Hywel Lloyd Davies Solicitor (Alternate Vice-Chairman) Lay + No  
Mr. Ron Evans Retired Teacher Lay + Yes 
Ms. Gillian Jones Student   Lay + Yes 
Dr. Mark Lord Consultant Pathologist  Expert Yes  
Dr. Neil McKenzie Retired Physicist  Lay + Yes 
Mr. Paramasivam Sathyamoorthy Consultant Orthopaedic Surgeon  Expert Yes 
Dr. Thanthullu Vasu Consultant Anaesthetist  Expert No 
Mr. Christopher John Whitaker Statistician  Expert Yes 
Dr. Philip Wayman White  General Practitioner (Vice-Chairman) Expert Yes  
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